

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/06513 A2

- (51) International Patent Classification⁷: **C12Q 1/00**
- (21) International Application Number: **PCT/US01/16525**
- (22) International Filing Date: **13 July 2001 (13.07.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/218,118 13 July 2000 (13.07.2000) US
60/283,880 13 April 2001 (13.04.2001) US
- (71) Applicant (*for all designated States except US*): **PHARMACIA & UPJOHN COMPANY** [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **HOMA, Fred, L.** [US/US]; 3430 Pine Grove Lane, Kalamazoo, MI 49008 (US). **WATHEN, Michael, W.** [US/US]; 6474 Pepperidge, Portage, MI 49002 (US). **HOPKINS, Todd, A.** [US/US]; 744 Sarah Street, Galesburg, MI 49053 (US). **THOMSEN, Darrel, R.** [US/US]; 6916 Willson Drive, Kalamazoo, MI 49009 (US).
- (74) Agent: **YANG, Lucy, X.**; Intellectual Property Legal Services, Pharmacia & Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **A METHOD FOR TREATING HERPES VIRUSES**

(57) Abstract: The present invention relates to a method for selecting an anti-herpes viral compound and a method for selectively inhibiting herpesvirus in a human host in need of such treatment. The present invention relates to a method for selecting an anti-herpes viral compound and a method for selectively inhibiting herpesvirus in a human host in need of such treatment.

WO 02/06513 A2

A METHOD FOR TREATING HERPES VIRUSES

FIELD OF THE INVENTION

The present invention relates to a method for selecting an anti-herpes viral
5 compound and a method for selectively inhibiting herpes viruses in a human host in need of such treatment.

BACKGROUND OF THE INVENTION

The herpesviruses comprise a large family of double stranded DNA viruses. Eight
10 of the herpes viruses, herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and human herpes viruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-8), have been shown to infect humans. Several of these viruses are important human pathogens.

HSV-1 is estimated to affect 100 million people in the U.S. Primary infection of
15 HSV-1 usually occurs between the ages of one and four. Cold sores, the visible symptom, typically appear at a later age, with 20-45% of the population over the age of fifteen affected (Whitley, Clin. Infect. Dis., 26:541-555, 1998).

Genital herpes (HSV-2) is the second most common sexually transmitted disease, with approximately 22% of the U.S population infected with this virus (Fleming 1997).

20 VZV is the causative agent of chicken pox upon primary infection and can recur in adults as zoster.

EBV results in approximately two million cases of infectious mononucleosis in the U.S. each year. It can also cause lymphomas in immunocompromised patients and has been associated with Burkitt's lymphoma, nasopharyngeal carcinoma, and Hodgkins disease.

25 Infection with HCMV often occurs during childhood and is typically asymptomatic except in immunocompromised patients where it causes significant morbidity and mortality.

HHV-6 is the causative agent of roseola and may be associated with multiple sclerosis and chronic fatigue syndrome. HHV-7 disease association is unclear, but it may
30 be involved in some cases of roseola. HHV-8 has been associated with Kaposi's sarcoma, body cavity based lymphomas, and multiple myeloma.

These viruses are capable of residing in a latent state within the host. Reactivation of latent virus results from response to environmental stimuli (ex. UV exposure, stress,

etc.). Infections or recurrence can be life threatening in immunocompromised patients such as AIDS or transplant patients where HCMV can result in retinitis, pneumonia, and gastrointestinal disease.

The increased immunocompromised population has created an unmet medical need for antivirals against herpesviruses because current therapies do not have a sufficiently broad spectrum against this family of viruses and/or they have limited utility due to toxicity. The present invention provides a method for selectively inhibiting herpesviruses DNA polymerase with compounds that have broad spectrum activity. The method offers a distinct advantage in the treatment of patients in need, particularly immunocompromised patients at risk of infection or reactivation by many members of the herpesvirus family.

SUMMARY OF THE INVENTION

The present invention provides a method of selecting compounds that inhibit herpes viruses comprising:

- a) measuring IC_{50} of a compound of interest that inhibits a wild type herpes virus,
- b) measuring IC_{50} of the same compound that inhibits a binding domain mutant herpes virus which is the same strain of the wild type herpes virus,
- c) comparing IC_{50} of step a with IC_{50} of step b; and
- d) selecting the compound of interest wherein the IC_{50} of step b is at least 3 times greater than the IC_{50} of step a.

In above method, the order of step a and step b are interchangeable.

The present invention further provides a method of selecting compounds that inhibit herpes viruses comprising:

- a) measuring IC_{50} of a compound of interest that inhibits a wild type HSV-1,
- b) measuring IC_{50} of the same compound that inhibits a binding domain mutant HSV-1 which is the same strain of the wild type herpes virus,
- c) comparing IC_{50} of step a with IC_{50} of step b; and
- d) selecting the compound of interest wherein the IC_{50} of step b is at least 3 times greater than the IC_{50} of step a.

In above method, the order of step a and step b are interchangeable.

The present invention further provides a method of selecting compounds that inhibit herpes viruses comprising:

- a) measuring IC_{50} of a compound of interest that inhibits a wild type HSV-2,

- b) measuring IC_{50} of the same compound that inhibits a binding domain mutant HSV-2 which is the same strain of the wild type herpes virus,
c) comparing IC_{50} of step a with IC_{50} of step b; and
d) selecting the compound of interest wherein the IC_{50} of step b is at least 3 times greater than the IC_{50} of step a.

In above method, the order of step a and step b are interchangeable.

The present invention further provides a method of selecting compounds that inhibit herpes viruses comprising:

- a) measuring IC_{50} of a compound of interest that inhibits a wild type HCMV,
b) measuring IC_{50} of the same compound that inhibits a binding domain mutant HCMV which is the same strain of the wild type herpes virus,
c) comparing IC_{50} of step a with IC_{50} of step b; and
d) selecting the compound of interest wherein the IC_{50} of step b is at least 3 times greater than the IC_{50} of step a.

In above method, the order of step a and step b are interchangeable.

The present invention further provides a method for selectively treating diseases caused by herpes viruses in a human host comprising administering a compound to a human in need of such treatment wherein said compound inhibits herpes viruses by interaction with the binding domain in the viral DNA polymerase.

The present invention further provides method for selectively inhibiting herpes viruses in a human host comprising administering a compound to a human in need of such treatment wherein IC_{50} of the compound that inhibits a binding domain mutant herpes virus is at least 3 times greater than IC_{50} of the compound that inhibits a wild type herpes virus which is the same strain as the mutant herpes virus.

The present invention further provides a compound for treating herpesviral infections in a human host wherein IC_{50} of the compound that inhibits a binding domain mutant herpes virus is at least 5 times greater than IC_{50} of the compound that inhibits a wild type herpes virus which is the same strain as the mutant herpes virus.

The present invention further provides a compound for treating herpesviral infections in a human host wherein said compound inhibits the herpesvirus by interacting with the binding domain in the viral DNA polymerase.

The present invention further provides a compound for the inhibiting of herpesvirus DNA polymerases wherein serial passage of a wild type herpes virus in the presence of said

compound results in a change of the wild type HSV-1 polymerase at amino acid 823 from valine to alanine.

The present invention further provides a compound for inhibiting herpesvirus DNA polymerases wherein serial passage of a wild type herpes virus in the presence of said
5 compound results a change of the wild type HCMV polymerase at amino acid 823 from valine to alanine and at amino acid 824 from valine to leucine.

The present invention further provides a mutant herpesvirus DNA molecule having a nucleotide sequence selected from a group consisting of SEQ.ID.NO. 1; SEQ.ID.NO. 3; SEQ.ID.NO. 5; SEQ.ID.NO. 7; SEQ.ID.NO. 9; and SEQ.ID.NO. 11.

10 The present invention further provides a mutant herpesvirus polymerase amino acid molecule having an amino acid sequence selected from a group consisting of SEQ.ID.NO. 2; SEQ.ID.NO. 4; SEQ.ID.NO. 6; SEQ.ID.NO. 8; SEQ.ID.NO. 10 and SEQ.ID.NO. 12.

BRIEF DESCRIPTION OF THE DRAWINGS

15 Figure 1 – examples of 4-oxo-DHQ and 4-oxo-DHTP compounds.

Figure 2 – Herpesvirus' polymerases amino acid conserved region.

Figure 3 – Recovered virus after serial passage of HSV-1 in presence of 20 μ M of compound No. 17.

Figure 4 – Comparison of Wild HSV-1 and HSV-2 herpesvirus DNA polymerase
20 amino acid sequences aligned by amino acid homology. (Seq. No: 14-19)

Figure 5 – Mutant Herpes Virus DNA and amino acid sequence list. (Seq. No: 1-12)

Figure 6 – Wild HCMV herpesvirus DNA polymerases amino acid sequence. (Seq. No 13)

25 DETAILED DESCRIPTION OF THE INVENTION


A key enzyme in the replication of all herpesviruses is the virus-coded DNA polymerase. Most of the currently available anti-herpes drugs target the viral DNA polymerase. Drugs such as Foscarnet acts by direct inhibition of the viral polymerase. These drugs are non-nucleoside inhibitors of herpesvirus DNA polymerases. Others such as the
30 nucleoside analogs, Acyclovir, Penciclovir and Ganciclovir must first be phosphorylated to the monophosphate forms by virus encoded kinases and, further phosphorylated to triphosphate by cellular enzymes before they are active inhibitors. The triphosphate forms of these nucleoside analogs inhibit polymerases by competing with the binding of natural

triphosphates and their subsequent insertion into growing DNA strands. These drugs are known as nucleoside inhibitors of herpesvirus DNA polymerases.

One of the limitations of the currently available drugs is that they are active against only a few of the eight human herpesviruses. For example, Acyclovir and Penciclovir inhibit HSV and VZV replication but have poor activity against CMV.

In order to identify antiviral compounds that would have the potential to inhibit replication of most of the human herpesviruses, compounds are *in vitro* screened for inhibitors of herpesvirus DNA polymerase activity. Because portions of the amino acid sequence of the polymerases are highly conserved within the herpesvirus family it is possible to discover small molecules that inhibit herpesvirus polymerases but not cellular DNA polymerases. Using this biochemical approach, several new classes of compounds such as the 4-hydroxyquinoline derivatives (4-HQ), 4-oxo-dihydroquinoline derivatives (4-oxo-DHQ) and 4-oxo-dihydrothienopyridine derivatives (4-oxo-DHTP) were discovered as potent, non-nucleoside herpesvirus DNA polymerase inhibitors. *In vitro* polymerase assays and/or *in vivo* cell culture assays have demonstrated that these compounds inhibit HSV-1, HSV-2, HCMV, VZV, EBV, and HHV-8 replication.

4-Oxo-DHQ and 4-oxo-DHTP are derivatives of formula I



I

wherein ring A is a saturated or unsaturated fused double or triple heterocyclic ring having 1, 2, 3 or 4 heteroatoms selected from group consisting of oxygen, sulfur, or nitrogen; and wherein R and X are the appropriated substitutents, respectively.

Examples of 4-HQ compounds, 4-oxo-DHQ compounds and 4-oxo-DHTP compounds are illustrated in Figure 1.

Antiviral activity of these examples are shown in Table 1 below. As shown in Table 1, these compounds inhibit HSV-1 and HSV-2 as well or better than the current commercially available drug Acyclovir.

Table 1
Antiviral Activity of 4-oxo DHQ/4-oxo DTHP Against HSV-1 and HSV-2

| virus | Compound IC ₅₀ (uM) | | | | | ACV |
|--------------|--------------------------------|-----|-----|-----|-----|-----|
| | 1 | 2 | 3 | 4 | 5 | |
| HSV-1 KOS | 2.0 | 3.8 | 3.2 | 3.2 | 3.3 | 3.6 |
| HSV-1 F | 2.5 | 2.3 | 2.2 | 2.1 | 2.6 | 1.3 |
| HSV-1 DJL | 2.5 | 2.6 | 1.8 | 2.2 | 2.7 | 1.8 |
| HSV-1 Patton | ND | 5.3 | 7.7 | 4.3 | 10 | 9.3 |
| HSV-2 MS | 2.0 | 2.5 | 2.8 | 2.5 | 2.5 | 10 |
| HSV-2 35D | ND | 5.4 | 5.0 | 3.2 | 8.1 | 6.0 |
| HSV-2 186 | 2.0 | 2.3 | 3.2 | 2.3 | 4.2 | >10 |

5 It has also been discovered that point mutations within the HSV-1 polymerase gene that confer resistance to Acyclovir and other nucleoside analogs do not result in resistance to the 4-HQ, 4-oxo-DHQs or 4-oxo-DHTPs. Serial passage of wild type HSV-1 in the presence of 4-oxo-DHQ results in the isolation of mutants that are highly resistant (>20 fold increase in the IC₅₀) to these compounds while retaining sensitivity to nucleoside inhibitors
 10 such as Acyclovir.

In order to determine the mechanism of action of 4-HQ, 4-oxo-DHQ and 4-oxo-DHTP compounds against herpes viruses, mutants resistant to these compounds are isolated by serial passage of the virus in the presence of a 4-oxo-DHQ compound. Sequencing analysis of HSV-1 and HSV-2 strains resistant to the 4-oxo-DHQ identifies that HSV-1
 15 (KOS strain) polymerase protein and its homologous HSV-2 have a conserved region (a binding domain), which is a critical contact point for these compounds. While amino acid numbering of the DNA polymerase may vary between strains of HSV-1 and HSV-2, this binding domain encompassing the HSV-1 (KOS) strain amino acid 823 is highly conserved in herpesviruses and can be identified by alligning the homologous amino acids of this
 20 domain as shown in Fig 2.

In HSV-1 and HSV-2 strains resistant to the 4-oxo-DHQ and similar compounds, a change of valine to an alanine at the binding domain provides full resistance.

In the HSV-1 DNA polymerase, resistance is also found when a valine changes to methionine at amino acid 823 but only when accompanied by a second amino acid change.

25 Isolation of HCMV resistant to 4-oxo-DHQ's is found to be very difficult. Comparison of the amino acid sequence of the HSV polymerase (Y-G-F-T-G-V-Q-H-G) and HCMV polymerase (Y-G-F-T-G-V-V-N-G) in the region of amino acid 823 (underlined amino acid) shows that there is a second valine at position 824 in the HCMV

polymerase. In vitro assay using mutant HCMV polymerases demonstrates that full resistance to the 4-oxo-DHQs requires changes at both amino acids 823 (a valine to alanine) and 824 (a valine to leucine). A HCMV polymerase gene containing V823A and V824L mutations is used in marker rescue experiments to generate a viral mutant. This mutant has an IC₅₀ approximately 7-fold above that of wild-type HCMV.

The HSV-1, HSV-2 and HCMV mutants are also found to be resistant to other non-nucleoside inhibitors such as the 4-oxo-DHTP and similar compounds. However, when the binding domain mutants (e. g. HSV-1 V823A, HSV-2-MS V826A, HSV-2-186 V828A, and HCMV V823A/V824L mutants) are tested in plaque reduction assays against a series of nucleoside polymerase inhibitors and the non-nucleoside inhibitor such as Foscarnet, replication of the mutants is found to be inhibited by all of the currently marketed anti-herpes polymerase inhibitors tested.

These studies demonstrate that certain non-nucleosides like 4-HQ, 4-oxo-DHQ and 4-oxo-DHTP compounds bind to a different site on the herpes polymerase than the nucleoside inhibitors and Foscarnet. The valine at the binding domain is conserved in the DNA polymerases of six of the eight human herpesviruses and several animal herpesviruses, and appears to play a critical role in the antiviral activity of the 4-HQ, 4-oxo-DHQ and 4-oxo-DHTP compounds. (See Figure 2)

Since mutation at the binding domain negates these non-nucleoside inhibitors' activities, compounds could be tested against wild type polymerases and the mutant polymerases to establish the probability of similar binding. We refer to this property of compounds as interaction with the binding domain. Since compounds that interact with the binding domain have exhibited broad-spectrum activity against herpesviruses, this invention provides a method for selecting compounds to treat individuals such as immunocompromised patients who are afflicted with multiple herpesvirus infections.

Definitions

The term " wild-type" refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source. A wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designated the "normal" or " wild-type" form of the gene.

In contrast, the term "mutant" refers to a gene or gene product which displays modifications in sequence and or functional properties (i.e., altered characteristics) when

compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.

IC₅₀ refers to concentration of a drug that inhibits virus growth by 50%.

5 Wild type HSV-1 and HSV-2 strains are listed in Figure 4.

Wild type HCMV is listed in SEQ. ID. NO.13.

The term "Iudr" refers to antiviral drug Iododeoxyuridine.

The term "Bvdu" refers to antiviral drug Bromovinyldeoxyuridine.

The term "ACV" refers to antiviral drug Acyclovir.

10 The term "AraC" refers to antiviral drug Arabinosylcytidine.

The term "AraT" refers to antiviral drug Arabinosylthymine.

The term "AraA" refers to antiviral drug Arabinosyladenine.

The term "GCV" refers to antiviral drug Ganciclovir.

The term "CDV" refers to antiviral drug Cidofovir.

15 The term "PFA" refers to antiviral drug Foscarnet.

The term "binding domain" refers to a conserved region in herpesvirus DNA polymerases. The herpesvirus DNA polymerases have seven (7) conserved regions. The binding domain is within the third conserved region (see Figure 2). When the binding domain contacts with an inhibitor, at least one amino acid in the binding domain mutates and provides the resistance. In general, the binding domain is at an amino acid sequence position 818-829 of the HSV-1 DNA polymerase or the homologous region in other herpes virus DNA polymerases (see Figure 2).

The term "a binding domain mutant herpes virus" refers to a herpes virus containing a binding domain mutation.

25 More specifically, the binding domain in HSV-1 strains, KOS, F, DJL and Patton are at amino acid sequence position 823. The binding domain in HSV-2 MS-M1 strain is at amino acid sequence position 826. The binding domain in HSV-2 186 strain is at amino acid sequence position 828. The binding domain in HCMV AD 169 strains is at amino acid sequence position 823-824.

30 The term "XxxxY" refers to an amino acid sequence position xxx, a single amino acid X in wild type is changed to an amino acid Y.

For example, the term "V823A" refers to an amino acid sequence position 823, a Valine found in wild type is changed to alanine in mutant strain.

The term "V824L" refers to an amino acid sequence position 824, a Valine found in wild type is changed to Leucine in mutant strain.

The term "V826A" refers to an amino acid sequence position 826, a Valine found in wild type is change to alanine in mutant strain.

- 5 The term "V828A" refers to an amino acid sequence position 828, a Valine found in wild type is change to alanine in mutant strain.

A table of amino acids and their representative abbreviations, symbols and codons is set forth below in the following Table.

10

| Amino acid | Abbrev. | Symbol | Codon(s) | | | | | |
|---------------|---------|--------|----------|-----|-----|-----|-----|-----|
| Alanine | Ala | A | GCA | GCC | GCG | GCU | | |
| Cysteine | Cys | C | UGC | UGU | | | | |
| Aspartic acid | Asp | D | GAC | GAU | | | | |
| Glutamic acid | Glu | E | GAA | GAG | | | | |
| Phenylalanine | Phe | F | UUC | UUU | | | | |
| Glycine | Gly | G | GGA | GGC | GGG | GGU | | |
| Histidine | His | H | CAC | CAU | | | | |
| Isoleucine | Ile | I | AUA | AUC | AUU | | | |
| Lysine | Lys | K | AAA | AAG | | | | |
| Leucine | Leu | L | UUA | UUG | CUA | CUC | CUG | CUU |
| Methionine | Met | M | AUG | | | | | |
| Asparagine | Asn | N | AAC | AAU | | | | |
| Proline | Pro | P | CCA | CCC | CCG | CCU | | |
| Glutamine | Gln | Q | CAA | CAG | | | | |
| Arginine | Arg | R | AGA | AGG | CGA | CGC | CGG | CGU |
| Serine | Ser | S | AGC | AGU | UCA | UCC | UCG | UCU |
| Threonine | Thr | T | ACA | ACC | ACG | ACU | | |
| Valine | Val | V | GUA | GUC | GUG | GUU | | |
| Tryptophan | Trp | W | UGG | | | | | |
| Tyrosine | Tyr | Y | UAC | UAU | | | | |

MATERIALS AND METHODS

Cell and Viruses

- African green monkey kidney cells (Vero) and human foreskin fibroblast cells (HFF) and herpes viruses can be obtained from the American Type Culture Collection (ATCC). Media is defined as Dulbecco's modified Eagle media (DMEM) containing 10% fetal bovine serum (FBS) and supplemented with antibiotics. Cells are maintained in media at 37°C in a humidified atmosphere of 5% CO². HSV-1 strains F, Patton and DJL, HSV-2 strains MS, 35D and 186, and HCMV strain AD169 are used in these studies. Strain DJL is a clinical isolate of HSV-1 isolated in our lab from a primary oral lesion.
- 15
- 20

Measuring IC₅₀ of a Compound of Interest That Inhibits Herpes Viruses

Preparation of Virus Stocks: HSV-1 and HSV-2 stocks are grown in Vero cells. HCMV stocks are grown in HFF cells. Approximately 1 ml of media containing sufficient virus to infect approximately 0.1% to 1% of the cells (multiplicity of infection of 0.001 to 0.01 PFU/cell) is added to a T-150 cell culture flask containing a confluent monolayer of cells. The cells are incubated at 37°C for approximately 1 hour. Approximately 50 ml of media is then added to the flask and the cells are incubated at 37°C until viral cytopathic effect (cpe) is apparent in 100% of the cells. The flask is then placed at -80°C for at least 30 min. The flask containing frozen media and cells is placed in a 37°C water bath until the media is thawed. This process disrupts the cells and releases virus into the media. 1 ml aliquots of media containing virus are dispensed into tubes and stored at -80°C. These aliquots of media containing virus are referred to as virus stocks.

Titration Virus Stocks: Aliquots of virus are thawed at 37°C and serially diluted (10 fold dilutions) in media. 0.1 ml of each dilution of virus is placed in a single well of 24-well cell culture dish containing a confluent monolayer of cells (Vero cells for HSV-1 and HSV-2, HFF cells for HCMV) and incubated at 37°C for 1 h. The virus inoculum is then removed and 1 ml of media containing 0.8% carboxymethylcellulose (CMC) is added to each well of the dish. The dish is incubated at 37°C for approximately 2-3 days (HSV-1 and HSV-2) or 6-9 days (HCMV) to allow sufficient growth of virus to form plaques in the cell monolayer. Plaques can be observed and counted microscopically or by staining the cells with 0.1% crystal violet in 20% ethanol. The virus titer which is expressed as plaque forming units (PFU) per ml is obtained by counting the plaques in a well and correcting for the dilution of the viral inoculum.

Plaque Reduction Assays: Antiviral activity of compounds against herpesviruses such as HSV-1, HSV-2, or HCMV can be measured using plaque reduction assays. 0.1 ml of media containing approximately 50 PFU of virus is added to each well of a 24-well cell culture dish containing a confluent monolayer of cells (Vero cells for HSV-1 and HSV-2, HFF cells for HCMV). Compounds are dissolved in 100% DMSO and diluted in 100% DMSO as 200x stocks of the desired final drug concentration. Typically 5-6 two-fold dilutions are prepared for each compound. Dilutions of compounds are then added to media containing 0.8% CMC resulting in a final 1x drug concentration. After the virus-infected cells have incubated for 1 h at 37°C, the virus inoculum is removed and 1 ml of media containing 0.8% CMC and the various concentrations of compound is added to each well of the dish.

The dish is incubated at 37°C for approximately 2-3 days (HSV-1 and HSV-2) or 6-9 days (HCMV) to allow sufficient growth of virus to form plaques in the cell monolayer. Plaques can be observed and counted microscopically or by staining the cells with 0.1% crystal violet in 20% ethanol. Virus inhibition is determined for each drug concentration by comparing the number of plaques in drug-containing wells to control wells that did not contain drug. Antiviral activity of a compound is expressed as the concentration of compound predicted to reduce the number of plaques in a well by 50% (IC₅₀). The IC₅₀ values are calculated by plotting the per cent inhibition vs. concentration of compound using EXCEL software for linear regression.

10

Selection of 4-oxo-DHQ resistant HSV-1 and HSV-2

Vero cells are plated out at a density of 3.5×10^5 cells per well in a six well tissue culture plate. Cells are infected with HSV-1 KOS at a multiplicity of infection (moi) of 0.1 pfu/cell and 1 h post infection the cells are overlayed with 3 ml media containing 20 uM of a 4-oxo-DHQ. Cultures are incubated for 20 h at 37°C, freeze/thawed to release cell-associated virus, and 0.1 ml of culture is used to infect a new monolayer of Vero cells (one passage). Serial passage is repeated seven times in the presence of 20 uM drug. Virus isolates are then plaque purified three times prior to preparation of stocks. Virus recovered from each passage in the presence of compound No. 17 is shown in **Figure 3**. 4-oxo-DHQ resistant HSV-1 and HSV-2 may also be selected by the marker transfer method described below using wild-type HSV DNA and the corresponding mutant HSV polymerase gene.

15
20

Marker Transfer of a HCMV Mutation

A plasmid containing the wild-type HCMV polymerase gene is modified to contain the V823A or V823A and V824L mutations using a site-directed mutagenesis Kit (Stratagene Corp.) and following the manufactures's protocol. HFF cells are plated into T25 tissue culture flasks to achieve 80% confluency at the time of the transfection. Wild type HCMV AD169 DNA and plasmid DNA containing the mutant HCMV polymerase gene are mixed at a ratio of 1:2 (2ug of viral DNA to 4 ug of plasmid DNA). DNA's are transfected using superfect transfection reagent according to methods recommended by the manufacturer (Quiagen Inc.). Cells are harvested five days posttransfection, freeze-thawed to release virus and half of the sample is used to infect HFF cell monolayers. Cells are overlayed with media containing 20 uM 4-oxo-DHQ compound 2 (see Figure 1). Serial

25
30

passage is repeated seven times in the presence of 20 uM compound 2 and virus isolates are then plaque purified three times prior to preparation of viral stock.

Isolation of HSV and HCMV viral DNA

5 HSV DNA is purified from the cytoplasm of infected Vero cells. Vero cells (50 % confluent) are infected at an multiplicity of 0.01 PFU/cell. At 3-5 days postinfection infected cells (100% cpe) are harvested by centrifugation at 1000 rpm in a Beckman GS-6R centrifuge. The pelleted cells are resuspended in TE buffer and placed on ice for 15 minutes. NP-40 is then added to a final concentration of 0.2% and incubated on ice for a
10 further 15 minutes. The cells are centrifuged at 2000 rpm for 10 minutes in a Beckman GS-6R centrifuge. The supernatant is removed and EDTA is added to a final concentration of 20 mM followed by the addition of SDS to a final concentration of 0.3% and proteinase K to a concentration of 50 ug/ml then incubated at 45C for 2 hours. HCMV DNA is isolated by infecting HFF cells (25% confluency) with HCMV at an multiplicity of 0.1 PFU/cell.
15 Cells and media are harvested 5-7 days postinfection (100% cpe) and subjected to low speed centrifugation to remove intact cells and cell debris followed by a high speed spin to pellet virus particles (2500 rpm's in a Beckman SW28 rotor for 1 hour). Following incubation of the HSV and HCMV samples, 1.5 volumes of saturated NaI is added to the digested extract and the refractive index is adjusted to 1.434 -1.435. Ethidium bromide is
20 added to a final concentration of 50 ug/ml. The samples are loaded into a VTI 50centrifuge tube and spun for 24 hours at 45,000 rpm. The DNA band is harvested extracted three times with n-butanol, then dialyzed against TE buffer followed by a dialysis against 95% ethanol and a final dialysis against TE buffer.

25 DNA Sequencing

HSV-1, HSV-2 or HCMV viral DNA's are sequenced directly using an ABI377 fluorescence sequencer (Perkin Elmer Applied Biosystems, Foster City, CA) and the ABI BigDye PRISMTM dRhodamine Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq FSTM DNA polymerase (PE Applied Biosystems). Each cycle sequencing
30 reaction contained about 1.0 ug of purified viral DNA. Cycle-sequencing is performed using an initial denaturation at 98°C for 1 min, followed by 50 cycles: 98°C for 30 sec, annealing at 50°C for 30 sec, and extension at 60°C for 4 min. Temperature cycles and times are controlled by a Perkin-Elmer 9700 thermocycler. Extension products are

purified using Centriflex™ gel filtration cartridges (Edge BioSystems, Gaithersburg, MD). Each reaction product is loaded by pipette onto the column, which is then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B table top centrifuge) at 750 x g for 1.5 min at room temperature. Column-purified samples are dried under vacuum for about 40 min and then dissolved in 4 ul of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples are then heated to 90°C for two min, and held at 4°C until loading. 1.5 ul of each sample is loaded into a single well of the ABI377 sequencer. Sequence chromatogram data files from the ABI377 are analyzed with the computer program Sequencher (Gene Codes, Ann Arbor, MI), for assembly of sequence fragments and correction of ambiguous base calls. Generally sequence reads of 600-700 bp are obtained. Potential sequencing errors are minimized by obtaining sequence information from both DNA strands and by re-sequencing difficult areas using primers at different locations until all sequencing ambiguities are removed.

The entire coding region of the polymerase genes from both the parent strains and the resistant viruses are sequenced. The DNA sequencing is done using viral DNA as the template thus avoiding cloning of the polymerase genes. The amino acid sequence of the DNA polymerases of HSV-1 KOS, F, Patton and DJL and HSV-2 MS and 186 are compared in Figure 4. Amino acids that are identical for the six polymerases are shaded in black while regions where amino acid differences are found are shaded in gray. The amino acid sequence of the four HSV-1 polymerases are essentially identical with only a few minor changes noted between the different HSV-1 strains. The majority of amino acid changes are found when the sequences of the HSV-1 and HSV-2 polymerases are compared.

Isolation and Characterization of HSV-1 and HSV-2 Mutants That Are Resistant To the 4-oxo-DHQ's and 4-oxo-DHTP Compounds

A panel of viruses consisting of four strains of HSV-1 (KOS, F, DJL, Patton) and three strains of HSV-2 (MS, 35D, 186) are tested in a plaque reduction assay against four different 4-oxo-DHQ compounds (# 1, 2, 4, 5 as shown in Figure 1), and one 4-oxo-DHTP compound (# 3 as shown in Figure 1) and against Acyclovir. The six drugs inhibited replication of the seven virus strains with IC₅₀ values ranging from 2-10 µM (Table 1). In order to select for 4-oxo-DHQ resistant mutants, HSV-1 strains KOS, F, and DJL along with HSV-2 strains 186 and MS are serially passaged in the presence of 20 µM compound

1. Following the seventh passage, 4-oxo-DHQ resistant virus from each strain are plaque purified three times and high-titer stocks are made. All of the resistant HSV mutants grew to high titers in Vero cells, indicating that the mutations in the resistant isolates did not significantly impair their growth. The mutants selected with 4-oxo-DHQ compound 1 exhibited >10 fold increase in IC₅₀ when tested in a plaque reduction assay against 4-oxo-DHQ compound 1. Data are shown in Table 2.

Table 2

4-oxo-DHQ Resistant Virus of HSV-1 and HSV-2

| Virus Mutants | Compound 1 IC₅₀ (uM) | Amino Acid Change in HSV DNA Polymerase |
|----------------------|--|--|
| HSV-1 Kos-M1 | >20 | - V823A |
| HSV-1 F-M1 | >20 | - V823A |
| HSV-1 DJL-M1 | >20 | -V823A |
| HSV-2 MS-M1 | >20 | - V826A |
| HSV-2 186-M1 | >20 | - V828A |

- *HSV-1 and HSV-2 isolates grown in the presence of 4-oxo-DHQ select for resistant virus.

DNA sequence analysis of the 4-oxo-DHQ resistant mutants (HSV-1 KOS-M1, HSV-1 F-M1, HSV-1 DJL-M1, HSV-2 186-M1, HSV-2 MS-M1) demonstrated that all five mutants contained a single point mutation of T to C at the binding domain resulting in a Valine to Alanine amino acid change.

Isolation and Characterization of A HCMV Mutant That Is Resistant to The 4-oxo-DHQ's and 4-oxo-DHTP Compounds

- In order to select for a 4-oxo-DHQ HCMV resistant mutant, virus (strain AD169) is serially passaged in the presence of 20 uM a 4-oxo-DHQ. Although we could readily select for HSV mutants using this procedure we failed to isolate an HCMV mutant, even when the virus is passaged at low drug concentrations (<5 uM). Comparison of the amino acid sequence of the HSV polymerase, Y-G-F-T-G-V-Q-H-G, and HCMV polymerase, Y-G-F-T-G-V-V-N-G, in the region of amino acid 823 (underlined amino acid) showed that there is a second valine at position 824 in the HCMV polymerase. In order to determine if both valines need to be changed in order to confer resistance to the 4-oxo-DHQ's, *in vitro* polymerase assays are done using mutant HCMV polymerases containing either V823A or V823A plus V824L (Table 3).

Table 3
HCMV Mutant Polymerase Exhibits Resistance to 4-oxo-DHQ*

| Polymerase | Compound 1 IC ₅₀ (uM) |
|------------------|----------------------------------|
| HCMV (wild) | 4.6 |
| HCMV V823A | 17.2 |
| HCMV V823A/V824L | 42.9 |

*Generation of the valine to alanine at amino acid 823 of HCMV results in a 3.5-fold increase in resistance.

*Mutation of the amino acid from valine to alanine and amino acid 824 from valine to leucine results in an 9-fold increase in resistance, relative to wild type.

The V823A alone resulted in a 3.5-fold increase in the IC₅₀ while the polymerase with the double amino acid change had nearly 10-fold increase in the IC₅₀. In order to isolate an HCMV resistant mutant marker rescue experiments are done. Plasmids containing the mutant polymerase genes are transfected into HFF cells along with wild type HCMV AD169 DNA. The resulting virus is then serially passaged in the presence of 20 uM compound 1 (see figure 1). A 4-oxo-DHQ resistant virus is isolated from marker rescue studies done with the HCMV polymerase gene containing mutations that result in the V823A, V824L amino acid changes, but not with the gene containing V823A change alone. The mutant selected with compound 1 (HCMV AD169-M1) exhibited ~7-fold increase in IC₅₀ when tested in a plaque reduction assay compared to Ganciclovir and cidofovir which has a \leq 2-fold change in sensitivity (Table 4).

Table 4
Plaque reduction assay of 4-oxo-DHQ resistant HCMV*

| Drug | HCMV AD169 IC ₅₀ (uM) | HCMV AD169 – M1 IC ₅₀ (uM) |
|-------------|-------------------------------------|--|
| Compound 1 | 0.7 | 4.7 |
| Ganciclovir | 0.9 | 1.0 |
| Cidofovir | 0.3 | 0.6 |

*Recombination of wild-type HCMV with a polymerase gene containing the valine to alanine at amino acid 823 and the valine to leucine at amino acid 824 allowed for selection of resistant virus with about 7-fold less sensitivity to compound 1.

*Sensitivity of resistant HCMV virus to Ganciclovir and Cidofovir verifies that the 4-oxo-DHQ's mechanism for inhibiting the polymerase protein is unique

The entire coding region of the HCMV polymerase genes from both the parent strain and the resistant virus are sequenced. The DNA sequencing is again done using viral DNA as the template thus avoiding cloning of the polymerase genes. Comparison of the DNA sequence of the two polymerase genes demonstrated that the resistant mutant
5 contained two point mutations that resulted in the predicted V823A, V824L amino acid changes. As with the HSV resistant viruses these results demonstrate the critical role of the region encompassing amino acid 823 for inhibition of polymerase activity by these compounds.

10 **Antiviral Activity of Nucleoside and Non-Nucleoside Polymerase Inhibitors Against 4-oxo-DHQ Resistant Mutants**

In order to determine if the 4-HQ binding domain mutations alter the sensitivity of the HSV-1, HSV-2 and HCMV mutants to both non-nucleoside (4-oxo-DHQ's) and nucleoside inhibitors (e.g Acyclovir and ganciclovir) several of the mutants are tested in
15 plaque reduction assays against a series of non-nucleoside compounds including Foscarnet (PFA), 4-HQ's 4-oxo-DHQ's and 4-oxo-DHTP's (Table 5). The mutants are also tested against a series of nucleoside inhibitors including acyclovir and ganciclovir (Table 5). The activity of these compounds against the mutants is compared to their activity against the wild type strains that are used to isolate the HSV and HCMV mutants. When tested against
20 a number of 4-HQ's, 4-oxo-DHQ's and 4-oxo-DHTP's and other related classes of compounds all of the drugs are found to inhibit the wild type virus with IC₅₀ values ranging from <0.1 uM to 30 uM. When these drugs are tested against the resistant viruses they are found to have IC₅₀ values 5 to 10 fold higher than the parent virus. There is little if any difference in the IC₅₀ values of the nucleoside compounds and the non-nucleoside PFA
25 between the wild type and mutant HSV-1, HSV-2, and HCMV viruses. These results demonstrate that the amino acid change in the binding domain (V823A in the HSV-1 polymerase, V826A in the HSV2-MS polymerase, V828A in the HSV2-186 polymerase, and the V823A/V824L changes in the HCMV polymerase) resulted in resistance to the 4-oxo-DHQ's and 4-oxo-DHTP's, which provides further evidence that these classes of
30 compounds share an affinity for a region we refer to as the binding domain. In contrast, these amino acid changes did not alter the activity of these viruses to other classes of polymerase inhibitors.

Table 5

Antiviral activity of nucleoside and non-nucleoside polymerase inhibitors
against HSV-1, HSV-2, and HCMV Isolates selected for 4-oxo-DHQ resistance*

| Drug | Plaque Reduction Assay – IC ₅₀ (μM) | | | | | |
|-------|--|----------------|--------------|-----------------|---------------|------------------|
| | HSV-2 MS | HSV-2 MS-M1 | HSV-1 KOS | HSV-1 KOS-M1 | HCMV AD169 | HCMV AD169-M1 |
| 6 | 28.8 | >50 | 24.6 | >50 | 5.1 | >16 |
| 7 | 8.8 | 27.9 | 6.5 | >50 | 0.3 | 3.4 |
| 8 | 2.3 | >50 | 5.1 | >50 | <0.1 | 1.1 |
| 9 | 0.9 | 48.7 | 1.9 | >50 | <0.1 | 3.1 |
| 10 | 29.2 | >50 | 15.8 | >50 | 1.1 | >16 |
| 11 | 3.0 | >50 | 3.1 | >50 | 0.7 | 3.9 |
| 12 | 0.4 | 12.5 | 1.3 | >50 | 0.2 | 1.1 |
| 13 | 5.3 | >50 | 5.5 | <25 | 2.7 | >16 |
| 14 | 1.6 | >50 | 28.4 | >50 | 0.9 | 18.4 |
| 2 | 1.3 | >50 | 3.3 | >50 | 0.4 | 4.0 |
| 4 | 2.1 | 28.4 | 4.2 | >50 | 0.6 | 2.1 |
| 3 | 0.8 | >50 | 4.0 | >50 | 1.5 | 6.2 |
| 15 | 5.9 | >50 | >50 | >50 | 0.7 | 7.7 |
| Iudr | 5.0 | 6.1 | 1.1 | 0.8 | ND | ND |
| Bvdu | 5.8 | 5.9 | 2.1 | 0.1 | ND | ND |
| ACV | 2.4 | 2.8 | 3.9 | 4.4 | ND | ND |
| AraC | 0.2 | 0.1 | 0.2 | 0.2 | ND | ND |
| AraT | 6.6 | 3.6 | 11.6 | 3.6 | ND | ND |
| AraA | 10.6 | 18.2 | 26.1 | 27.2 | ND | ND |
| GCVir | ND | ND | ND | ND | 0.8 | 0.8 |
| CDV | ND | ND | ND | ND | 0.4 | 0.3 |
| PFA | ND | ND | ND | ND | 38 | <20 |

5 *HSV-2 MS, HSV-1 KOS, HCMV AD169: wild type strains

*HSV-2 MS-M1, HSV-1 KOS-M1, HCMV AD169-M1: mutants selected for 4-oxo-DHQ resistance

*ND – Not Done.

Antiviral compounds identified by the present invention can conveniently be
10 administered in a pharmaceutical composition containing the compound in combination
with a suitable excipient, the composition being useful in combating viral infections.
Pharmaceutical compositions containing a compound appropriate for antiviral use are
prepared by methods and contain excipients which are well known in the art. A generally
recognized compendium of such methods and ingredients is Remington's Pharmaceutical
15 Sciences by E.W. Martin (Mark Publ. Co., 15th Ed., 1975).

Antiviral compounds identified by the present invention and their compositions can
be administered parenterally (for example, by intravenous, intraperitoneal or intramuscular

injection), topically, orally, or rectally, depending on whether the preparation is used to treat internal or external viral infections.

For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.

The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.

Antiviral compounds identified by the present invention and their compositions can also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

Pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which

are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

15 Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.

For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers. Thickeners such as synthetic polymers, fatty acids,

fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

5 Examples of useful dermatological compositions which can be used to deliver the compounds of formula I to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

10 Useful dosages of the compounds of formula I can be determined by comparing their *in vitro* activity, and *in vivo* activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.

The compound is conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form. The desired dose may conveniently be presented in
15 a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

For internal infections, the compositions can be administered orally or parenterally
20 at dose levels, calculated as the free base, of about 0.1 to 300 mg/kg, preferably 1.0 to 30 mg/kg of mammal body weight, and can be used in man in a unit dosage form, administered one to four times daily in the amount of 1 to 1000 mg per unit dose.

For parenteral administration or for administration as drops, as for eye infections, the compounds are presented in aqueous solution in a concentration of from about 0.1 to
25 about 10%, more preferably about 0.1 to about 7%. The solution may contain other ingredients, such as emulsifiers, antioxidants or buffers.

Generally, the concentration of the compound(s) of formula I in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder
30 will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.

The exact regimen for administration of the compounds and compositions disclosed herein will necessarily be dependent upon the needs of the individual subject being treated, the type of treatment and, of course, the judgment of the attending practitioner.

The antiviral activity of a compound of the invention can be determined using pharmacological models which are well known to the art, or using Test A described below.

The compounds of formula (I) and pharmaceutically acceptable salts thereof are useful as antiviral agents. Thus, they are useful to combat viral infections in animals,
5 including man. The compounds are generally active against herpes viruses, and are particularly useful against the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus, the human herpes virus type 8 (HHV-8) and the cytomegalovirus (CMV).

10

CLAIMS

We claim:

1. A method of selecting compounds that inhibit herpes viruses comprising:
 - a) measuring IC_{50} of a compound of interest that inhibits a wild type herpes virus,
 - 5 b) measuring IC_{50} of the same compound that inhibits a binding domain mutant herpes virus which is the same strain as the wild type herpes virus,
 - c) comparing IC_{50} of step a with IC_{50} of step b; and
 - d) selecting the compound of interest wherein the IC_{50} of step b is at least 3 times greater than the IC_{50} of step a.
- 10 2. A method of selecting compounds that inhibit herpes viruses comprising:
 - a) measuring IC_{50} of a compound of interest that inhibits a binding domain mutant herpes virus,
 - b) measuring IC_{50} of the same compound that inhibits a wild type herpes virus which is
15 the same strain as the mutant herpes virus,
 - c) comparing IC_{50} of step a with IC_{50} of step b; and
 - d) selecting the compound of interest wherein the IC_{50} of step a is at least 3 times greater than the IC_{50} of step b.
- 20 3. The method of claim 1 or 2 wherein the herpes virus is HSV-1, HSV-2, HCMV, VZV, EBV, or HHV-8.
4. A method of selecting compounds that inhibit herpes viruses comprising:
 - a) measuring IC_{50} of a compound of interest that inhibits a wild type HSV-1,
 - 25 b) measuring IC_{50} of the same compound that inhibits a binding domain mutant HSV-1 which is the same strain as the wild type herpes virus,
 - c) comparing IC_{50} of step a with IC_{50} of step b; and
 - d) selecting the compound of interest wherein the IC_{50} of step b is at least 3 times greater than the IC_{50} of step a.
- 30 5. A method of selecting compounds that inhibit herpes viruses comprising:
 - a) measuring IC_{50} of a compound of interest that inhibits a binding domain mutant HSV-1,

- b) measuring IC_{50} of the same compound that inhibits a wild type herpes virus which is the same strain as the mutant HSV-1,
- c) comparing IC_{50} of step a with IC_{50} of step b; and
- d) selecting the compound of interest wherein the IC_{50} of step a is at least 3 times greater than the IC_{50} of step b.
- 5
6. The method of claim 4 or 5 wherein HSV-1 is HSV-1 KOS, HSV-1 F, HSV-1 DJL or HSV-1 Patton.
- 10 7. The method of claim 5 or 6 wherein the mutation of a wild type herpes virus to mutant herpes virus is at amino acid 823 from valine to alanine.
8. A method of selecting compounds that inhibit herpes viruses comprising:
- a) measuring IC_{50} of a compound of interest that inhibits a wild type HSV-2,
- 15 b) measuring IC_{50} of the same compound that inhibits a binding domain mutant HSV-2 which is the same strain as the wild type herpes virus,
- c) comparing IC_{50} of step a with IC_{50} of step b; and
- d) selecting the compound of interest wherein the IC_{50} of step b is at least 3 times greater than the IC_{50} of step a.
- 20
9. A method of selecting compounds that inhibit herpes viruses comprising:
- a) measuring IC_{50} of a compound of interest that inhibits a binding domain mutant HSV-2,
- b) measuring IC_{50} of the same compound that inhibits a wild type herpes virus which is the same strain as the mutant HSV-2,
- 25 c) comparing IC_{50} of step a with IC_{50} of step b; and
- d) selecting the compound of interest wherein the IC_{50} of step a is at least 3 times greater than the IC_{50} of step b.
- 30 10. The method of claim 8 or 9 wherein HSV-2 is HSV-2 MS, HSV-2 35D, or HSV-2 186.
11. A method of selecting compounds that inhibit herpes viruses comprising:






- a) measuring IC_{50} of a compound of interest that inhibits a wild type HCMV,
 - b) measuring IC_{50} of the same compound that inhibits a binding domain mutant HCMV which is the same strain as the wild type herpes virus,
 - c) comparing IC_{50} of step a with IC_{50} of step b; and
 - 5 d) selecting the compound of interest wherein the IC_{50} of step b is at least 3 times greater than the IC_{50} of step a.
-
12. A method of selecting compounds that inhibit herpes viruses comprising:
 - a) measuring IC_{50} of a compound of interest that inhibits a binding domain mutant
10 HCMV,
 - b) measuring IC_{50} of the same compound that inhibits a wild type herpes virus which is the same strain of the mutant HCMV,
 - c) comparing IC_{50} of step a with IC_{50} of step b; and
 - d) selecting the compound of interest wherein the IC_{50} of step a is at least 3 times
15 greater than the IC_{50} of step b.
 13. The method of claim 8 or 9 wherein HCMV is AD169.
 14. The methods of claims 1, 4, 8, or 11 wherein IC_{50} of step b is at least 5 times greater
20 than the IC_{50} of step a.
 15. The methods of claims 2, 5, 9, or 12 wherein IC_{50} of step a is at least 5 times greater than the IC_{50} of step b.
 - 25 16. A use of compounds for manufacturing of medicinals for selectively treating diseases caused by herpes viruses in a human host comprising administering a compound to a human in need of such treatment wherein said compound inhibits herpes viruses by interaction with the binding domain in the viral DNA polymerase.
 - 30 17. A use of compounds for manufacturing of medicinals for selectively inhibiting herpes viruses in a human host comprising administering a compound to a human in need of such treatment wherein IC_{50} of the compound that inhibits a binding domain

mutant herpes virus is at least 3 times greater than IC_{50} of the compound that inhibits a wild type herpes virus which is the same strain as the mutant herpes virus.


18. The use of claim 17 wherein IC_{50} of the compound that inhibits a binding domain mutant herpes virus is at least 5 times greater than IC_{50} of the compound that inhibits a wild type herpes virus which is the same strain as the mutant herpes virus.
19. The use of claim 17 wherein herpes viruses is HSV-1, HSV-2, HCMV, VZV, EBV, or HHV-8.
20. A use of compounds for manufacturing of medicinals for treating herpesviral infections in a human host wherein IC_{50} of the compound that inhibits a binding domain mutant herpes virus is at least 5 times greater than IC_{50} of the compound that inhibits a wild type herpes virus which is the same strain as the mutant herpes virus.
21. A use of compounds for manufacturing of medicinals for treating herpesviral infections in a human host wherein said compound inhibits the herpesvirus by interacting with the binding domain in the viral DNA polymerase.
22. The herpesviral infection of claim 20 or 21 which is HSV-1, HSV-2, HCMV, VZV, EBV, or HHV-8 infection.
23. A compound for the inhibiting of herpesvirus DNA polymerases wherein passage of a wild type herpes virus in the presence of said compound results a change of the wild type HSV-1 polymerases at amino acid 823 from valine to alanine.
24. A compound for inhibiting herpesvirus DNA polymerases wherein passage of a wild type herpes virus in the presence of said compound results in a change of the wild type HCMV polymerases at amino acid 823 from valine to alanine and at amino acid 824 from valine to leucine.

25. A mutant herpesvirus DNA molecule having a nucleotide sequence selected from a group consisting of SEQ.ID.NO. 1; SEQ.ID.NO. 3; SEQ.ID.NO. 5; SEQ.ID.NO. 7; SEQ.ID.NO. 9; and SEQ.ID.NO. 11.
- 5 26. A mutant herpesvirus polymerase amino acid molecule having an amino acid sequence selected from a group consisting of SEQ.ID.NO. 2; SEQ.ID.NO. 4; SEQ.ID.NO. 6; SEQ.ID.NO. 8; SEQ.ID.NO. 10 and SEQ.ID.NO. 12.


10

Figure 1 4-HQ, 4-oxo-DHQ and 4-oxo-DHTP antiviral compounds


(Figure 1 continue)




Compound No. 6




Compound No. 7



Compound No. 8







Compound No. 9




Compound No. 10


(Figure 1 continue)



(Figure 1 continue)




Compound No.15



Compound 17

Figure 2. The HSV1 (KOS Strain) DNA Polymerase Amino Acid 823 is Critical for Resistance to 4-Hydroxyquinolines and Related Compounds



Schematic of HSV1 polymerase illustrating the conserved regions A and I-VI found in class 2 polymerases. Also shown are the amino acid sequence for the highly conserved herpesvirus domain in region III which surrounds the HSV1 amino acid 823.

Figure 3 Serial Passage of HSV-1 in Presence of 20 μ M compound 17




Figure 4 Comparison of Wild type HSV-1 and HSV-2 DNA Polymerases Amino Acid Sequences Aligned by Amino Acid Homology*

| | | | | | | | |
|----|-------------|------------|------------|------------|------------|------------|------|
| 5 | HSV2-MS | MFCAAGGPTS | PGGKSAARAA | SGFFAPHNPR | GATQTAPPPC | RRQNFYNPHL | -50 |
| | HSV2-186 | MFCAAGGPAS | PGGKSAARAA | SGFFAPHNPR | GATQTAPPPC | RRQNFYNPHL | -50 |
| | HSV1-Kos | MFSGGGGPLS | PGGKSAARAA | SGFFAPAGPR | GAGR.GPPPC | LRQNFYNPYL | -49 |
| | HSV1-Patton | MFSGGGGPLS | PGGKSAARAA | SGFFAPAGPR | GAGR.GPPPC | LRQNFYNPYL | -49 |
| | HSV1-DJL | MFSGGGGPLS | PGGKSAARAA | SGFFAPAGPR | GAGR.GPPPC | LRQNFYNPYL | -49 |
| | HSV1-F | MFSGGGGPLS | PGGKSAARAA | SGFFAPAGPR | GAGR.GPPPC | LRQNFYNPYL | -49 |
| 10 | HSV2-MS | AQTGTQPKAP | GPAQRHTYYS | ECDEFRFIAP | RSLDEDAPAE | QRTGVHDGRL | -100 |
| | HSV2-186 | AQTGTQPKAP | GPAQRHTYYS | ECDEFRFIAP | RSLDEDAPAE | QRTGVHDGRL | -100 |
| | HSV1-Kos | APVGTQQKPT | GPTQRHTYYS | ECDEFRFIAP | RVLDEDAPPE | KRAGVHDGHL | -99 |
| | HSV1-Patton | APVGTQQKPT | GPTQRHTYYS | ECDEFRFIAP | RVLDEDAPPE | KRAGVHDGHL | -99 |
| | HSV1-DJL | APVGTQQKPT | GPTQRHTYYS | ECDEFRFIAP | RVLDEDAPPE | KRAGVHDGHL | -99 |
| | HSV1-F | APVGTQQKPT | GPTQRHTYYS | ECDEFRFIAP | RVLDEDAPPE | KRAGVHDGHL | -99 |
| 20 | HSV2-MS | RRAPKVYCGG | DERDVLRVGP | EGFWPRLRL | WGGADHAPKG | FDPTVTVFHV | -150 |
| | HSV2-186 | RRAPKVYCGG | DERDVLRVGP | EGFWPRLRL | WGGADHAPKG | FDPTVTVFHV | -150 |
| | HSV-Kos | KRAPKVYCGG | DERDVLRVGS | GGFWPRLRL | WGGVDHAPAG | FNPTVTVFHV | -149 |
| | HSV1-Patton | KRAPKVYCGG | DERDVLRVGS | GGFWPRLRL | WGGVDHAPAG | FNPTVTVFHV | -149 |
| | HSV1-DJL | KRAPKVYCGG | DERDVLRVGS | GGFWPRLRL | WGGVDHAPAG | FNPTVTVFHV | -149 |
| | HSV1-F | KRAPKVYCGG | DERDVLRVGS | GGFWPRLRL | WGGVDHAPAG | FNPTVTVFHV | -149 |
| 25 | HSV2-MS | YDILEHVEHA | YSMRAAQLHE | RFMDAITPAG | TVITLLGLTP | EGHRVAVHVV | -200 |
| | HSV2-186 | YDILEHVEHA | YSMRAAQLHE | RFMDAITPAG | TVITLLGLTP | EGHRVAVHVV | -200 |
| | HSV-Kos | YDILENVEHA | YGMRAAQFHA | RFMDAITPTG | TVITLLGLTP | EGHRVAVHVV | -199 |
| | HSV1-Patton | YDILENVEHA | YGMRAAQFHA | RFMDAITPTG | TVITLLGLTP | EGHRVAVHVV | -199 |
| | HSV1-DJL | YDILENVEHA | YGMRAAQFHA | RFMDAITPTG | TVITLLGLTP | EGHRVAVHVV | -199 |
| | HSV1-F | YDILENVEHA | YGMRAAQFHA | RFMDAITPTG | TVITLLGLTP | EGHRVAVHVV | -199 |
| 30 | HSV2-MS | GTRQYFYMNK | AEVDRHLQCR | APRDLCEMLA | AALRESPGAS | FRGISADHFE | -250 |
| | HSV2-186 | GTRQYFYMNK | AEVDRHLQCR | APRDLCEMLA | AALRESPGAS | FRGISADHFE | -250 |
| | HSV-Kos | GTRQYFYMNK | EEVDRHLQCR | APRDLCEMLA | AALRESPGAS | FRGISADHFE | -249 |
| | HSV1-Patton | GTRQYFYMNK | EEVDRHLQCR | APRDLCEMLA | AALRESPGAS | FRGISADHFE | -249 |
| | HSV1-DJL | GTRQYFYMNK | EEVDRHLQCR | APRDLCEMLA | AALRESPGAS | FRGISADHFE | -249 |
| | HSV1-F | GTRQYFYMNK | EEVDRHLQCR | APRDLCEMLA | AALRESPGAS | FRGISADHFE | -249 |
| 40 | HSV2-MS | AEVVERADVY | YYETRPTLYY | RVFVRSGRAL | AYLCDNFPCA | IRKYEGGVDA | -300 |
| | HSV2-186 | AEVVERADVY | YYETRPTLYY | RVFVRSGRAL | AYLCDNFPCA | IRKYEGGVDA | -300 |
| | HSV-Kos | AEVVERTDVY | YYETRPALFY | RVYVRSGRVL | SYLCDNFPCA | IKKYEGGVDA | -299 |
| | HSV1-Patton | AEVVERTDVY | YYETRPALFY | RVYVRSGRVL | SYLCDNFPCA | IKKYEGGVDA | -299 |
| | HSV1-DJL | AEVVERTDVY | YYETRPALFY | RVYVRSGRVL | SYLCDNFPCA | IKKYEGGVDA | -299 |
| | HSV1-F | AEVVERTDVY | YYETRPALFY | RVYVRSGRVL | SYLCDNFPCA | IKKYEGGVDA | -299 |
| 45 | HSV2-MS | TTRFILDNPG | FVTFGWYRLK | PGRGNAPAQ | RPPTAFGTSS | DVEFNCTADN | -350 |
| | HSV2-186 | TTRFILDNPG | FVTFGWYRLK | PGRGNAPAQ | RPPTAFGTSS | DVEFNCTADN | -350 |
| | HSV-Kos | TTRFILDNPG | FVTFGWYRLK | PGRNNTLAQP | RAPMAFGTSS | DVEFNCTADN | -349 |
| | HSV1-Patton | TTRFILDNPG | FVTFGWYRLK | PGRNNTLAQP | RAPMAFGTSS | DVEFNCTADN | -349 |
| | HSV1-DJL | TTRFILDNPG | FVTFGWYRLK | PGRNNTLAQP | RAPMAFGTSS | DVEFNCTADN | -349 |
| | HSV1-F | TTRFILDNPG | FVTFGWYRLK | PGRNNTLAQP | RAPMAFGTSS | DVEFNCTADN | -349 |
| 50 | HSV2-MS | LAVEGAMCDL | PAYKLMCFDI | ECKAGGEDEL | AFPVAERPED | LVIQISCLLY | -400 |
| | HSV2-186 | LAVEGAMCDL | PAYKLMCFDI | ECKAGGEDEL | AFPVAERPED | LVIQISCLLY | -400 |
| | HSV-Kos | LAIEGGMSDL | PAYKLMCFDI | ECKAGGEDEL | AFPVAGHPED | LVIQISCLLY | -399 |
| | HSV1-Patton | LAIEGGMSDL | PAYKLMCFDI | ECKAGGEDEL | AFPVAGHPED | LVIQISCLLY | -399 |
| | HSV1-DJL | LAIEGGMSDL | PAYKLMCFDI | ECKAGGEDEL | AFPVAGHPED | LVIQISCLLY | -399 |
| | HSV1-F | LAIEGGMSDL | PAYKLMCFDI | ECKAGGEDEL | AFPVAGHPED | LVIQISCLLY | -399 |
| 60 | HSV2-MS | DLSTTALEHI | LLFSLGSCDL | PESHLSDLAS | RGLPAPVVLE | FDSEFEMLLA | -450 |
| | HSV2-186 | DLSTTALEHI | LLFSLGSCDL | PESHLSDLAS | RGLPAPVVLE | FDSEFEMLLA | -450 |
| | HSV-Kos | DLSTTALEHV | LLFSLGSCDL | PESHNLNLA | RGLPTPVVLE | FDSEFEMLLA | -449 |
| | HSV1-Patton | DLSTTALEHV | LLFSLGSCDL | PESHNLNLA | RGLPTPVVLE | FDSEFEMLLA | -449 |
| | HSV1-DJL | DLSTTALEHV | LLFSLGSCDL | PESHNLNLA | RGLPTPVVLE | FDSEFEMLLA | -449 |
| | HSV1-F | DLSTTALEHV | LLFSLGSCDL | PESHNLNLA | RGLPTPVVLE | FDSEFEMLLA | -449 |
| 65 | | | | | | | |

| | | | | | | | |
|----|-------------|-------------|-------------|------------|-------------|-------------|------|
| | HSV2-MS | FMTFVKQYGP | EFVTGYNIIN | FDWPFVLTCL | TEIYKVPLDG | YGRMNNGRGVF | -500 |
| | HSV2-186 | FMTFVKQYGP | EFVTGYNIIN | FDWPFVLTCL | TEIYKVPLDG | YGRMNNGRGVF | -500 |
| | HSV-Kos | FMTLVKQYGP | EFVTGYNIIN | FDWPFLLAKL | TDIYKVPLDG | YGRMNNGRGVF | -499 |
| | HSV1-Patton | FMTLVKQYGP | EFVTGYNIIN | FDWPFLLAKL | TDIYKVPLDG | YGRMNNGRGVF | -499 |
| 5 | HSV1-DJL | FMTLVKQYGP | EFVTGYNIIN | FDWPFLLAKL | TDIYKVPLDG | YGRMNNGRGVF | -499 |
| | HSV1-F | FMTLVKQYGP | EFVTGYNIIN | FDWPFLLAKL | TDIYKVPLDG | YGRMNNGRGVF | -499 |
| | HSV2-MS | RVWDIGQSHF | QKRSKIKNVNG | MVNIDMYGII | TDKVKLSSYK | LNVAEAVLK | -550 |
| | HSV2-186 | RVWDIGQSHF | QKRSKIKNVNG | MVNIDMYGII | TDKVKLSSYK | LNVAEAVLK | -550 |
| 10 | HSV-Kos | RVWDIGQSHF | QKRSKIKNVNG | MVNIDMYGII | TDKIKLSSYK | LNVAEAVLK | -549 |
| | HSV1-Patton | RVWDIGQSHF | QKRSKIKNVNG | MVNIDMYGII | TDKIKLSSYK | LNVAEAVLK | -549 |
| | HSV1-DJL | RVWDIGQSHF | QKRSKIKNVNG | MVNIDMYGII | TDKIKLSSYK | LNVAEAVLK | -549 |
| | HSV1-F | RVWDIGQSHF | QKRSKIKNVNG | MVNIDMYGII | TDKIKLSSYK | LNVAEAVLK | -549 |
| | HSV2-MS | DKKKDLSYRD | IPAYYASGPA | QRGVIGEYCV | QDSSLVGQLF | FKFLPHLELS | -600 |
| 15 | HSV2-186 | DKKKDLSYRD | IPAYYASGPA | QRGVIGEYCV | QDSSLVGQLF | FKFLPHLELS | -600 |
| | HSV-Kos | DKKKDLSYRD | IPAYYAAGPA | QRGVIGEYCI | QDSSLVGQLF | FKFLPHLELS | -599 |
| | HSV1-Patton | DKKKDLSYRD | IPAYYAAGPA | QRGVIGEYCI | QDSSLVGQLF | FKFLPHLELS | -599 |
| | HSV1-DJL | DKKKDLSYRD | IPAYYAAGPA | QRGVIGEYCI | QDSSLVGQLF | FKFLPHLELS | -599 |
| 20 | HSV1-F | DKKKDLSYRD | IPAYYAAGPA | QRGVIGEYCI | QDSSLVGQLF | FKFLPHLELS | -599 |
| | HSV2-MS | AVARLAGINI | TRTIYDGQOI | RVFTCLLRLA | GQKGFILPDT | QGRFRGLDKE | -650 |
| | HSV2-186 | AVARLAGINI | TRTIYDGQOI | RVFTCLLRLA | GQKGFILPDT | QGRFRGLDKE | -650 |
| | HSV-Kos | AVARLAGINI | TRTIYDGQOI | RVFTCLLRLA | DQKGFILPDT | QGRFRGAGGE | -649 |
| 25 | HSV1-Patton | AVARLAGINI | TRTIYDGQOI | RVFTCLLRLA | DQKGFILPDT | QGRFRGAGGE | -649 |
| | HSV1-DJL | AVARLAGINI | TRTIYDGQOI | RVFTCLLRLA | DQKGFILPDT | QGRFRGAGGE | -649 |
| | HSV1-F | AVARLAGINI | TRTIYDGQOI | RVFTCLLRLA | DQKGFILPDT | QGRFRGGGGE | -649 |
| | HSV2-MS | APKRPAVPRG | EGERP GDNG | DEKDDDE.. | DEGDERE.E | VARETGGRHV | -697 |
| 30 | HSV2-186 | APKRPAVPRG | EGERP GDNG | DEKDDDEDEG | DEGDERE.E | VARETGGRHV | -697 |
| | HSV-Kos | APKRPAARE | DEERP..... | EEGEDEDER | EEGGGEREPE | GARETAGRHV | -694 |
| | HSV1-Patton | APKRPAARE | DEERP..... | EEGEDEDER | EEGGGEREPE | GARETAGRHV | -694 |
| | HSV1-DJL | APKRPAARE | DEERP..... | EEGEDENER | EEGGGEREPE | GARETAGRHV | -694 |
| | HSV1-F | APKRPAARE | DEERP..... | EEGEDEDER | EEGGGEREPE | GARETAGRHV | -694 |
| 35 | HSV2-MS | GYQGARVLD | TSGFHVDPV | VDFASLYPS | IIQAHNLCFS | TLSLRPEAVA | -747 |
| | HSV2-186 | GYQGARVLD | TSGFHVDPV | VDFASLYPS | IIQAHNLCFS | TLSLRPEAVA | -749 |
| | HSV-Kos | GYQGARVLD | TSGFHVNPV | VDFASLYPS | IIQAHNLCFS | TLSLRADAVA | -744 |
| | HSV1-Patton | GYQGARVLD | ISGFHVNPV | VDFASLYPS | IIQAHNLCFS | TLSLRADAVA | -744 |
| 40 | HSV1-DJL | GYQGARVLD | TSGFHVNPV | VDFASLYPS | IIQAHNLCFS | TLSLRADAVA | -744 |
| | HSV1-F | GYQGARVLD | TSGFHVNPV | VDFASLYPS | IIQAHNLCFS | TLSLRADAVA | -744 |
| | HSV2-MS | HLEADR DYLE | IEVGGRRLFF | VKAHVRESLL | SILLRDWLAM | RKQIRSRIPQ | -797 |
| | HSV2-186 | HLEADR DYLE | IEVGGRRLFF | VKAHVRESLL | SILLRDWLAM | RKQIRSRIPQ | -799 |
| 45 | HSV-Kos | HLEAGKDYLE | IEVGGRRLFF | VKAHVRESLL | SILLRDWLAM | RKQIRSRIPQ | -794 |
| | HSV1-Patton | HLEAGKDYLE | IEVGGRRLFF | VKAHVRESLL | SILLRDWLAM | RKQIRSRIPQ | -794 |
| | HSV1-DJL | HLEAGKDYLE | IEVGGRRLFF | VKAHVRESLL | SILLRDWLAM | RKQIRSRIPQ | -794 |
| | HSV1-F | HLEAGKDYLE | IEVGGRRLFF | VKAHVRESLL | SILLRDWLAM | RKQIRSRIPQ | -794 |
| | HSV2-MS | STPEEAVLLD | KQQAIAKVVC | NSVYGFTGVQ | HGLLPCLHVA | ATVTTIGREM | -847 |
| 50 | HSV2-186 | SPPEEAVLLD | KQQAIAKVVC | NSVYGFTGVQ | HGLLPCLHVA | ATVTTIGREM | -849 |
| | HSV-Kos | SSPEEAVLLD | KQQAIAKVVC | NSVYGFTGVQ | HGLLPCLHVA | ATVTTIGREM | -844 |
| | HSV1-Patton | SSPEEAVLLD | KQQAIAKVVC | NSVYGFTGVQ | HGLLPCLHVA | ATVTTIGREM | -844 |
| | HSV1-DJL | SSPEEAVLLD | KQQAIAKVVC | NSVYGFTGVQ | HGLLPCLHVA | ATVTTIGREM | -844 |
| 55 | HSV1-F | SSPEEAVLLD | KQQAIAKVVC | NSVYGFTGVQ | HGLLPCLHVA | ATVTTIGREM | -844 |
| | HSV2-MS | LLATRAYVHA | RWAEFDQLA | DFPEAAGMRA | PGPYSMRIIY | GDTDSIFVLC | -897 |
| | HSV2-186 | LLATRAYVHA | RWAEFDQLA | DFPEAAGMRA | PGPYSMRIIY | GDTDSIFVLC | -899 |
| | HSV-Kos | LLATREYVHA | RWAAFEQLA | DFPEAADMRA | PGPYSMRIIY | GDTDSIFVLC | -894 |
| 60 | HSV1-Patton | LLATREYVHA | RWAAFEQLA | DFPEAADMRA | PGPYSMRIIY | GDTDSIFVLC | -894 |
| | HSV1-DJL | LLATREYVHA | RWAAFEQLA | DFPEAADMRA | PGPYSMRIIY | GDTDSIFVLC | -894 |
| | HSV1-F | LLATREYVHA | RWAAFEQLA | DFPEAADMRA | PGPYSMRIIY | GDTDSIFVLC | -894 |
| | HSV2-MS | RGLTAAGLVA | MGDKMASHIS | RALFLPPIKL | ECEKTF TKLL | LIAKKKYIGV | -947 |
| 65 | HSV2-186 | RGLTAAGLVA | MGDKMASHIS | RALFLPPIKL | ECEKTF TKLL | LIAKKKYIGV | -949 |
| | HSV-Kos | RGLTAAGLTA | MGDKMASHIS | RALFLPPIKL | ECEKTF TKLL | LIAKKKYIGV | -944 |
| | HSV1-Patton | RGLTAAGLTA | MGDKMASHIS | RALFLPPIKL | ECEKTF TKLL | LIAKKKYIGV | -944 |

| | | | | | | | |
|----|-------------|------------|------------|------------|------------|------------|-------|
| | HSV1-DJL | RGLTAAGLTA | VGDKMASHIS | RALFLPPIKL | ECEKTFTKLL | LIAKKKYIGV | -944 |
| | HSV1-F | RGLTAAGLTA | VGDKMASHIS | RALFLSPIKL | ECEKTFTKLL | LIAKKKYIGV | -944 |
| 5 | HSV2-MS | ICGGKMLIK | VDLVRKNNCA | FINRTSRALV | DLLFYDDTVS | GAAAALAERP | -997 |
| | HSV2-186 | ICGGKMLIK | VDLVRKNNCA | FINRTSRALV | DLLFYDDTVS | GAAAALAERP | -999 |
| | HSV-Kos | IYGGKMLIK | VDLVRKNNCA | FINRTSRALV | DLLFYDDTVS | GAAAALAERP | -994 |
| | HSV1-Patton | IYGGKMLIK | VDLVRKNNCA | FINRTSRALV | DLLFYDDTVS | GAAAALAERP | -994 |
| | HSV1-DJL | IYGGKMLIK | VDLVRKNNCA | FINRTSRALV | DLLFYDDTVS | GAAAALAERP | -994 |
| 10 | HSV1-F | IYGGKMLIK | VDLVRKNNCA | FINRTSRALV | DLLFYDDTVS | GAAAALAERP | -994 |
| | HSV2-MS | AEEWLARPLP | EGLQAFGAVL | VDAHRRITDP | ERDIQDFVLT | AELSRHPRAY | -1047 |
| | HSV2-186 | AEEWLARPLP | EGLQAFGAVL | VDAHRRITDP | ERDIQDFVLT | AELSRHPRAY | -1049 |
| | HSV-Kos | AEEWLARPLP | EGLQAFGAVL | VDAHRRITDP | ERDIQDFVLT | AELSRHPRAY | -1044 |
| | HSV1-Patton | AEEWLARPLP | EGLQAFGAVL | VDAHRRITDP | ERDIQDFVLT | AELSRHPRAY | -1044 |
| 15 | HSV1-DJL | AEEWLARPLP | EGLQAFGAVL | VDAHRRITDP | ERDIQDFVLT | AELSRHPRAY | -1044 |
| | HSV1-F | AEEWLARPLP | EGLQAFGAVL | VDAHRRITDP | ERDIQDFVLT | AELSRHPRAY | -1044 |
| 20 | HSV2-MS | TNKRLAHLTV | YYKLMARRAQ | VPSIKDRIPY | VIVAQTREVE | ETVARLAALR | -1097 |
| | HSV2-186 | TNKRLAHLTV | YYKLMARRAQ | VPSIKDRIPY | VIVAQTREVE | ETVARLAALR | -1099 |
| | HSV-Kos | TNKRLAHLTV | YYKLMARRAQ | VPSIKDRIPY | VIVAQTREVE | ETVARLAALR | -1094 |
| | HSV1-Patton | TNKRLAHLTV | YYKLMARRAQ | VPSIKDRIPY | VIVAQTREVE | ETVARLAALR | -1094 |
| | HSV1-DJL | TNKRLAHLTV | YYKLMARRAQ | VPSIKDRIPY | VIVAQTREVE | ETVARLAALR | -1094 |
| 25 | HSV1-F | TNKRLAHLTV | YYKLMARRAQ | VPSIKDRIPY | VIVAQTREVE | ETVARLAALR | -1094 |
| | HSV2-MS | ELDAAAPGDE | PAPPAALPSP | AKRPRETPSH | ADPPGGASKP | RKLLVSELAE | -1147 |
| | HSV2-186 | ELDAAAPGDE | PAPPAALPSP | AKRPRETPSH | ADPPGGASKP | RKLLVSELAE | -1149 |
| | HSV-Kos | ELDAAAPGDE | PAPPAALPSP | AKRPRETPSH | ADPPGGASKP | RKLLVSELAE | -1144 |
| | HSV1-Patton | ELDAAAPGDE | PAPPAALPSP | AKRPRETPSP | ADPPGGASKP | RKLLVSELAE | -1144 |
| 30 | HSV1-DJL | ELDAAAPGDE | PAPPAALPSP | AKRPRETPSP | ADPPGGASKP | RKLLVSELAE | -1144 |
| | HSV1-F | ELDAAAPGDE | PAPPAALPSP | AKRPRETPLH | ADPPGGASKP | RKLLVSELAE | -1144 |
| 35 | HSV2-MS | DPGYAIARGV | PLNTDYYFSH | LLGAACVTFK | ALFGNNAKIT | ESLLKRFIPE | -1197 |
| | HSV2-186 | DPGYAIARGV | PLNTDYYFSH | LLGAACVTFK | ALFGNNAKIT | ESLLKRFIPE | -1199 |
| | HSV-Kos | DPAYAIAHGV | ALNTDYYFSH | LLGAACVTFK | ALFGNNAKIT | ESLLKRFIPE | -1194 |
| | HSV1-Patton | DPAYAIAHGV | ALNTDYYFSH | LLGAACVTFK | ALFGNNAKIT | ESLLKRFIPE | -1194 |
| | HSV1-DJL | DPAYAIAHGV | ALNTDYYFSH | LLGAACVTFK | ALFGNNAKIT | ESLLKRFIPE | -1194 |
| 40 | HSV1-F | DPAYAIAHGV | ALNTDYYFSH | LLGAACVTFK | ALFGNNAKIT | ESLLKRFIPE | -1194 |
| | HSV2-MS | TWHPPDDVAA | RLRAAGFGPA | GAGATAEETR | RMLHRAFDTL | A* | -1238 |
| | HSV2-186 | TWHPPDDVAA | RLRAAGFGPA | GAGATAEETR | RMLHRAFDTL | A* | -1240 |
| | HSV-Kos | VWHPPDDVAA | RLRAAGFGAV | GAGATAEETR | RMLHRAFDTL | A* | -1235 |
| | HSV1-Patton | VWHPPDDVTA | RLRAAGFGAV | GAGATAEETR | RMLHRAFDTL | A* | -1235 |
| 45 | HSV1-DJL | VWHPPDDVAA | RLRTAGFGAV | GAGATAEETR | RMLHRAFDTL | A* | -1235 |
| | HSV1-F | VWHPPDDVAA | RLRAAGFGAV | GAGATAEETR | RMLHRAFDTL | A* | -1235 |

*Amino acid alignment demonstrates difference in amino acid's sequences.

*The gaps "....." indicate missing amino acids relative to other stanins.

*Wild HSV2-MS is listed as SEQ. ID NO 14.

*Wild HSV2-186 is listed as SEQ. ID NO 15.

50 *Wild HSV-Kos is listed as SEQ. ID NO 16.

*Wild HSV1-Patton is listed as SEQ. ID NO 17.

*Wild HSV1-DJL is listed as SEQ. ID NO 18.

*Wild HSV1-F is listed as SEQ. ID NO 19.

55

Figure 5 DNA and amino acid sequence list**SEQ. ID. NO. 1** DNA sequence of DNA polymerase gene for HSV2-MS-M1

5 1 ATGTTTTGTG CCGCGGGCGG CCCGACTTCC CCCGGGGGGA AGTCGGCGGC
51 TCGGGCGGCG TCTGGGTTTT TTGCCCCCA CAACCCCGG GGAGCCACCC
101 AGACGGCACC GCCGCTTGC CGCCGGCAGA ACTTCTACAA CCCCCACCTC
10 151 GCTCAGACCG GAACGCAGCC AAAGGCCCCC GGGCCGGCTC AGCGCCATAC
201 GTACTACAGC GAGTGCACG AATTTCGATT TATCGCCCCG CGTTCGCTGG
15 251 ACGAGGACGC CCCCGCGGAG CAGCGCACC GGTCCACGA CGGCCGCCTC
301 CGGCGCGCCC CTAAGGTGTA CTGCGGGGG GACGAGCGCG ACGTCCTCCG
351 CGTGGGCCCC GAGGGCTTCT GGCCGCGTCG CTTGCGCCTG TGGGGCGGTG
20 401 CGGACCATGC CCCCAAGGGG TTCGACCCA CCGTCACCGT CTCCACGTG
451 TACGACATCC TGGAGCACGT GGAACACGCG TACAGCATGC GCGCCGCCCA
25 501 GCTCCACGAG CGATTTATGG ACGCCATCAC GCCCGCCGGG ACCGTCATCA
551 CGCTTCTGGG TCTGACCCCC GAAGGCCATC GCGTCGCCGT TCACGTCTAC
601 GGCACGCGGC AGTACTTTTA CATGAACAAG GCGGAGGTGG ATCGGCACCT
30 651 GCAGTGCCGT GCGCCGCGCG ATCTCTGCGA GCGCCTGGCG GCGGCCCTGC
701 GCGAGTCGCC GGGGGCGTCG TTCCGCGGCA TCTCCGCGGA CCACTTCGAG
35 751 GCGGAGGTGG TGGAGCGCGC CGACGTGTAC TATTACGAAA CGCGCCCGAC
801 CCTGTACTAC CGCGTCTTCG TGCGAAGCGG GCGCGCGCTG GCCTACCTGT
851 GCGACAACTT TTGCCCCGCG ATCAGGAAGT ACGAGGGGGG CGTCGACGCC
40 901 ACCACCCGGT TTATCCTGGA CAACCCGGGG TTTGTCACCT TCGGCTGGTA
951 CCGCCTCAAG CCCGGCCGCG GGAACGCGCC GGCCCAACCG CGCCCCCGA
45 1001 CGGCGTTCGG AACCTCGAGC GACGTCGAGT TTAAGTGCAC GGCGGACAAC
1051 CTGGCCGTCG AGGGGGCCAT GTGTGACCTG CCGGCCTACA AGTCATGTG
1101 CTTGATATC GAATGCAAGG CCGGGGGGGA GGACGAGCTG GCCTTTCCGG
50 1151 TCGCGGAACG CCCGGAAGAC CTCGTCATCC AGATCTCCTG TCTGCTCTAC
1201 GACCTGTCCA CCACCGCCCT CGAGCACATC CTCCTGTTTT CGCTCGGATC
55 1251 CTGCGACCTC CCCGAGTCCC ACCTCAGCGA TCTCGCCTCC AGGGGCCTGC
1301 CGGCCCCCGT CGTCCTGGAG TTTGACAGCG AATTCGAGAT GCTGCTGGCC

1351 TTCATGACCT TCGTCAAGCA GTACGGCCCC GAGTTCGTGA CCGGGTACAA
1401 CATCATCAAC TTCGACTGGC CCTTCGTCCT GACCAAGCTG ACGGAGATCT
5 1451 ACAAGGTCCC GCTCGACGGG TACGGGCGCA TGAACGGCCG GGGTGTGTTC
1501 CGCGTGTGGG ACATCGGCCA GAGCCACTTT CAGAAGCGCA GCAAGATCAA
1551 GGTGAACGGG ATGGTGAACA TCGACATGTA CGGCATCATC ACCGACAAGG
10 1601 TCAAACCTCTC CAGCTACAAG CTGAACGCCG TCGCCGAGGC CGTCTTGAAG
1651 GACAAGAAGA AGGATCTGAG CTACCGCGAC ATCCCCGCCT ACTACGCCTC
1701 CGGGCCCGCG CAGCGCGGGG TGATCGGCGA GTATTGTGTG CAGGACTCGC
1751 TGCTGGTCGG GCAGCTGTTT TTCAAGTTTC TGCCGCACCT GGAGCTTTCC
1801 GCCGTCGCGC GCCTGGCGGG CATCAACATC ACCCGCACCA TCTACGACGG
20 1851 CCAGCAGATC CGCGTCTTCA CGTGCCTCCT GCGCCTTGCG GGCCAGAAGG
1901 GCTTCATCCT GCCGGACACC CAGGGGCGGT TTCGGGGCCT CGACAAGGAG
25 1951 GCGCCCAAGC GCCCGGCCGT GCCTCGGGGG GAAGGGGAGC GGCCGGGGGA
2001 CGGGAACGGG GACGAGGATA AGGACGACGA CGAGGACGAG GACGGGGACG
2051 AGCGCGAGGA GGTCGCGCGC GAGACCGGGG GCCGGCACGT TGGGTACCAG
30 2101 GGGGCCCCGG TCCTCGACCC CACCTCCGGG TTTCACGTCG ACCCCGTGGT
2151 GGTGTTTGAC TTTGCCAGCC TGTACCCAG CATCATCCAG GCCACAACC
35 2201 TGTGCTTCAG TACGCTCTCC CTGCGGCCCC AGGCCGTCGC GCACCTGGAG
2251 GCGGACCGGG ACTACCTGGA GATCGAGGTG GGGGGCCGAC GGCTGTTCTT
2301 CGTGAAGGCC CACGTACGCG AGAGCCTGCT GAGCATCCTG CTGCGCGACT
40 2351 GGCTGGCCAT GCGAAAGCAG ATCCGCTCGC GGATCCCCCA GAGCACCCCC
2401 GAGGAGGCCG TCCTCCTCGA CAAGCAACAG GCCGCCATCA AGGTGGTGTG
45 2451 CAACTCGGTG TACGGGTTCA CCGGGGCGCA GCACGGTCTT CTGCCCTGCC
2501 TGCACGTGGC CGCCACCGTG ACGACCATCG GCCGCGAGAT GCTCCTCGCG
2551 ACGCGCGCGT ACGTGCACGC GCGCTGGGCG GAGTTCGATC AGCTGCTGGC
50 2601 CGACTTTCCG GAGGCGGCCG GCATGCGCGC CCGGGTCCG TACTCCATGC
2651 GCATCATCTA CGGGGACACG GACTCCATTT TCGTTTTGTG CCGCGGCCTC
55 2701 ACGGCCGCGG GCCTGGTGGC CATGGGCGAC AAGATGGCGA GCCACATCTC
2751 GCGCGCGCTG TTCCTCCCCC CGATCAAGCT CGAGTGCGAA AAAACGTTCA
2801 CCAAGCTGCT GCTCATCGCC AAGAAAAAGT ACATCGGCGT CATCTGCGGG
60

2851 GGCAAGATGC TCATCAAGGG CGTGGATCTG GTGCGCAAAA ACAACTGCGC
2901 GTTTATCAAC CGCACCTCCA GGGCCCTGGT CGACCTGCTG TTTTACGACG
5 2951 ATACCGTATC CGGAGCGGCC GCCGCGTTAG CCGAGCGCCC CGCAGAGGAG
3001 TGGCTGGCGC GACCCCTGCC CGAGGGACTG CAGGCGTTCG GGGCCGTCCT
3051 CGTAGACGCC CATCGGCGCA TCACCGACCC GGAGAGGGAC ATCCAGGACT
10 3101 TTGTCCTCAC CGCCGAACTG AGCAGACACC CGCGCGCGTA CACCAACAAG
3151 CGCCTGGCCC ACCTGACGGT GTATTACAAG CTCATGGCCC GCCGCGCGCA
15 3201 GGTCCCGTCC ATCAAGGACC GGATCCCGTA CGTGATCGTG GCCCAGACCC
3251 GCGAGGTAGA GGAGACGGTC GCGCGGCTGG CCGCCCTCCG CGAGCTAGAC
3301 GCCGCCGCC CAGGGGACGA GCCCGCCCCC CCAGCGGCCC TGCCCTCCCC
20 3351 GGCCAAGCGC CCCCAGGAGA CGCCGTCGCA TGCCGACCCC CCGGGAGGCG
3401 CGTCCAAGCC CCGCAAGCTG CTGGTGTCCG AGCTGGCGGA GGATCCCGGG
25 3451 TACGCCATCG CCCGGGGCGT TCCGCTCAAC ACGGACTATT ACTTCTCGCA
3501 CCTGCTGGGG GCGGCCTGCG TGACGTTCAA GGCCCTGTTT GGAAATAACG
3551 CCAAGATCAC CGAGAGTCTG TTAAAGAGGT TTATTCCCGA GACGTGGCAC
30 3601 CCCCCGGACG ACGTGGCCGC GCGGCTCAGG GCCGCGGGGT TCGGGCCGGC
3651 GGGGGCCGGC GCTACGGCGG AGGAAACTCG TCGAATGTTG CATAGAGCCT
35 3701 TTGATACTCT AGCATGA

SEQ. ID. NO. 2 Amino acid sequence of DNA polymerase for HSV2-MS-M1

1 MFCAAGGPTS PGGKSAARAA SGFFAPHNPR GATQTAPPPC RRQNFYNPHL
5 51 AQTGTQPKAP GPAQRHTYYS ECDEFRIAP RSLDEDAPAE QRTGVHDGRL
101 RRAPKVYCGG DERDVLRVGP EGFWRRLRL WGGADHAPKG FDPTVTVFHV
151 YDILEHVEHA YSMRAAQLHE RFMDAITPAG TVITLLGLTP EGHRVAVHVY
10 201 GTRQYFYMNK AEVDRLQCR APRDLCERLA AALRESPGAS FRGISADHFE
251 AEVVERADVY YYETRPTLYY RVFVRSGRAL AYLCDNFCPA IRKYEGGVDA
15 301 TTRFILDNPG FVTFGWYRLK PGRGNAPAQP RPPTAFGTSS DVEFNCTADN
351 LAVEGAMCDL PAYKLMCFDI ECKAGGEDEL AFPVAERPED LVIQISCLLY
401 DLSTTALEHI LLFSLGSCDL PESHLSDLAS RGLPAPVVLE FDSEFEMLLA
20 451 FMTFVKQYGP EFVTGYNIIN FDWPFVLTKL TEIYKVPLDG YGRMNGRGVF
501 RVWDIGQSHF QKRISKIVNG MVNIDMYGII TDKVKLSSYK LNAVAEAVLK
25 551 DKKKDLSYRD IPAYYASGPA QRGVIGEYCV QDSSLVGQLF FKFLPHLELS
601 AVARLAGINI TRTIYDGQOI RVFTCLLRLA GQKGFILPDT QGRFRGLDKE
651 APKRPAVPRG EGERPGDGNG DEDKDDDEDE DGDREEVAR ETGGRHVGYYQ
30 701 GARVLDPTSG FHVDPVVVFD FASLYPSIIQ AHNLCFSTLS LRPEAVAHLE
751 ADRDYLEIEV GGRRLFFVKA HVRESLLSIL LRDWLAMRKQ IRSRIPQSTP
35 801 EEAVLLDKQQ AAIKVV CNSV YGFTGAQHGL LPCLHVAATV TTIGREMLLA
851 TRAYVHARWA EFDQLLADFP EAAGMRAPGP YSMRIY GDT DSIFVLCRGL
901 TAAGLVAMGD KMASHISRAL FLPIKLECE KTFTKLLLIA KKKYIGVICG
40 951 GKMLIKGVDL VRKNNCAFIN RTSRALVDLL FYDDTVSGAA AALAERPAEE
1001 WLARPLPEGL QAFGAVLVDA HRRITDPERD IQDFVLTAEL SRHPRAYTNK
45 1051 RLAHLTVYYK LMARRAQVPS IKDRIPYVIV AQTREVEETV ARLAALRELD
1101 AAAPGDEPAP PAALPSPAKR PRETPSHADP PGGASKPRKL LVSELAEDPG
1151 YAIARGVPLN TDYYFSHLLG AACVTFKALF GNNAKITESL LKRFPETWH
50 1201 PPDDVAARLR AAGFGPAGAG ATAEETRRML HRAFDTLA*

SEQ.ID.NO. 3 DNA sequence of DNA polymerase gene for HSV2-186-M1

1 ATGTTTTGTG CCGCGGGCGG CCCGGCTTCC CCCGGGGGGA AGTCGGCGGC
5 51 TCGGGCGGCG TCTGGGTTTT TTGCCCCCA CAACCCCGG GGAGCCACCC
101 AGACGGCACC GCCGCCTTGC CGCCGGCAGA ACTTCTACAA CCCCCACCTC
151 GCTCAGACCG GAACGCAGCC AAAGGCCCCC GGGCCGGCTC AGCGCCATAC
10 201 GTACTACAGC GAGTGCGACG AATTTCGATT TATCGCCCCG CGTTCGCTGG
251 ACGAGGACGC CCCCGCGGAG CAGCGCACCG GGTTCACGA CGGCCGCCTC
15 301 CGGCGCGCCC CTAAGGTGTA CTGCGGGGGG GACGAGCGCG ACGTCCTCCG
351 CGTGGGCCCC GAGGGCTTCT GGCCGCGTCG CTTGCGCCTG TGGGGCGGTG
401 CGGACCATGC CCCCGAGGGG TTCGACCCA CCGTCACCGT CTTCCACGTG
20 451 TACGACATCC TGGAGCACGT GGAACACGCG TACAGCATGC GCGCCGCCCA
501 GCTCCACGAG CGATTTATGG ACGCCATCAC GCCCGCCGGG ACCGTCATCA
25 551 CGCTTCTGGG TCTGACCCCC GAAGGCCATC GCGTCGCCGT TCACGTCTAC
601 GGCACGCGGC AGTACTTTTA CATGAACAAG GCGGAGGTGG ATCGGCACCT
651 GCAGTGCCGT GCCCCGCGCG ATCTCTGCGA GCGCCTGGCG GCGGCCCTGC
30 701 GCGAGTCGCC GGGGGCGTCG TTCCGCGGCA TCTCCGCGGA CCACTTCGAG
751 GCGGAGGTGG TGGAGCGCGC CGACGTGTAC TATTACGAAA CGCGCCCGAC
35 801 CCTGTACTAC CGCGTCTTCG TGCGAAGCGG GCGCGCGCTG GCCTACCTGT
851 GCGACAACTT TTGCCCCGCG ATCAGGAAGT ACGAGGGGGG CGTCGACGCC
901 ACCACCCGGT TTATCCTGGA CAACCCGGGG TTTGTCACCT TCGGCTGGTA
40 951 CCGCCTCAAG CCCGGCCGCG GGAACGCGCC GGCCCAACCG CGCCCCCGA
1001 CGGCGTTCGG AACCTCGAGC GACGTCGAGT TTAAGTGCAC GGCGGACAAC
45 1051 CTGGCCGTCG AGGGGGCCAT GTGTGACCTG CCGGCCTACA AGCTCATGTG
1101 CTTGATATC GAATGCAAGG CCGGGGGGGA GGACGAGCTG GCCTTCCGG
1151 TCGCGGAACG CCCGGAAGAC CTCGTCATCC AGATCTCCTG TCTGCTCTAC
50 1201 GACCTGTCCA CCACCGCCCT CGAGCACATC CTCCTGTTTT CGCTCGGATC
1251 CTGCGACCTC CCCGAGTCCC ACCTCAGCGA TCTCGCCTCC AGGGGCCTGC
55 1301 CGGCCCCCGT CGTCCTGGAG TTTGACAGCG AATTCGAGAT GCTGCTGGCC
1351 TTCATGACCT TCGTCAAGCA GTACGGCCCC GAGTTCGTGA CCGGGTACAA
60 1401 CATCATCAAC TTCGACTGGC CCTTCGTCCT GACCAAGCTG ACGGAGATCT

15/34

2951 ACGACGATAC CGTATCCGGA GCGGCCGCGG CGTTAGCCGA GCGCCCCGCA
3001 GAGGAGTGGC TGGCGCGACC CCTGCCCCGAG GGA CTGCAGG CGTTCGGGGC
5 3051 CGTCCTCGTA GACGCCCATC GCGGCATCAC CGACCCGGAG AGGGACATCC
3101 AGGACTTTGT CCTCACCGCC GAACTGAGCA GACACCCGCG CGCGTACACC
3151 AACAAGCGCC TGGCCCACCT GACGGTGTAT TACAAGCTCA TGGCCCCGCC
10 3201 CGCGCAGGTC CCGTCCATCA AGGACCGGAT CCCGTACGTG ATCGTGGCCC
3251 AGACCCGCGA GGTAGAGGAG ACGGTCGCGC GGCTGGCCGC CCTCCGCGAG
15 3301 CTAGACGCCG CCGCCCCAGG GGACGAGCCC GCGCCCCCAG CGGCCCTGCC
3351 CTCCCCGGCC AAGCGCCCC GGGAGACGCC GTCGCATGCC GACCCCCCGG
3401 GAGGCGCGTC CAAGCCCCGC AAGCTGCTGG TGTCCGAGCT GCGGAGGAT
20 3451 CCCGGGTACG CCATCGCCCG GGGCGTTCCG CTCAACACGG ACTATTACTT
3501 CTCGCACCTG CTGGGGGCGG CCTGCGTGAC GTTCAAGGCC CTGTTTGAA
25 3551 ATAACGCCAA GATCACCGAG AGTCTGTAA AGAGGTTTAT TCCCGAGACG
3601 TGGCACCCCC CGGACGACGT GGCCGCGCGG CTCAGGGCCG CGGGGTTCCG
3651 GCCGGCGGGG GCCGGCGCTA CGGCGGAGGA AACTCGTCGA ATGTTGCATA
30 3701 GAGCCTTTGA TACTCTAGCA TGA

SEQ.ID.NO. 4 Amino acid sequence of DNA polymerase for HSV2-186-M1

5 1 MFCAAGGPAS PGGKSAARAA SGFFAPHNPR GATQTAPPPC RRQNFYNPHL
51 AQTGTQPKAP GPAQRHTYYS ECDEFRIAP RSLDEDAPAE QRTGVHDGRL
101 RRAPKVYCGG DERDVLRVGP EGFWRRLRL WGGADHAPEG FDPVTVTVFHV
10 151 YDILEHVEHA YSMRAAQLHE RFMDAITPAG TVITLLGLTP EGHRVAVHVV
201 GTRQYFYMNK AEVDRHLQCR APRDLCERLA AALRESPGAS FRGISADHFE
15 251 AEVVERADVY YYETRPTLYY RVFVRSRAL AYLCDNFCPA IRKYEGGVDA
301 TTRFILDNPG FVTFGWYRLK PGRGNAPAQP RPPTAFGTSS DVEFNCTADN
351 LAVEGAMCDL PAYKLMCFDI ECKAGGEDEL AFPVAERPED LVIQISCLLY
20 401 DLSTTALEHI LLFSLGSCDL PESHLSDLAS RGLPAPVVLE FDSEFEMLLA
451 FMTFVKQYGP EFVTGYNIIN FDWPFVLTCL TEIYKVPLDG YGRMNGRGVF
25 501 RVWDIGQSHF QKRSKIKVNG MVNIDMYGII TDKVKLSSYK LNAVAEAVLK
551 DKKKDLSDYRD IPAYYASGPA QRGVIGEYCV QDSSLVGQLF FKFLPHLELS
601 AVARLAGINI TRTTYDGQOI RVFTCLRLA GQKGFILPDT QGRFRGLDKE
30 651 APKRPAVPRG EGERPGDGNG DEDKDDDEDG DEDGDEREEV ARETGGRHVG
701 YQGARVLDPT SGFHVDPVVV FDFASLYPSI IQAHNLCFST LSLRPEAVAH
35 751 LEARDYLEI EVGGRRLFFV KAHVRESLLS ILLRDWLAMR KQIRSRIPQS
801 PPEEAVLLDK QQAAIKVVCN SVYGFTGAQH GLLPCLHVAA TVTTIGREML
851 LATRAYVHAR WAEFDQLLAD FPEAAGMRAP GPYSMRIYG DTDSIFVLCR
40 901 GLTAAGLVAM GDKMASHISR ALFLPPIKLE CEKTFTKLLL IAKKKYIGVI
951 CGGKMLIKGV DLVRKNNCAF INRTSRALVD LLFYDDTVSG AAAALAERPA
45 1001 EEWLARPLPE GLQAFGAVLV DAHRRITDPE RDIQDFVLT AELSRHPRAYT
1051 NKRLAHLTVY YKLMARRAQV PSIKDRIPYV IVAQTREVEE TVARLAALRE
1101 LDAAAPGDEP APPAALPSPA KRPRETPSHA DPPGGASKPR KLLVSELAED
50 1151 PGYAIARGVP LNTDYYFSHL LGAACVTFKA LFGNNAKITE SLLKRIFPET
1201 WHPPDDVAAR LRAAGFGPAG AGATAEETRR MLHRAFDTLA *

SEQ.ID.NO. 5 DNA sequence of DNA polymerase gene for HSV1-KOS-M1

1 ATGTTTTCCG GTGGCGGCGG CCCGCTGTCC CCCGGAGGAA AGTCGGCGGG
5 51 CAGGGCGGCG TCCGGGTTTT TTGCGCCCGC CGGCCCTCGC GGAGCCGGCC
101 GGGGACCCCC GCCTTGTTTG AGGCAAACT TTTACAACCC CTACCTCGCC
15 151 CCAGTCGGGA CGCAACAGAA GCCGACCGGG CCAACCCAGC GCCATACGTA
201 CTATAGCGAA TGCGATGAAT TTCGATTCAT CGCCCCGCGG GTGCTGGACG
251 AGGATGCCCC CCCGGAGAAG CGCGCCGGGG TGCACGACGG TCACCTCAAG
15 301 CGCGCCCCCA AGGTGTACTG CGGGGGGGAC GAGCGCGACG TCCTCCGCGT
351 CGGGTCGGGC GGCTTCTGGC CGCGGCGCTC GCGCCTGTGG GGCGGCGTGG
401 ACCACGCCCC GGCGGGGTTC AACCCACCG TCACCGTCTT TCACGTGTAC
20 451 GACATCCTGG AGAACGTGGA GCACGCGTAC GGCATGCGCG CGGCCCAGTT
501 CCACGCGCGG TTTATGGACG CCATCACACC GACGGGGACC GTCATCACGC
25 551 TCCTGGGCCT GACTCCGGAA GGCCACCGGG TGGCCGTTCA CGTTTACGGC
601 ACGCGGCAGT ACTTTTACAT GAACAAGGAG GAGGTTGACA GGCACCTACA
651 ATGCCGCGCC CCACGAGATC TCTGCGAGCG CATGGCCGCG GCCCTGCGCG
30 701 AGTCCCCGGG CGCGTCGTTT CGCGGCATCT CCGCGGACCA CTTCGAGGCG
751 GAGGTGGTGG AGCGCACCGA CGTGTACTAC TACGAGACGC GCCCCGCTCT
35 801 GTTTTACCGC GTCTACGTCC GAAGCGGGCG CGTGCTGTCG TACCTGTGCG
851 ACAACTTCTG CCCGGCCATC AAGAAGTACG AGGGTGGGGT CGACGCCACC
901 ACCCGGTTCA TCCTGGACAA CCCC GG GTTC GTCACCTTCG GCTGGTACCG
40 951 TCTCAAACCG GGCCGGAACA ACACGCTAGC CCAGCCGCGG GCCCCGATGG
1001 CCTTCGGGAC ATCCAGCGAC GTCGAGTTTA ACTGTACGGC GGACAACCTG
45 1051 GCCATCGAGG GGGGCATGAG CGACCTACCG GCATACAAGC TCATGTGCTT
1101 CGATATCGAA TGCAAGGCGG GGGGGGAGGA CGAGCTGGCC TTTCCGGTGG
1151 CCGGGCACCC GGAGGACCTG GTTATTCAGA TATCCTGTCT GCTCTACGAC
50 1201 CTGTCCACCA CCGCCCTGGA GCACGTCTC CTGTTTTCGC TCGGTTCTCT
1251 CGACCTCCCC GAATCCCACC TGAACGAGCT GCGCGCCAGG GGCTTGCCCA
55 1301 CGCCCGTGGT TCTGGAATTC GACAGCGAAT TCGAGATGCT GTTGGCCTTC
1351 ATGACCCTTG TGAAACAGTA CGGCCCCGAG TTCGTGACCG GGTACAACAT
60 1401 CATCAACTTC GACTGGCCCT TCTTGCTGGC CAAGTTGACG GACATTTACA

19/34

2951 CCGGAGCGGC CGCCGCGTTA GCCGAGCGCC CCGCAGAGGA GTGGCTGGCG
3001 CGACCCCTGC CCGAGGGACT GCAGGCGTTC GGGGCCGTCC TCGTAGACGC
5 3051 CCATCGGCGC ATCACCGACC CGGAGAGGGA CATCCAGGAC TTTGTCTCA
3101 CCGCCGA ACT GAGCAGACAC CCGCGCGCGT ACACCAACAA GCGCCTGGCC
3151 CACCTGACGG TGTATTACAA GTCATGGCC CGCCGCGCGC AGGTCCCGTC
10 3201 CATCAAGGAC CGGATCCCGT ACGTGATCGT GGCCAGACC CGCGAGGTAG
3251 AGGAGACGGT CGCGCGGCTG GCCGCCCTCC GCGAGCTAGA CGCCGCCGCC
15 3301 CCAGGGGACG AGCCCGCCCC CCGCGGGCC CTGCCCTCCC CGGCCAAGCG
3351 CCCCCGGGAG ACGCCGTCGC ATGCCGACCC CCCGGGAGGC GCGTCCAAGC
3401 CCCGCAAGCT GCTGGTGTCC GAGCTGGCCG AGGATCCCGC ATACGCCATT
20 3451 GCCCACGGCG TCGCCCTGAA CACGGA CTAT TACTTCTCCC ACCTGTTGGG
3501 GCGGGCGTGC GTGACATTCA AGGCCCTGTT TGGGAATAAC GCCAAGATCA
25 3551 CCGAGAGTCT GTTAAAAAGG TTTATTCCCG AAGTGTGGCA CCCCCGGAC
3601 GACGTGGCCG CGCGGCTCCG GGCCGCAGGG TTCGGGGCGG TGGGTGCCGG
3651 CGCTACGGCG GAGGAACTC GTCGAATGTT GCATAGAGCC TTTGATACTC
30 3701 TAGCATGA

SEQ.ID.NO. 6 Amino acid sequence of DNA polymerase for HSV1-KOS-M1

1 MFSGGGGPLS PGGKSAARAA SGFFAPAGPR GAGRGPPPCL RQNFYNPYLA
5 51 PVGTQQKPTG PTQRHTYYSE CDEFRIAPR VLDEDAPPEK RAGVHDGHLK
101 RAPKVYCGGD ERDVLRVGSG GFWPRRSRLW GGVDHAPAGF NPTVTVFHVY
10 151 DILENVEHAY GMRAAQFHAR FMDAITPTGT VITLLGLTPE GHRVAVHVYG
201 TRQYFYMNKE EVDRHLQCRA PRDLCERMAA ALRESPGASF RGISADHFEA
251 EVVERTDVYY YETRPALFYR VYVRSGRVLS YLCDNFCAI KKYEGGVDAT
15 301 TRFILDNPGF VTFGWYRLKP GRNNTLAQPR APMAFGTSSD VEFNCTADNL
351 AIEGGMSDLP AYKLMCFDIE CKAGGEDELA FPVAGHPEDL VIQISCLLYD
20 401 LSTTALEHVL LFSLGSCDLP ESHLNELAAR GLPTPVVLEF DSEFEMLLAF
451 MTLVKQYGPE FVTGYNIINF DWPFLAKLT DIYKVPLDGY GRMNGRGVFR
501 VWDIGQSHFQ KRSEIKVNGM VNIDMYGIIT DKIKLSSYKL NAVA EAVLKD
25 551 KKKDLSYRDI PAYYAAGPAQ RGVIGEYCIQ DSVLVGQLFF KFLPHLELSA
601 VARLAGINIT RTTYDGQQIR VFTCLRLAD QKGFLPDTQ GRFRGAGGEA
30 651 PKRPAAARED EERPEEEGED EDEREEGGGE REPEGARETA GRHVG YQGAR
701 VLDPTSGFHV NPVVVFDFAS LYPSIIQAHN LCFSTLSLRA DAVAHLEAGK
751 DYLEIEVGGR RLFFVKAHVR ESLLSILLRD WLAMRKQIRS RIPQSSPEEA
35 801 VLLDKQQA AI KVCNSVYGF TGAQHGLLPC LHVAATVTTI GREMLLATRE
851 YVHARWAAFE QLLADFPEAA DMRAPGPYSM RIYGD TDSI FVLCRGLTAA
40 901 GLTAMGDKMA SHISRALFLP PIKLECEKTF TKLLLIAKKK YIGVIYGGKM
951 LIKGVDLVRK NNCAFINRTS RALVDLLFYD DTVSGAAAAL AERPAAEWLA
1001 RPLPEGLQAF GAVLVDAHRR ITDPERDIQD FVLTAELSRH PRAYTNKRLA
45 1051 HLTVYYKLMA RRAQVPSIKD RPYVIVAQT REVEETVARL AALRELDAAA
1101 PGDEPAPPAA LPSPAKRPRE TP SHADPPGG ASKPRKLLVS ELAEDPAYAI
50 1151 AHGVALNTDY YFSHLLGAAC VTFKALFGNN AKITESLLKR FIPEVWHPPD
1201 DVAARLRAAG FGAVGAGATA EETRRMLHRA FDTLA*

SEQ.ID.NO. 7 DNA sequence of HSV polymerase gene for HSV1-F-M1

1 ATGTTTTCCTG GTGGCGGCGG CCCGCTGTCC CCCGGAGGAA AGTCGGCGGC
5 51 CAGGGCGGCG TCCGGGTTTT TTGCGCCCGC CGGCCCTCGC GGAGCCGGCC
101 GGGGACCCCC GCCTTGCTTG AGGCAAACT TTTACAACCC CTACCTCGCC
15 151 CCAGTCGGGA CGCAACAGAA GCCGACCGGG CCAACCCAGC GCCATACGTA
201 CTATAGCGAA TCGATGAAT TTCGATTCAT CGCCCCGCGG GTGCTGGACG
251 AGGATGCCCC CCCGGAGAAG CGCGCCGGGG TGCACGACGG TCACCTCAAG
15 301 CGCGCCCCCA AGGTGTACTG CGGGGGGGAC GAGCGCGACG TCCTCCGCGT
351 CGGGTCGGGC GGCTTCTGGC CGCGGCGCTC GCGCCTGTGG GCGGGCGTGG
20 401 ACCACGCCCC GCGGGGGTTC AACCCACCG TCACCGTCTT TCACGTGTAC
451 GACATCCTGG AGAACGTGGA GCACGCGTAC GGCATGCGCG CGGCCAGTT
501 CCACGCGCGG TTTATGGACG CCATCACACC GACGGGGACC GTCATCACGC
25 551 TCCTGGGCCT GACTCCGGAA GGCCACCGGG TGGCCGTTCA CGTTTACGGC
601 ACGCGGCAGT ACTTTTACAT GAACAAGGAG GAGGTCGACA GGCACCTACA
30 651 ATGCCGCGCC CCACGAGATC TCTGCGAGCG CATGGCCGCG GCCCTGCGCG
701 AGTCCCCGGG CGCGTCGTTC CGCGGCATTT CCGCGGACCA CTTGAGGCG
751 GAGGTGGTGG AGCGCACCGA CGTGACTACT TACGAGACGC GCCCCGCTCT
35 801 GTTTTACCGC GTCTACGTCC GAAGCGGGCG CGTGCTGTCT TACCTGTGCG
851 ACAACTTCTG CCCGGCCATC AAGAAGTACG AGGGTGGGGT CGACGCCACC
40 901 ACCCGGTTCA TCCTGGACAA CCCCAGGTTC GTCACCTTCG GCTGGTACCG
951 TCTCAAACCG GGCCGGAACA ACACGCTAGC CCAGCCGCGG GCCCGATGG
1001 CCTTCGGGAC ATCCAGCGAC GTCGAGTTTA ACTGTACGGC GGACAACCTG
45 1051 GCCATCGAGG GGGGCATGAG CGACCTACCG GCATACAAGC TCATGTGCTT
1101 CGATATCGAA TGCAAGGCGG GGGGGGAGGA CGAGCTGGCC TTTCCGGTGG
50 1151 CCGGGCACCC GGAGGACCTG GTCATCCAGA TATCCTGTCT GCTCTACGAC
1201 CTGTCCACCA CCGCCCTGGA GCACGTCCTC CTGTTTTTCG TCGGTTCCCTG
1251 CGACCTCCCC GAATCCCACC TGAACGAGCT GGCGGCCAGG GGCCTGCCCCA
55 1301 CGCCCGTGGT TCTGGAATTC GACAGCGAAT TCGAGATGCT GTTGGCCTTC
1351 ATGACCCTTG TGAAACAGTA CGGCCCCGAG TTCGTGACCG GGTACAACAT
60 1401 CATCAACTTC GACTGGCCCT TCTTGCTGGC CAAGCTGACG GACATTTACA
1451 AGGTCCCCCT GGACGGGTAC GGCCGCATGA ACGGCCGGGG CGTGTTTTCG
1501 GTGTGGGACA TAGGCCAGAG CCACTTCCAG AAGCGCAGCA AGATAAAGGT
65 1551 GAACGGCATG GTGAACATCG ACATGTACGG GATTATAACC GACAAGATCA

1601 AGCTCTCGAG CTACAAGCTC AACGCCGTGG CCGAAGCCGT CCTGAAGGAC
 1651 AAGAAGAAGG ACCTGAGCTA TCGCGACATC CCCGCCTACT ACGCCGCCGG
 5 1701 GCCCGCGCAA CGCGGGGTGA TCGGCGAGTA CTGCATACAG GATTCCCTGC
 1751 TGGTGGGCCA GCTGTTTTTT AAGTTTTTGC CCCATCTGGA GCTCTCGGCC
 10 1801 GTCGCGCGCT TGGCGGGTAT TAACATCACC CGCACCATCT ACGACGGCCA
 1851 GCAGATCCGC GTCTTTACGT GCCTGCTGCG CCTGGCCGAC CAGAAGGGCT
 1901 TTATTCTGCC GGACACCCAG GGGCGATTTA GGGGCGGCGG GGGGGAGGCG
 15 1951 CCCAAGCGTC CGGCCGCAGC CCGGGAGGAC GAGGAGCGGC CAGAGGAGGA
 2001 GGGGGAGGAC GAGGACGAAC GCGAGGAGGG CGGGGGCGAG CGGGAGCCGG
 20 2051 AGGGCGCGCG GGAGACCGCC GGCCGGCACG TGGGGTACCA GGGGGCCAGG
 2101 GTCCTTGACC CCACTTCCGG GTTTCATGTG AACCCCGTGG TGGTGTTCGA
 2151 CTTTGCCAGC CTGTACCCCA GCATCATCCA GGCCCACAAC CTGTGCTTCA
 25 2201 GCACGCTCTC CCTGAGGGCC GACGCAGTGG CGCACCTGGA GGCGGGCAAG
 2251 GACTACCTGG AGATCGAGGT GGGGGGGCGA CGGCTGTTCT TCGTCAAGGC
 30 2301 TCACGTGCGA GAGAGCCTCC TCAGCATCCT CCTGCGGGAC TGGCTCGCCA
 2351 TGCGAAAGCA GATCCGCTCG CGGATTCCCC AGAGCAGCCC CGAGGAGGCC
 2401 GTGCTCCTGG ACAAGCAGCA GGCCGCCATC AAGGTCGTGT GTAACTCGGT
 35 2451 TTACGGGTTC ACGGGAGCGC AGCACGGACT CCTGCCGTGC CTGCACGTTG
 2501 CCGCGACGGT GACGACCATC GGCCGCGAGA TGCTGCTCGC GACCCGCGAG
 40 2551 TACGTCCACG CGCGCTGGGC GGCTTCGAA CAGCTCCTGG CCGATTTCCC
 2601 GGAGGCGGCC GACATGCGCG CCCCCGGGCC CTATTCCATG CGCATCATCT
 2651 ACGGGGACAC GGACTCCATC TTTGTGCTGT GCCGCGGCCT CACGGCCGCC
 45 2701 GGGCTGACGG CCGTGGGCGA CAAGATGGCG AGCCACATCT CGCGCGCGCT
 2751 GTTTCTGTCC CCCATCAAAC TCGAGTGCGA AAAGACGTTT ACCAAGCTGC
 50 2801 TGCTGATCGC CAAGAAAAAG TACATCGGCG TCATCTACGG GGGTAAGATG
 2851 CTCATCAAGG GCGTGGATCT GGTGCGCAAA AACAACTGCG CGTTTATCAA
 2901 CCGCACCTCC AGGGCCCTGG TCGACCTGCT GTTTTACGAC GATACCGTAT
 55 2951 CCGGAGCGGC CGCCGCGTTA GCCGAGCGCC CCGCAGAGGA GTGGCTGGCG
 3001 CGACCCCTGC CCGAGGGACT GCAGGCGTTC GGGGCCGTCC TCGTAGACGC
 60 3051 CCATCGGCGC ATCACCAGACC CGGAGAGGGA CATCCAGGAC TTTGTCTCTA
 3101 CCGCCGAACT GAGCAGACAC CCGCGCGCGT ACACCAACAA GCGCTTGGCC
 3151 CACCTGACGG TGTATTACAA GCTCATGGCC CGCCGCGCGC AGGTCCCGTC
 65 3201 CATCAAGGAC CGGATCCCGT ACGTGATCGT GGCCAGACC CGCGAGGTAG

3251 AGGAGACGGT CGCGCGGCTG GCCGCCCTCC GCGAGCTCGA CGCCGCCGCC
3301 CCAGGGGACG AGCCCGCCCC CCCC GCGGCC CTGCCCTCCC CGGCCAAGCG
5 3351 CCCCCGGGAG ACGCCGTTGC ATGCCGACCC CCCGGGAGGC GCGTCCAAGC
3401 CCCGCAAGCT GCTGGTGTCC GAGCTGGCCG AGGATCCCGC ATACGCCATT
3451 GCCCACGGCG TCGCCCTGAA CACGGACTAT TACTTCTCCC ACCTGTTGGG
10 3501 GGCGGCGTGC GTGACATTCA AGGCCCTGTT TGGGAATAAC GCCAAGATCA
3551 CCGAGAGTCT GTTAAAAAGG TTTATTCCCG AAGTGTGGCA CCCCCCGGAC
15 3601 GACGTGGCCG CGCGGCTCCG GGCCGCAGGG TTCGGGGCGG TGGGTGCCCG
3651 CGCTACGGCG GAGGAAACTC GTCGAATGTT GCATAGAGCC TTTGATACTC
3701 TAGCATGA

SEQ.ID.NO. 8 Amino acid sequence of DNA polymerase for HSV1-F-M1

1 MFSGGGGPLS PGGKSAARAA SGFFAPAGPR GAGRGPPPCL RQNFYNPYLA
5 51 PVGTQQKPTG PTQRHTYYSE CDEFRIAPR VLDEDAPPEK RAGVHDGHLK
101 RAPKVYCGGD ERDVLRVGSG GFWPRRSRLW GGVDHAPAGF NPTVTVFHVY
151 DILENVEHAY GMRAAQFHAR FMDAITPTGT VITLLGLTPE GHRVAVHVYG
10 201 TRQYFYMNKE EVDRHLQCRA PRDLCERMAA ALRESPGASF RGISADHFEA
251 EVVERTDVYY YETRPALFYR VYVRSRVL S YLCDNFCAI KKYEGGV DAT
15 301 TRFILDNPGF VTFGWYRLKP GRNNTLAQPR APMAFGTSSD VEFNCTADNL
351 AIEGGMSDLP AYKLMCFDIE CKAGGEDELA FPVAGHPEDL VIQISCLLYD
401 LSTTALEHVL LFSLGSCDLP ESHLNELAAR GLPTPVVLEF DSEFEMLLAF
20 451 MTLVKQYGPE FVTGYNIN F DWPFLAKLT DIYKVPLDGY GRMNGRGVFR
501 VWDIGQSHFQ KRSKIKVNGM VNIDMYGIIT DKIKLSSYKL NAVAEAVLKD
25 551 KKKDLSYRDI PAYYAAGPAQ RGVIGEYCIQ DSLLVGQLFF KFLPHLELSA
601 VARLAGINIT RTIYDGQQIR VFTCLLRLAD QKGFIPLDTQ GRFRGGGGEEA
651 PKRPAAAREE EERPEEEGED EDEREEGGGE REPEGARETA GRHVGYYQGAR
30 701 VLDPTSGFHV NPVVVFDFAS LYPSTLQAHN LCFSTLSLRA DAVAHLEAGK
751 DYLEIEVGGR RLFFVKAHVR ESLLSILLRD WLAMRKQIRS RIPQSSPEEA
35 801 VLLDKQQA AI KVCNSVYGF TGAQHGLLPC LHVAATVTTI GREMLLATRE
851 YVHARWAAFE QLLADFPEAA DMRAPGPYSM RIIYGD TDSI FVLCRGLTAA
901 GLTAVGDKMA SHISRALFLS PIKLECEKTF TKLLLI AKKK YIGVIYGGKM
40 951 LIKGVDLVRK NNCAFINRTS RALVDLLFYD DTVSGAAAAL AERPAAEWLA
1001 RPLPEGLQAF GAVLVDAHRR ITDPERDIQD FVLTAELSRH PRAYTNKRLA
45 1051 HLTVYYKLMA RRAQVPSIKD RPYVIVAQT REVEETVARL AALRELDAAA
1101 PGDEPAPPAA LPSPAKRPRE TPLHADPPGG ASKPRKLLVS ELAEDPAYAI
1151 AHGVALNTDY YFSHLLGAAC VTFKALFGNN AKITESLLKR FIPEVWHPPD
50 1201 DVAARLRAAG FGAVGAGATA EETRMLHRA FDTLA*

SEQ.ID.NO. 9 DNA sequence of HSV polymerase gene for HSV1-DJL-M1

1 ATGTTTTCCG GTGGCGGCGG CCCGCTGTCC CCCGGAGGAA AGTCGGCGGC
5 51 CAGGGCGGCG TCCGGGTTTT TTGCGCCCGC CGGCCCTCGC GGAGCCGGCC
101 GGGGACCCCC GCCTTGTTTG AGGCAAACT TTTACAACCC CTACCTCGCC
151 CCAGTCGGGA CGCAACAGAA GCCGACCGGG CCAACCCAGC GCCATACGTA
10 201 CTATAGCGAA TCGATGAAT TTCGATTCAT CGCCCCGCGG GTGCTGGACG
251 AGGATGCCCC CCCGGAGAAG CGCGCCGGGG TGCACGACGG TCACCTCAAG
15 301 CGCGCCCCCA AGGTGTACTG CGGGGGGGAC GAGCGCGACG TCCTCCGCGT
351 CGGGTCGGGC GGCTTCTGGC CGCGGCGCTC GCGCCTGTGG GGCGGCGTGG
401 ACCACGCCCC GGCGGGGTTC AACCCACCG TCACCGTCTT TCACGTGTAT
20 451 GACATCCTGG AGAACGTGGA GCACGCGTAC GGCATGCGCG CGGCCAGTT
501 CCACGCGCGG TTTATGGACG CCATCACACC GACGGGGACC GTCATCACGC
25 551 TCCTGGGCCT GACTCCGGAA GGCCACCGGG TGGCCGTTCA CGTTTACGGC
601 ACGCGGCAGT ACTTTTACAT GAACAAGGAG GAGGTTGACA GGCACCTACA
651 ATGCCGCGCC CCACGAGATC TCTGCGAGCG CATGGCCGCG GCCCTGCGCG
30 701 AGTCCCCGGG CGCGTCGTTT CGCGGCATCT CCGCGGACCA CTTCGAGGCG
751 GAGGTGGTGG AGCGCACCGA CGTGTACTAC TACGAGACGC GCCCCGCTCT
35 801 GTTTTACCGC GTCTACGTCC GAAGCGGGCG CGTGCTGTCG TACCTGTGCG
851 ACAACTTCTG CCCGGCCATC AAGAAGTACG AGGGTGGGGT CGACGCCACC
901 ACCCGGTTCA TCCTGGACAA CCCC GG GTTC GTCACCTTCG GCTGGTACCG
40 951 TCTCAAACCG GGCCGGAACA ACACGCTAGC CCAGCCGCGG GCCCCGATGG
1001 CCTTCGGGAC ATCCAGCGAT GTCGAGTTTA ACTGTACGGC GGACAACCTG
45 1051 GCCATCGAGG GGGGCATGAG CGACCTACCG GCATACAAGC TCATGTGCTT
1101 CGATATCGAA TGCAAGGCGG GGGGGGAGGA CGAGCTGGCC TTTCCGGTGG
1151 CCGGGCACCC GGAGGACCTG GTCATCCAGA TATCCTGTCT GCTCTACGAC
50 1201 CTGTCCACCA CCGCCCTGGA GCACGTCCTC CTGTTTTTCG TCGGTTCTTG
1251 CGACCTCCCC GAATCCCACC TGAACGAGCT GGCGGCCAGG GGCCTGCCCA
55 1301 CGCCCGTGGT TCTGGAATTC GACAGCGAAT TCGAGATGCT GTTGGCCTTC
1351 ATGACCCTTG TGAAACAGTA CGGCCCCGAG TTCGTGACCG GTTACAACAT
1401 AATCAACTTC GACTGGCCCT TCTTGCTGGC CAAGCTGACG GACATTTACA

1451 AGGTCCCCCT GGACGGGTAC GGCCGCATGA ACGGCCGGGG CGTGTTTCGC
1501 GTGTGGGACA TAGGCCAGAG CCACTTCCAG AAGCGCAGCA AGATAAAGGT
5 1551 GAACGGCATG GTGAACATCG ACATGTACGG GATTATAACC GACAAGATCA
1601 AGCTCTCGAG CTACAAGCTC AACGCCGTGG CCGAAGCCGT CCTGAAGGAC
10 1651 AAGAAGAAGG ACCTGAGCTA TCGCGACATC CCCACCTACT ACGCCGCCGG
1701 GCCCGCGCAA CGCGGGGTGA TCGGCGAGTA CTGCATACAG GATTCCCTGC
1751 TGGTGGGCCA GCTGTTTTTT AAGTTTTTGC CCCATCTGGA GCTCTCGGCC
15 1801 GTCGCGCGCT TGGCGGGTAT TAACATCACC CGCACCATCT ACGACGGCCA
1851 GCAGATCCGC GTCTTTACGT GCCTGCTGCG CCTGGCCGAC CAGAAGGGCT
20 1901 TTATTCTGCC GGACACCCAG GGGCGATTTA GGGGCGCCGG GGGGGAGGCG
1951 CCAAGCGTC CGGCCGCAGC CCGGGAGGAC GAGGAGCGGC CAGAGGAGGA
2001 GGGGGAGGAC GAGAACGAAC GCGAGGAGGG CGGGGGCGAG CGGGAGCCGG
25 2051 AGGGCGCGCG GGAGACCGCC GGCCGGCACG TGGGGTACCA GGGGGCCAGG
2101 GTCCTTGACC CCACTTCCGG GTTTCACGTG AACCCCGTGG TGGTGTTTCA
30 2151 CTTTGCCAGC CTGTACCCCA GCATCATCCA GGCCCACAAC CTGTGCTTCA
2201 GCACGCTCTC CCTGAGGGCC GACGCA GTGG CGCACCTGGA GGCGGGCAAG
2251 GACTACCTGG AGATCGAGGT GGGGGGGCGA CGGCTGTTCT TCGTCAAGGC
35 2301 TCACGTGCGA GAGAGCCTCC TCAGCATCCT CCTGCGGGAC TGGCTCGCCA
2351 TCGAAAGCA GATCCGCTCG CGGATTCCCC AGAGCAGCCC CGAGGAGGCC
40 2401 GTGCTCCTGG ACAAGCAGCA GGCCGCCATC AAGGTCGTGT GTAACCTCGGT
2451 TTACGGGTTC ACGGGAGCGC AGCACGGA CTCTGCCGTGC CTGCACGTTG
2501 CCGCGACGGT GACGACCATC GGCCGCGAGA TGCTGCTCGC GACCCGCGAG
45 2551 TACGTCCACG CGCGCTGGGC GGCCTTCGAA CAGCTCCTGG CCGATTTCCT
2601 GGAGGCGGCC GACATGCGCG CCCCCGGGCC CTATTCCATG CGCATCATCT
50 2651 ACGGGGACAC GGA CTCCATA TTTGTGCTGT GCCGCGGCCT CACGGCCGCC
2701 GGGCTGACGG CCGTGGGCGA CAAGATGGCG AGCCACATCT CGCGCGCGCT
2751 GTTCTGCCC CCCATCAAAC TCGAGTGCGA AAAGACGTT ACCTAAGCTGC
55 2801 TGCTGATCGC CAAGAAAAAG TACATCGGCG TCATCTACGG GGGTAAGATG
2851 CTCATCAAGG GCGTGGATCT GGTGCGCAA AACAACTGCG CGTTTATCAA
60 2901 CCGCACCTCC AGGGCCCTGG TCGACCTGCT GTTTTACGAC GATACCGTAT

2951 CCGGAGCGGC CGCCGCGTTA GCCGAGCGCC CCGCAGAGGA GTGGCTGGCG
3001 CGACCCCTGC CCGAGGGACT GCAGGCGTTC GGGGCCGTCC TCGTAGACGC
5 3051 CCATCGGCGC ATCACCGACC CGGAGAGGGA CATCCAGGAC TTTGTTCTCA
3101 CCGCCGA ACT GAGCAGACAC CCGCGCGCGT ACACCAACAA GCGCCTGGCC
10 3151 CACCTGACGG TGTATTACAA GCTCATGGCC CGCCGCGCGC AGGTCCCCTC
3201 CATCAAGGAC CGGATCCCGT ACGTGATCGT GGCCAGACC CGCGAGGTAG
3251 AGGAGACGGT CCGCGGGCTG GCCGCCCTCC GCGAGCTAGA CGCCGCCGCC
15 3301 CCAGGGGACG AGCCCGCCCC CCGCGGGCC CTGCCCTCCC CGGCCAAGCG
3351 CCCCCGGGAG ACGCCGTCGC CTGCCGACCC CCGGGAGGC GCGTCCAAGC
20 3401 CCCGCAAGCT GCTGGTGTCC GAGCTGGCCG AGGATCCCGC ATACGCCATT
3451 GCCCACGGCG TCGCCCTGAA CACGGACTAT TACTTCTCCC ACCTGTTGGG
3501 GCGGGCGTGC GTGACATTCA AGGCCCTGTT TGGGAATAAC GCCAAGATCA
25 3551 CCGAGAGTCT GTTAAAAAGG TTTATTCCCG AAGTGTGGCA CCCCCGGAC
3601 GACGTGGCCG CGCGGCTCCG GACCGCAGGG TTCGGGGCGG TGGGTGCCGG
30 3651 CGCTACGGCG GAGGAACTC GTCGAATGTT GCATAGAGCC TTTGATACTC
3701 TAGCATGA

SEQ.ID.NO. 10 Amino acid sequence of DNA polymerase for HSV1-DJL-M1

1 MFSGGGGPLS PGGKSAARAA SGFFAPAGPR GAGRGPPPCL RQNFYNPYLA
5 51 PVGTQQKPTG PTQRHTYYSE CDEFRIAPR VLDEDAPPEK RAGVHDGHLK
101 RAPKVYCGGD ERDVLRVGSG GFWPRRSRLW GGVDHAPAGF NPTVTVFHVY
151 DILENVEHAY GMRAAQFHAR FMDAITPTGT VITLLGLTPE GHRVAVHVYG
10 201 TRQYFYMNKE EVDRHLQCRA PRDLCERMAA ALRESPGASF RGISADHFEA
251 EVVERTDVYY YETRPALFYR VYVRSGRVLS YLCDNFCPAI KKYEGGVDAT
15 301 TRFILDNPGF VTFGWYRLKP GRNNTLAQPR APMAFGTSSD VEFNCTADNL
351 AIEGGMSDLP AYKLMCFDIE CKAGGEDELA FPVAGHPEDL VIQISCLLYD
401 LSTTALEHVL LFSLGSCDLP ESHLNELAAR GLPTPVVLEF DSEFEMLLAF
20 451 MTLVKQYGPE FVTGYNIINF DWPFLAKLT DIYKVPLDGY GRMNGRGVFR
501 VWDIGQSHFQ KRSKIKVNGM VNIDMYGIIT DKIKLSSYKL NAVA EAVLKD
25 551 KKKDLSYRDI PTYYAAGPAQ RGVIGEYCIQ DSVLVGQLFF KFLPHLELSA
601 VARLAGINTT RTIYDGQQIR VFTCLRLAD QKGFILPDTQ GRFRGAGGEA
651 PKRPAAARED EERPEEEGED ENEREEGGGE REPEGARETA GRHVG YQGAR
30 701 VLDPTSGFHV NPVVVFDFAS LYPSTIQAHN LCFSTLSLRA DAVAHLEAGK
751 DYLEIEVGGR RLFFVKAHVR ESLLSILLRD WLAMRKQIRS RIPQSSPEEA
35 801 VLLDKQQA AI KVCNSVYGF TGAQHGLLPC LHVAATVTTI GREMLLATRE
851 YVHARWAAFE QLLADFPEAA DMRAPGPYSM RIIYGD TDSI FVLCRGLTAA
901 GLTAVGDKMA SHISRALFLP PIKLECEKTF TKLLLI AKKK YIGVIYGGKM
40 951 LIKGVDLVRK NNCAFINRTS RALVDLLFYD DTVSGAAAAL AERP AEWLA
1001 RPLPEGLQAF GAVLVDAHRR ITDPERDIQD FVLTAELSRH PRAYTNKRLA
45 1051 HLTVYYKLMA RRAQVPSIKD RPYVIVAQT REVEETVARL AALRELDAAA
1101 PGDEPAPPAA LPSPAKRPRE TPSPADPPGG ASKPRKLLVS ELAEDPAYAI
1151 AHGVALNTDY YFSHLLGAAC VTFKALFGNN AKITESLLKR FIPEVWHPPD
50 1201 DVAARLRTAG FGAVGAGATA EETRRMLHRA FDTLA*

SEQ.ID.NO. 11 DNA sequence of DNA polymerase gene for HCMV-AD169-M1

1 ATGTTTTTCA ACCCGTATCT GAGCGGCGGC GTGACCGGCG GTGCGGTTCG
5 51 GGGTGGCCGG CGTCAGCGTT CGCAGCCCGG CTCCGCGCAG GGCTCGGGCA
101 AGCGGCCGCC ACAGAAACAG TTTTTCAGAG TCGTGCCGCG AGGTGTCATG
151 TTCGACGGTC AGACGGGGTT GATCAAGCAT AAGACGGGAC GGCTGCCTCT
10 201 CATGTTCTAT CGAGAGATTA AACATTTGTT GAGTCATGAC ATGGTTTGGC
251 CGTGTCTTGG GCGCGAGACC CTGGTGGGTC GCGTGGTGGG ACCTATTCGT
15 301 TTTACACCT ACGATCAGAC GGACGCCGTG CTCTTCTTCG ACTCGCCCCA
351 AAACGTGTCG CCGCGCTATC GTCAGCATCT GGTGCCTTCG GGGAACGTGT
401 TCGTTTTCTT CGGGGCCACA GAACACGGCT ACAGTATCTG CGTCAACGTT
20 451 TTCGGGCAGC GCAGCTACTT TTAAGTGTAG TACAGCGACA CCGATAGGCT
501 GCGTGAGGTC ATTGCCAGCG TGGGCGAACT AGTGCCCGAA CCGCGGACGG
25 551 CATAAGCCGT GTCTGTCACG CCGGCCACCA AGACCTCCAT CTATGGGTAC
601 GGGACGCGAC CCGTGCCCGA TTTGCAAGTG GTGTCTATCA GCAACTGGAC
651 CATGGCCAGA AAAATCGGCG AGTATCTGCT GGAGCAGGGT TTTCCCGTGT
30 701 ACGAGGTCCG TGTGGATCCG CTGACGCGTT TGGTCATCGA TCGGCGGATC
751 ACCACGTTTC GCTGGTGCTC CGTGAATCGT TACGACTGGC GGCAGCAGGG
35 801 TCGCGCGTCG ACTTGTGATA TCGAGGTAGA CTGCGATGTC TCTGACCTGG
851 TGGCTGTGCC CGACGACAGC TCGTGGCCGC GCTATCGATG CCTGTCTTC
901 GATATCGAGT GCATGAGCGG CGAGGGTGGT TTTCCCTGCG CCGAGAAGTC
40 951 CGATGACATT GTCATTCAGA TCTCGTGCGT GTGCTACGAG ACGGGGGGAA
1001 ACACCGCCGT GGATCAGGGG ATCCCAAACG GGAACGATGG TCGGGGCTGC
45 1051 ACTTCGGAGG GTGTGATCTT TGGGCACTCG GGTCTTCATC TCTTTACGAT
1101 CGGCACCTGC GGGCAGGTGG GCCCAGACGT GGACGTCTAC GAGTTCCTT
1151 CCGAATACGA GCTGCTGCTG GGCTTTATGC TTTTCTTTCA ACGGTACGCG
50 1201 CCGGCCTTTG TGACCGGTTA CAACATCAAC TCTTTTGAAT TGAAGTACAT
1251 CCTCACGCGT CTCGAGTACC TGTATAAGGT GGACTCGCAG CGCTTCTGCA
55 1301 AGTTGCCTAC GGCAGAGGGC GGCCGTTTCT TTTTACACAG CCCCAGCGTG
1351 GGTTTTAAGC GGCAGTACGC CGCCGCTTTT CCCTCGGCTT CTCACAACAA
1401 TCCGGCCAGC ACGGCCGCCA CCAAGGTGTA TATTGCGGGT TCGGTGGTTA

1451 TCGACATGTA CCCTGTATGC ATGGCCAAGA CTAAGTCGCC CAACTATAAG
1501 CTCAACACTA TGGCCGAGCT TTACCTGCGG CAACGCAAGG ATGACCTGTC
5 1551 TTACAAGGAC ATCCCGCGTT GTTTCGTGGC TAATGCCGAG GGCCGCGCCC
1601 AGGTAGGCCG TTAAGTCTG CAGGACGCCG TATTGGTGCG CGATCTGTTC
10 1651 AACACCATTA ATTTTCACTA CGAGGCCGGG GCCATCGCGC GGCTGGCTAA
1701 AATTCCGTTG CGGCGTGTCA TCTTTGACGG ACAGCAGATC CGTATCTACA
1751 CCTCGCTGCT GGACGAGTGC GCCTGCCGCG ATTTTATCCT GCCCAACCAC
15 1801 TACAGCAAAG GTACGACGGT GCGCGAAACG AATAGCGTTG CTGTGTCACC
1851 TAACGCTGCT ATCATCTCTA CCGCCGCTGT GCGCGGCGAC GCGGGTTCTG
20 1901 TGGCGGCTAT GTTTCAGATG TCGCCGCCCT TGCAATCTGC GCCGTCCAGT
1951 CAGGACGGCG TTTCACCCGG CTCCGGCAGT AACAGTAGTA GCAGCGTCGG
2001 CGTTTTTCAGC GTCGGCTCCG GCAGTAGTGG CGGCGTCGGC GTTTCCAACG
25 2051 ACAATCACGG CGCCGGCGGT ACTGCGGCGG TTTCGTACCA GGGCGCCACG
2101 GTGTTTGAGC CCGAGGTGGG TTAAGTACAAC GACCCCGTGG CCGTGTTCTGA
2151 CTTTGCCAGC CTCTACCCTT CCATCATCAT GGCCCAACAAC CTCTGCTACT
30 2201 CCACCCTGCT GGTGCCGGGT GGCGAGTACC CTGTGGACCC CGCCGACGTA
2251 TACAGCGTCA CGCTAGAGAA CGGCGTGACC CACCGCTTTG TCGTGCTTC
35 2301 GGTGCGCGTC TCGGTGCTCT CGGAAGTGT CAACAAGTGG GTTTCGCAGC
2351 GCGGTGCCGT GCGCGAATGC ATGCGCGAGT GTCAAGACCC TGTGCGCCGT
40 2401 ATGCTGCTCG ACAAGGAACA GATGGCGCTC AAAGTAACGT GCAACGCTTT
2451 CTACGGTTTT ACCGGCGCGC TGAACGGTAT GATGCCGTGT CTGCCCATCG
2501 CCGCCAGCAT CACGCGCATC GGTCGCGACA TGCTAGAGCG CACGGCGCGG
45 2551 TTCATCAAAG ACAACTTTTC AGAGCCGTGT TTTTGCACA ATTTTTTTAA
2601 TCAGGAAGAC TATGTAGTGG GAACGCGGGA GGGGGATTCTG GAGGAGAGCA
50 2651 GCGCGTTACC GGAGGGGCTC GAAACATCGT CAGGGGGCTC GAACGAACGG
2701 CGGGTGGAGG CGCGGGTCAT CTACGGGGAC ACGGACAGCG TGTGTGTCGG
2751 CTTTCGTGGC CTGACGCCGC AGGCTCTGGT GGCGCGTGGG CCCAGCCTGG
55 2801 CGCACTACGT GACGGCCTGT CTTTTGTGG AGCCCGTCAA GCTGGAGTTT
2851 GAAAAGGTCT TCGTCTCTCT TATGATGATC TGCAAGAAAC GTTACATCGG
60 2901 CAAAGTGGAG GGCGCCTCGG GTCTGAGCAT GAAGGGCGTG GATCTGGTGC

2951 GCAAGACGGC CTGCGAGTTC GTCAAGGGCG TCACGCGTGA CGTCCTCTCG
3001 CTGCTCTTTG AGGATCGCGA GGTCTCGGAA GCAGCCGTGC GCCTGTCGCG
5 3051 CCTCTCACTC GATGAAGTCA AGAAGTACGG CGTGCCACGC GGTTCCTGGC
3101 GTATCTTACG CCGCTTGGTG CAGGCCCCGCG ACGATCTGTA CCTGCACCGT
10 3151 GTGCGTGTCG AGGACCTGGT GCTTTCGTCTG GTGCTCTCTA AGGACATCTC
3201 GCTGTACCGT CAATCTAACC TGCCGCACAT TGCCGTCATT AAGCGATTGG
3251 CGGCCCCGTTT TGAGGAGCTA CCCTCGGTCTG GGGATCGGGT CTTTTACGTT
15 3301 CTGACGGCGC CCGGTGTCCG GACGGCGCCG CAGGGTTCCT CCGACAACGG
3351 TGATTCTGTA ACCGCCGGCG TGGTTTCCCG GTCGGACGCG ATTGATGGCA
20 3401 CGGACGACGA CGCTGACGGC GGCGGGGTAG AGGAGAGCAA CAGGAGAGGA
3451 GGAGAGCCGG CAAAGAAGAG GGCGCGGAAA CCACCGTCGG CCGTGTGCAA
3501 CTACGAGGTA GCCGAAGATC CGAGCTACGT GCGCGAGCAC GGCGTGCCCA
25 3551 TTCACGCCGA CAAGTACTTT GAGCAGGTTT TCAAGGCTGT AACTAACGTG
3601 CTGTCGCCCCG TCTTCCCGG CGGCGAAACC GCGCGCAAGG ACAAGTTTTT
30 3651 GCACATGGTG CTGCCGCGGC GCTTGCACTT GGAGCCGGCT TTTCTGCCGT
3701 ACAGTGTCOA GGCGCACGAA TGCTGTTGA

SEQ. ID. NO. 12 Amino acid sequence of DNA polymerase for HCMV-AD169-M1

1 MFFNPYLSGG VTGGAVAGGR RQRSQPGSAQ GSGKRPPQKQ FLQIVPRGVM
5 51 FDGQTGLIKH KTGRPLPMFY REIKHLLSHD MVWPCPWRET LVGRVVGPIR
101 FHTYDQTDV LFFDSPENV S PRYRQHLVPS GNVLRFFGAT EHGYSICNVN
10 151 FGQRSYFYCE YSDTDLREV IASVGELVPE PRTPYAVSVT PATKTSIYGY
201 GTRPVPDLQC VSISNWTMAR KIGEYLLEQG FPVYEV RVDP LTRLVIDRRI
251 TTFGWCSVNR YDWRQQGRAS TCDIEVDCDV SDLVAVPDDS SWPRYRCLSF
15 301 DIECMSGEGG FPCAESDDI VIQISCVCYE TGGNTAVDQG IPNGNDGRGC
351 TSEGVIFGHS GLHLFTIGTC GQVGPDVDVY EFPSEYELL GFMLFFQRYA
401 PAFVTGYNIN SFDLKYILTR LEYLYK VDSQ RFCKLPTAQG GRFFLHSPAV
20 451 GFKRQYAAAF PSASHNNPAS TAATKVYIAG SVVIDMYPVC MAKTNSPNYK
501 LNTMAELYL RQRKDDLSYKD IPRCFVANAE GRAQVGRYCL QDAVLVRDLF
25 551 NTINFHYEAG AIARLAKIPL RRVIFDGQQI RIYTSLLDEC ACRDFILPNH
601 YSKGTTVPET NSVAVSPNAA IISTAAVPGD AGSVAAMFQM SPPLQSAPSS
30 651 QDGVSPGSGS NSSSSVGVFS VSGSGSGGVG VSNDNHGAGG TAAVSYQGAT
701 VFEPEVGYYN DPVAVFDFAS LYP SIIMAHN LCYSTLLVPG GEYPVDPADV
751 YSVTLENGVT HRFVRASVRV SVLSELLNKW VSQRRVREC MRECQDPVRR
35 801 MLLDKEQMAL KVT CNAFYGF TGALNGMMPC LPIAASITRI GRDMLERTAR
851 FIKDNFSEPC FLHNFFNQED YVVG TREGDS EESSALPEGL ETSSGGSNER
901 RVEARVTYGD TDSVFVRFRG LTPQALVARG PSLAHYVTAC LFVEPVKLEF
40 951 EKV FVSLMMI CKKRYIGKVE GASGLSMKGV DLVRKTACEF VKGVTRDVLS
1001 LLFEDREVSE AAVRLSRLSL DEVKKYGVPR GFWRILRLV QARDDLYLHR
45 1051 VRVEDLV LSS VLSKDISLYR QSNLPHIAVI KRLAARSEEL PSVGDRVFYV
1101 LTAPGVRTAP QGSSDNGDSV TAGVVSRSDA IDGTDDDADG GGVEESNRRG
50 1151 GEP AKKRARK PPSAVCNYEV AEDPSYVREH GVPIHADKYF EQVLKAVTNV
1201 LSPVFPGET ARKDKFLHMV LPRRLHLEPA FLPYSVKAHE CC*

Figure 6**SEQ.ID.NO.13****Amino acid sequence of DNA polymerase for HCMV-AD169**

5 1 MFFNPYLSSG VTGGAVAGGR RQRSQPGSAQ GSGKRPPQKQ FLQIVPRGVM
51 FDGQTGLIKH KTGRPLMFY REIKHLLSHD MVWPCPWRET LVGRVVGPIR
101 FHTYDQTDV LFFDSPENV S PRYRQHLVPS GNVLRFFGAT EHGYSICNVV
10 151 FGQRSYFYCE YSDTDRLREV IASVGELVPE PRTPYAVSVT PATKTSIYGY
201 GTRPVPDLQC VSISNWTMAR KIGEYLLSEQ FPVYEVVRDP LTRLVIDRRI
15 251 TTFGWCSVNR YDWRQQGRAS TCDIEVDCDV SDLVAVPDDS SWPRYRCLSF
301 DIECMSGEGG FPCAESDDI VIQISCVCYE TGGNTAVDQG IPNGNDGRGC
351 TSEGVIFGHS GLHLFTIGTC GQVGPDVDVY EFPSEYELL GFMLFFQRYA
20 401 PAFVTGYNIN SFDLKYILTR LEYLYKVDSQ RFCKLPTAAG GRFFLHSPAV
451 GFKRQYAAAF PSASHNNPAS TAATKVYIAG SVVIDMYPVC MAKTNPNYK
25 501 LNTMAELYLR QRKDDLSYKD IPRCFVANAE GRAQVGGRYCL QDAVLVRDLF
551 NTINFHYEAG AIARLAKIPL RRVIFDGQOI RIYTSLLDEC ACRDFILPNH
601 YSKGTTVPET NSVAVSPNAA IISTAAVPGD AGSVAAMFQM SPPLQSAPSS
30 651 QDGVSPGSGS NSSSSVGVFS VGSGSSGGVG VSNDNHGAGG TAAVSYQGAT
701 VFEPEVGYYN DPVAVFDFAS LYPSTMAHN LCYSTLLVPG GEYPVDPADV
35 751 YSVTLENGVT HRFVRASVRV SVLSELLNKW VSQRRVREC MRECQDPVRR
801 MLLDKEQMAL KVTCTAFYGF TGVVNGMMPC LPAAASITRI GRDMLERTAR
851 FIKDNFSEPC FLHNFFNQED YVVGTRREGDS EESSALPEGL ETSSGGSNER
40 901 RVEARVIYGD TDSVFVRFRG LTPQALVARG PSLAHYVTAC LFVEPVKLEF
951 EKVFSLSMMI CKKRYIGKVE GASGLSMKGV DLVRKTACEF VKGVTRDVLS
45 1001 LLFEDREVSE AAVRLSRLSL DEVKKYGVPR GFWRLRRLV QARDDLYLHR
1051 VRVEDLVLS VLSKDISLYR QSNLPHIAVI KRLAARSEEL PSVGDRVFYV
1101 LTAPGVRTAP QGSSDNGDSV TAGVVSRS DA IDGTDDDADG GGVEESNRRG
50 1151 GEPAKKRARK PPSAVCNYEV AEDPSYVREH GVPIHADKYF EQVLKAVTNV
1201 LSPVFPGGET ARKDKFLHMV LPRRLHLEPA FLPYSVKAHE CC*

55

SEQUENCE LISTING

<110> Homa, Fred
 Wathen, Michael
 Hopkins, Todd
 Thomsen, Darrell

<120> A Method for Treating Herpes Virus

<130> 00221

<160> 19

<170> PatentIn version 3.0

<210> 1

<211> 3717

<212> DNA

<213> herpes simplex

<400> 1

```

atgttttgtg ccgcgggcgg cccgacttcc cccgggggga agtcggcggc tcgggcggcg      60
tctgggtttt ttgcccccca caacccccgg ggagccaccc agacggcacc gccgccttgc      120
cgccggcaga acttctacaa cccccacctc gctcagaccg gaacgcagcc aaaggccccc      180
gggcccggctc agcgccatac gtactacagc gagtgcgacg aatttcgatt tatcgccccg      240
cgttcgctgg acgaggacgc ccccgcgagg cagcgcaccg ggggtccacga cggccgcctc      300
gggcgcgccc ctaaggtgta ctgcgggggg gacgagcgcg acgtcctccg cgtgggcccc      360
gagggcttct ggccgcgtcg cttgcgcctg tggggcggtg cggaccatgc cccaagggg      420
ttcgacccca ccgtcacctg cttccacgtg tacgacatcc tggagcacgt ggaacacgcg      480
tacagcatgc gcgcgcacca gctccacgag cgatttatgg acgccatcac gcccgccggg      540
accgtcatca cgcttctggg tctgaccccc gaaggccatc gcgtcgccgt tcacgtctac      600
ggcacgcggc agtactttta catgaacaag gcggaggtgg atcggcacct gcagtgcctg      660
gccccgcgcg atctctgcga gcgcctggcg gcggccctgc gcgagtcgcc gggggcgctg      720
ttccgcggca tctccgcgga ccacttcgag gcggaggtgg tggagcgcgc cgacgtgtac      780
tattacgaaa cgcgccccgac cctgtactac cgcgtcttcg tgcgaagcgg gcgcgcgctg      840
gcctacctgt gcgacaactt ttgccccgcg atcaggaagt acgagggggg cgtcgacgcc      900
accacccggt ttatcctgga caacccgggg tttgtcacct tcggctggta ccgcctcaag      960
cccgcccgcg ggaacgcgcc ggcccaaccg cggccccga cggcgcttcg aacctcgagc     1020
gacgtcgagt ttaactgcac ggcggaacaac ctggccgctc agggggccat gtgtgacctg     1080
ccggcctaca agctcatgtg cttcgatatc gaatgcaagg ccggggggga ggacgagctg     1140
gcctttccgg tcgcggaacg cccggaagac ctcgatcatc agatctcctg tctgctctac     1200
gacctgtcca ccaccgcct cgagcacatc ctctgtttt cgctcggatc ctgcgacctc     1260

```

cccgagtgccc acctcagcga tctcgctctcc agggggcctgc cggcccccggt cgtcctggag 1320
 tttgacagcg aattcgagat gctgctggcc ttcattgacct tcgtcaagca gtacggcccc 1380
 gagttcgtga cgggttaca catcatcaac ttcgactggc ccttcgtcct gaccaagctg 1440
 acggagatct acaagggtccc gctcgacggg tacggggcgca tgaacggccg ggggtgtgttc 1500
 cgcgtgtggg acatcggcca gagccacttt cagaagcgca gcaagatcaa ggtgaacggg 1560
 atggtgaaca tcgacatgta cggcatcatc accgacaagg tcaaactctc cagctacaag 1620
 ctgaacgcgc tcgccgaggc cgtcttgaag gacaagaaga aggatctgag ctaccgcgac 1680
 atccccgcct actacgcctc cggggccgcg cagcgcgggg tgatcggcga gtattgtgtg 1740
 caggactcgc tgctggtcgg gcagctgttc ttcaagtttc tgccgcacct ggagctttcc 1800
 gccgtcgcgc gcttggcggg catcaacatc acccgcacca tctacgacgg ccagcagatc 1860
 cgcgtcttca cgtgcctcct gcgccttgcg ggccagaagg gcttcatcct gccggacacc 1920
 caggggcggt ttccgggcct cgacaaggag gcgcccgaag gcccggccgt gcctcggggg 1980
 gaaggggagc ggccggggga cgggaacggg gacgaggata aggacgacga cgaggacgag 2040
 gacggggacg agcgcgagga ggtcgcgcgc gagaccgggg gccggcacgt tgggtaccag 2100
 gggggccggg tcctcgaccc cactccggg ttccacgtcg acccgtggg ggtgtttgac 2160
 tttgccagcc tgtaccccag catcatccag gccacaacc tgtgcttcag tacgtctcc 2220
 ctgcggcccc aggccgtcgc gcacctggag gcggaccggg actacctgga gatcgaggtg 2280
 gggggccgac ggctgttctt cgtgaaggcc cacgtacgcg agagcctgct gagcatcctg 2340
 ctgcgcgact ggctggccat gcgaaagcag atccgctcgc ggatccccca gagcaccccc 2400
 gagggaggccg tcctcctcga caagcaacag gccgccatca aggtgggtgtg caactcgggtg 2460
 tacgggttca cgggggcgca gcacgggtct ctgcctgccc tgcacgtggc cgccaccgtg 2520
 acgaccatcg gccgcgagat gctcctcgcg acgcgcgcgt acgtgcacgc gcgctggggc 2580
 gagttcgatc agctgctggc cgactttccg gagggcgccg gcatgcgcgc ccccggtccg 2640
 tactccatgc gcatcatcta cggggacacg gactccattt tcgttttgtg ccgcggcctc 2700
 acggccgcgg gcctgggtggc catgggcgac aagatggcga gccacatctc gcgcgcgctg 2760
 ttctctcccc cgatcaagct cgagtgcgaa aaaacgttca ccaagctgct gctcatcgcc 2820
 aagaaaaagt acatcggcgt catctgcggg ggcaagatgc tcatcaaggg cgtggatctg 2880
 gtgcgcaaaa acaactgcgc gtttatcaac cgcacctcca gggccctggg cgacctgctg 2940
 ttttacgacg ataccgtatc cggagcggcc gccgcgttag ccgagcgccc cgagaggag 3000
 tggctggcgc gaccctgcc cgagggactg caggcgttcg gggccgtcct cgtagacgcc 3060
 catcggcgca tcaccgaccc ggagagggac atccaggact ttgtcctcac cgccgaactg 3120

```

agcagacacc cgcgcgcgta caccaacaag cgcctggccc acctgacggt gtattacaag 3180
ctcatggccc gccgcgcgca ggtcccgtcc atcaaggacc ggatcccgtg cgtgatcgtg 3240
gcccagaccc gcgaggtaga ggagacggtc gcgcgggtgg ccgccctccg cgagctagac 3300
gccgccgccc cagggggacga gcccgcctcc ccagcggccc tgcctcccc ggccaagcgc 3360
ccccgggaga cgccgtcgca tgccgacccc ccggggaggcg cgtccaagcc ccgcaagctg 3420
ctggtgtccg agctggcgga ggatcccggg tacgccatcg cccggggcgt tccgctcaac 3480
acggactatt acttctcgca cctgctgggg gcggcctgcg tgacgttcaa ggccctgttt 3540
ggaaataacg ccaagatcac cgagagtctg ttaaagaggt ttattcccga gacgtggcac 3600
ccccggacg acgtggccgc gcggctcagg gccgcggggt tcgggccggc gggggccggc 3660
gctacggcgg aggaaaactcg tcgaatgttg catagagcct ttgatactct agcatga 3717

```

```

<210> 2
<211> 1238
<212> PRT
<213> herpes simplex

```

```

<400> 2

```

```

Met Phe Cys Ala Ala Gly Gly Pro Thr Ser Pro Gly Gly Lys Ser Ala
1           5           10           15

Ala Arg Ala Ala Ser Gly Phe Phe Ala Pro His Asn Pro Arg Gly Ala
          20           25           30

Thr Gln Thr Ala Pro Pro Pro Cys Arg Arg Gln Asn Phe Tyr Asn Pro
          35           40           45

His Leu Ala Gln Thr Gly Thr Gln Pro Lys Ala Pro Gly Pro Ala Gln
          50           55           60

Arg His Thr Tyr Tyr Ser Glu Cys Asp Glu Phe Arg Phe Ile Ala Pro
65           70           75           80

Arg Ser Leu Asp Glu Asp Ala Pro Ala Glu Gln Arg Thr Gly Val His
          85           90           95

Asp Gly Arg Leu Arg Arg Ala Pro Lys Val Tyr Cys Gly Gly Asp Glu
          100          105          110

Arg Asp Val Leu Arg Val Gly Pro Glu Gly Phe Trp Pro Arg Arg Leu
          115          120          125

Arg Leu Trp Gly Gly Ala Asp His Ala Pro Lys Gly Phe Asp Pro Thr
          130          135          140

Val Thr Val Phe His Val Tyr Asp Ile Leu Glu His Val Glu His Ala
          145          150          155          160

Tyr Ser Met Arg Ala Ala Gln Leu His Glu Arg Phe Met Asp Ala Ile
          165          170          175

```


Thr Pro Ala Gly Thr Val Ile Thr Leu Leu Gly Leu Thr Pro Glu Gly
 180 185 190
 His Arg Val Ala Val His Val Tyr Gly Thr Arg Gln Tyr Phe Tyr Met
 195 200 205
 Asn Lys Ala Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp
 210 215 220
 Leu Cys Glu Arg Leu Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser
 225 230 235 240
 Phe Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg
 245 250 255
 Ala Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Thr Leu Tyr Tyr Arg Val
 260 265 270
 Phe Val Arg Ser Gly Arg Ala Leu Ala Tyr Leu Cys Asp Asn Phe Cys
 275 280 285
 Pro Ala Ile Arg Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe
 290 295 300
 Ile Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys
 305 310 315 320
 Pro Gly Arg Gly Asn Ala Pro Ala Gln Pro Arg Pro Pro Thr Ala Phe
 325 330 335
 Gly Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala
 340 345 350
 Val Glu Gly Ala Met Cys Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe
 355 360 365
 Asp Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val
 370 375 380
 Ala Glu Arg Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr
 385 390 395 400
 Asp Leu Ser Thr Thr Ala Leu Glu His Ile Leu Leu Phe Ser Leu Gly
 405 410 415
 Ser Cys Asp Leu Pro Glu Ser His Leu Ser Asp Leu Ala Ser Arg Gly
 420 425 430
 Leu Pro Ala Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu
 435 440 445
 Leu Ala Phe Met Thr Phe Val Lys Gln Tyr Gly Pro Glu Phe Val Thr
 450 455 460
 Gly Tyr Asn Ile Ile Asn Phe Asp Trp Pro Phe Val Leu Thr Lys Leu
 465 470 475 480
 Thr Glu Ile Tyr Lys Val Pro Leu Asp Gly Tyr Gly Arg Met Asn Gly
 485 490 495
 Arg Gly Val Phe Arg Val Trp Asp Ile Gly Gln Ser His Phe Gln Lys
 500 505 510

Arg Ser Lys Ile Lys Val Asn Gly Met Val Asn Ile Asp Met Tyr Gly
 515 520 525
 Ile Ile Thr Asp Lys Val Lys Leu Ser Ser Tyr Lys Leu Asn Ala Val
 530 535 540
 Ala Glu Ala Val Leu Lys Asp Lys Lys Lys Asp Leu Ser Tyr Arg Asp
 545 550 555 560
 Ile Pro Ala Tyr Tyr Ala Ser Gly Pro Ala Gln Arg Gly Val Ile Gly
 565 570 575
 Glu Tyr Cys Val Gln Asp Ser Leu Leu Val Gly Gln Leu Phe Phe Lys
 580 585 590
 Phe Leu Pro His Leu Glu Leu Ser Ala Val Ala Arg Leu Ala Gly Ile
 595 600 605
 Asn Ile Thr Arg Thr Ile Tyr Asp Gly Gln Gln Ile Arg Val Phe Thr
 610 615 620
 Cys Leu Leu Arg Leu Ala Gly Gln Lys Gly Phe Ile Leu Pro Asp Thr
 625 630 635 640
 Gln Gly Arg Phe Arg Gly Leu Asp Lys Glu Ala Pro Lys Arg Pro Ala
 645 650 655
 Val Pro Arg Gly Glu Gly Glu Arg Pro Gly Asp Gly Asn Gly Asp Glu
 660 665 670
 Asp Lys Asp Asp Asp Glu Asp Glu Asp Gly Asp Glu Arg Glu Glu Val
 675 680 685
 Ala Arg Glu Thr Gly Gly Arg His Val Gly Tyr Gln Gly Ala Arg Val
 690 695 700
 Leu Asp Pro Thr Ser Gly Phe His Val Asp Pro Val Val Val Phe Asp
 705 710 715 720
 Phe Ala Ser Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu Cys Phe
 725 730 735
 Ser Thr Leu Ser Leu Arg Pro Glu Ala Val Ala His Leu Glu Ala Asp
 740 745 750
 Arg Asp Tyr Leu Glu Ile Glu Val Gly Gly Arg Arg Leu Phe Phe Val
 755 760 765
 Lys Ala His Val Arg Glu Ser Leu Leu Ser Ile Leu Leu Arg Asp Trp
 770 775 780
 Leu Ala Met Arg Lys Gln Ile Arg Ser Arg Ile Pro Gln Ser Thr Pro
 785 790 795 800
 Glu Glu Ala Val Leu Leu Asp Lys Gln Gln Ala Ala Ile Lys Val Val
 805 810 815
 Cys Asn Ser Val Tyr Gly Phe Thr Gly Ala Gln His Gly Leu Leu Pro
 820 825 830
 Cys Leu His Val Ala Ala Thr Val Thr Thr Ile Gly Arg Glu Met Leu

| 835 | 840 | 845 |
|--|------|---------|
| Leu Ala Thr Arg Ala Tyr Val His Ala Arg Trp Ala Glu Phe Asp Gln 850 | 855 | 860 |
| Leu Leu Ala Asp Phe Pro Glu Ala Ala Gly Met Arg Ala Pro Gly Pro 865 | 870 | 875 880 |
| Tyr Ser Met Arg Ile Ile Tyr Gly Asp Thr Asp Ser Ile Phe Val Leu 885 | 890 | 895 |
| Cys Arg Gly Leu Thr Ala Ala Gly Leu Val Ala Met Gly Asp Lys Met 900 | 905 | 910 |
| Ala Ser His Ile Ser Arg Ala Leu Phe Leu Pro Pro Ile Lys Leu Glu 915 | 920 | 925 |
| Cys Glu Lys Thr Phe Thr Lys Leu Leu Leu Ile Ala Lys Lys Lys Tyr 930 | 935 | 940 |
| Ile Gly Val Ile Cys Gly Gly Lys Met Leu Ile Lys Gly Val Asp Leu 945 | 950 | 955 960 |
| Val Arg Lys Asn Asn Cys Ala Phe Ile Asn Arg Thr Ser Arg Ala Leu 965 | 970 | 975 |
| Val Asp Leu Leu Phe Tyr Asp Asp Thr Val Ser Gly Ala Ala Ala Ala 980 | 985 | 990 |
| Leu Ala Glu Arg Pro Ala Glu Glu Trp Leu Ala Arg Pro Leu Pro Glu 995 | 1000 | 1005 |
| Gly Leu Gln Ala Phe Gly Ala Val Leu Val Asp Ala His Arg Arg 1010 | 1015 | 1020 |
| Ile Thr Asp Pro Glu Arg Asp Ile Gln Asp Phe Val Leu Thr Ala 1025 | 1030 | 1035 |
| Glu Leu Ser Arg His Pro Arg Ala Tyr Thr Asn Lys Arg Leu Ala 1040 | 1045 | 1050 |
| His Leu Thr Val Tyr Tyr Lys Leu Met Ala Arg Arg Ala Gln Val 1055 | 1060 | 1065 |
| Pro Ser Ile Lys Asp Arg Ile Pro Tyr Val Ile Val Ala Gln Thr 1070 | 1075 | 1080 |
| Arg Glu Val Glu Glu Thr Val Ala Arg Leu Ala Ala Leu Arg Glu 1085 | 1090 | 1095 |
| Leu Asp Ala Ala Ala Pro Gly Asp Glu Pro Ala Pro Pro Ala Ala 1100 | 1105 | 1110 |
| Leu Pro Ser Pro Ala Lys Arg Pro Arg Glu Thr Pro Ser His Ala 1115 | 1120 | 1125 |
| Asp Pro Pro Gly Gly Ala Ser Lys Pro Arg Lys Leu Leu Val Ser 1130 | 1135 | 1140 |
| Glu Leu Ala Glu Asp Pro Gly Tyr Ala Ile Ala Arg Gly Val Pro 1145 | 1150 | 1155 |

Leu Asn Thr Asp Tyr Tyr Phe Ser His Leu Leu Gly Ala Ala Cys
 1160 1165 1170
 Val Thr Phe Lys Ala Leu Phe Gly Asn Asn Ala Lys Ile Thr Glu
 1175 1180 1185
 Ser Leu Leu Lys Arg Phe Ile Pro Glu Thr Trp His Pro Pro Asp
 1190 1195 1200
 Asp Val Ala Ala Arg Leu Arg Ala Ala Gly Phe Gly Pro Ala Gly
 1205 1210 1215
 Ala Gly Ala Thr Ala Glu Glu Thr Arg Arg Met Leu His Arg Ala
 1220 1225 1230
 Phe Asp Thr Leu Ala
 1235

<210> 3
 <211> 3723
 <212> DNA
 <213> herpes simplex

<400> 3
 atgtttttgtg ccgcgggcg cccggcttcc cccgggggga agtcggcggc tcgggcgggcg 60
 tctgggtttt ttgccccca caacccccgg ggagccaccc agacggcacc gccgccttgc 120
 cgccggcaga acttctacaa cccccacctc gctcagaccg gaacgcagcc aaaggccccc 180
 gggccgggctc agcgccatac gtactacagc gagtgcgacg aatttcgatt tatcgccccg 240
 cgttcgctgg acgaggacgc ccccgcgag cagcgccaccg gggtcacga cggccgcctc 300
 cggcgcgccc ctaaggtgta ctgcgggggg gacgagcgcg acgtcctccg cgtgggccccg 360
 gagggcttct ggccgcgctc gttgcgcctg tggggcggtg cggaccatgc ccccaggggg 420
 ttcgacccca ccgtcacctg ctccacgtg tacgacatcc tggagcacgt ggaacacgcg 480
 tacagcatgc gcgccgcca gctccacgag cgatttatgg acgccatcac gcccgccggg 540
 accgtcatca cgcttctggg tctgaccccc gaaggccatc gcgtcgccgt tcacgtctac 600
 ggcacgcggc agtactttta catgaacaag gcggaggtgg atcggcacct gcagtgccgt 660
 gccccgcgcg atctctgcga gcgcctggcg gcggccctgc gcgagtcgcc gggggcgctc 720
 ttccgcggca tctccgcgga ccacttcgag gcggaggtgg tggagcgcg cgacgtgtac 780
 tattacgaaa cgcgccccgac cctgtactac cgcgtcttcg tgcgaagcgg gcgcgcgctg 840
 gcctacctgt gcgacaactt ttgccccgcg atcaggaagt acgagggggg cgtcgacgcc 900
 accacccggt ttatcctgga caacccgggg tttgtcacct tcggctggta ccgcctcaag 960
 cccggccgcg ggaacgcgcc ggccaaccg cgcggccga cggcggttcgg aacctcgagc 1020
 gacgtcgagt ttaactgcac ggcggacaac ctggccgctc agggggccat gtgtgacctg 1080
 ccggcctaca agctcatgtg ctccgatatc gaatgcaagg ccggggggga ggacgagctg 1140

gcctttccgg tcgcggaacg cccggaagac ctcgtcatcc agatctcctg tctgctctac 1200
 gacctgtcca ccaccgccct cgagcacatc ctctgtttt cgctcggatc ctgcgacctc 1260
 cccgagtccc acctcagcga tctgcctcc aggggctgc cgcccccggt cgtcctggag 1320
 tttgacagcg aattcgagat gctgctggcc ttcattgacct tcgtcaagca gtacggcccc 1380
 gagttcgtga ccgggtacaa catcatcaac ttcgactggc ctttcgtcct gaccaagctg 1440
 acggagatct acaagggtccc gctcgacggg tacggggcga tgaacggccg ggggtgtgttc 1500
 cgcgtgtggg acatcggcca gagccacttt cagaagcgca gcaagatcaa ggtgaacggg 1560
 atgggtgaaca tcgacatgta cggcatcatc accgacaagg tcaaactctc cagctacaag 1620
 ctgaacgccg tcgccgaggc cgtcttgaag gacaagaaga aggatctgag ctaccgcgac 1680
 atccccgcct actacgcctc cgggccccgcg cagcgcgggg tgatcggcga gtattgtgtg 1740
 caggactcgc tgctggtcgg gcagctgttc ttcaagtttc tgccgcacct ggagctttcc 1800
 gccgtcgcgc gcctggcggg catcaacatc acccgcacca tctacgacgg ccagcagatc 1860
 cgcgtcttca cgtgcctcct gcgccttgcg ggccagaagg gcttcatcct gccggacacc 1920
 caggggcggg ttcggggcct cgacaaggag gcgcccagc gcccgccgt gcctcggggg 1980
 gaaggggagc ggccggggga cgggaacggg gacgaggata aggacgacga cgaggacggg 2040
 gacgaggacg gggacgagcg cgaggaggtc gcgcgcgaga ccggggggccg gcacgttggg 2100
 taccaggggg cccgggtcct cgaccccacc tccgggtttc acgtcgacct cgtggtgggtg 2160
 tttgactttg ccagcctgta cccagcatc atccaggccc acaacctgtg cttcagtaag 2220
 ctctccctgc ggcccgaggc cgtcgcgcac ctggaggcgg accgggacta cctggagatc 2280
 gaggtggggg gccgacggct gttcttcgtg aaggccacg tacgcgagag cctgctgagc 2340
 atcctgctgc gcgactggct ggccatgcga aagcagatcc gctcgcggat ccccgagagc 2400
 ccccccaggg aggccgtcct cctcgacaag caacaggccg ccatcaagggt ggtgtgcaac 2460
 tcggtgtacg gggttcaccg ggcgagcac ggtcttctgc cctgcctgca cgtggccgcc 2520
 accgtgacga ccatcggccg cgagatgctc ctcgcgacgc gcgcgtacgt gcacgcgcgc 2580
 tggggcgagt tcgatcagct gctggccgac tttccggagg cggccggcat gcgcgcccc 2640
 ggtccgtact ccatgcgcat catctacggg gacacggact ccattttcgt tttgtgccgc 2700
 ggcctcacgg ccgcgggcct ggtggccatg ggcgacaaga tggcgagcca catctcgcgc 2760
 gcgctgttcc tcccccgat caagctcgag tgcgaaaaaa cgttcaccaa gctgctgctc 2820
 atcgccaaga aaaagtacat cggcgtcatc tgcgggggca agatgctcat caagggcggtg 2880
 gatctggtgc gcaaaaacaa ctgcgcgttt atcaaccgca cctccagggc cctggctgac 2940
 ctgctgtttt acgacgatac cgtatccgga gcggccggcg cgttagccga gcgccccgca 3000

gaggagtggc tggcgcgacc cctgcccagag ggactgcagg cgttcggggc cgtcctcgta 3060
 gacgcccata ggcgcatcac cgacccggag agggacatcc aggactttgt cctcaccgcc 3120
 gaactgagca gacaccgcgc cgcgtaacac aacaagcgcc tggcccacct gacggtgtat 3180
 tacaagctca tggcccgcgc cgcgaggtc ccgtccatca aggaccggat cccgtacgtg 3240
 atcgtggccc agaccgcga ggtagaggag acggtcgccg ggctggccgc cctccgcgag 3300
 ctagacgcgc cgcgccagc ggacgagccc gccccccag cggccctgcc ctccccggcc 3360
 aagcgcccc gggagacgcc gtcgcatgcc gaccccccg gaggcgcgtc caagccccgc 3420
 aagctgctgg tgtccgagct ggcgaggat cccgggtacg ccatcgccc gggcggtccg 3480
 ctcaacacgc actattactt ctgcacctg ctgggggcgc cctgcgtgac gttcaaggcc 3540
 ctgtttggaa ataacgcaa gatcaccgag agtctgttaa agaggtttat tcccagagacg 3600
 tggcaccccc cggacgacgt ggccgcgcgc ctcagggccg cgggggttcgc gccggcgggg 3660
 gccggcgcta cggcgaggga aactcgtcga atgttgata gagcctttga tactctagca 3720
 tga 3723

<210> 4
 <211> 1240
 <212> PRT
 <213> herpes simplex

<400> 4

Met Phe Cys Ala Ala Gly Gly Pro Ala Ser Pro Gly Gly Lys Ser Ala
 1 5 10 15
 Ala Arg Ala Ala Ser Gly Phe Phe Ala Pro His Asn Pro Arg Gly Ala
 20 25 30
 Thr Gln Thr Ala Pro Pro Pro Cys Arg Arg Gln Asn Phe Tyr Asn Pro
 35 40 45
 His Leu Ala Gln Thr Gly Thr Gln Pro Lys Ala Pro Gly Pro Ala Gln
 50 55 60
 Arg His Thr Tyr Tyr Ser Glu Cys Asp Glu Phe Arg Phe Ile Ala Pro
 65 70 75 80
 Arg Ser Leu Asp Glu Asp Ala Pro Ala Glu Gln Arg Thr Gly Val His
 85 90 95
 Asp Gly Arg Leu Arg Arg Ala Pro Lys Val Tyr Cys Gly Gly Asp Glu
 100 105 110
 Arg Asp Val Leu Arg Val Gly Pro Glu Gly Phe Trp Pro Arg Arg Leu
 115 120 125
 Arg Leu Trp Gly Gly Ala Asp His Ala Pro Glu Gly Phe Asp Pro Thr
 130 135 140
 Val Thr Val Phe His Val Tyr Asp Ile Leu Glu His Val Glu His Ala

| | | | |
|---|-------------------------------------|---------------------|---------|
| 145 | 150 | 155 | 160 |
| Tyr Ser Met Arg | Ala Ala Gln Leu His | Glu Arg Phe Met Asp | Ala Ile |
| | 165 | 170 | 175 |
| Thr Pro Ala Gly | Thr Val Ile Thr Leu Leu Gly | Leu Thr Pro Glu Gly | |
| | 180 | 185 | 190 |
| His Arg Val Ala Val His Val | Tyr Gly Thr Arg Gln Tyr Phe Tyr Met | | |
| | 195 | 200 | 205 |
| Asn Lys Ala Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp | | | |
| | 210 | 215 | 220 |
| Leu Cys Glu Arg Leu Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser | | | |
| | 225 | 230 | 235 |
| Phe Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg | | | |
| | 245 | 250 | 255 |
| Ala Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Thr Leu Tyr Tyr Arg Val | | | |
| | 260 | 265 | 270 |
| Phe Val Arg Ser Gly Arg Ala Leu Ala Tyr Leu Cys Asp Asn Phe Cys | | | |
| | 275 | 280 | 285 |
| Pro Ala Ile Arg Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe | | | |
| | 290 | 295 | 300 |
| Ile Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys | | | |
| | 305 | 310 | 315 |
| Pro Gly Arg Gly Asn Ala Pro Ala Gln Pro Arg Pro Pro Thr Ala Phe | | | |
| | 325 | 330 | 335 |
| Gly Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala | | | |
| | 340 | 345 | 350 |
| Val Glu Gly Ala Met Cys Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe | | | |
| | 355 | 360 | 365 |
| Asp Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val | | | |
| | 370 | 375 | 380 |
| Ala Glu Arg Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr | | | |
| | 385 | 390 | 395 |
| Asp Leu Ser Thr Thr Ala Leu Glu His Ile Leu Leu Phe Ser Leu Gly | | | |
| | 405 | 410 | 415 |
| Ser Cys Asp Leu Pro Glu Ser His Leu Ser Asp Leu Ala Ser Arg Gly | | | |
| | 420 | 425 | 430 |
| Leu Pro Ala Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu | | | |
| | 435 | 440 | 445 |
| Leu Ala Phe Met Thr Phe Val Lys Gln Tyr Gly Pro Glu Phe Val Thr | | | |
| | 450 | 455 | 460 |
| Gly Tyr Asn Ile Ile Asn Phe Asp Trp Pro Phe Val Leu Thr Lys Leu | | | |
| | 465 | 470 | 475 |
| | | | 480 |

Thr Glu Ile Tyr Lys Val Pro Leu Asp Gly Tyr Gly Arg Met Asn Gly
 485 490 495
 Arg Gly Val Phe Arg Val Trp Asp Ile Gly Gln Ser His Phe Gln Lys
 500 505 510
 Arg Ser Lys Ile Lys Val Asn Gly Met Val Asn Ile Asp Met Tyr Gly
 515 520 525
 Ile Ile Thr Asp Lys Val Lys Leu Ser Ser Tyr Lys Leu Asn Ala Val
 530 535 540
 Ala Glu Ala Val Leu Lys Asp Lys Lys Lys Asp Leu Ser Tyr Arg Asp
 545 550 555 560
 Ile Pro Ala Tyr Tyr Ala Ser Gly Pro Ala Gln Arg Gly Val Ile Gly
 565 570 575
 Glu Tyr Cys Val Gln Asp Ser Leu Leu Val Gly Gln Leu Phe Phe Lys
 580 585 590
 Phe Leu Pro His Leu Glu Leu Ser Ala Val Ala Arg Leu Ala Gly Ile
 595 600 605
 Asn Ile Thr Arg Thr Ile Tyr Asp Gly Gln Gln Ile Arg Val Phe Thr
 610 615 620
 Cys Leu Leu Arg Leu Ala Gly Gln Lys Gly Phe Ile Leu Pro Asp Thr
 625 630 635 640
 Gln Gly Arg Phe Arg Gly Leu Asp Lys Glu Ala Pro Lys Arg Pro Ala
 645 650 655
 Val Pro Arg Gly Glu Gly Glu Arg Pro Gly Asp Gly Asn Gly Asp Glu
 660 665 670
 Asp Lys Asp Asp Asp Glu Asp Gly Asp Glu Asp Gly Asp Glu Arg Glu
 675 680 685
 Glu Val Ala Arg Glu Thr Gly Gly Arg His Val Gly Tyr Gln Gly Ala
 690 695 700
 Arg Val Leu Asp Pro Thr Ser Gly Phe His Val Asp Pro Val Val Val
 705 710 715 720
 Phe Asp Phe Ala Ser Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu
 725 730 735
 Cys Phe Ser Thr Leu Ser Leu Arg Pro Glu Ala Val Ala His Leu Glu
 740 745 750
 Ala Asp Arg Asp Tyr Leu Glu Ile Glu Val Gly Gly Arg Arg Leu Phe
 755 760 765
 Phe Val Lys Ala His Val Arg Glu Ser Leu Leu Ser Ile Leu Leu Arg
 770 775 780
 Asp Trp Leu Ala Met Arg Lys Gln Ile Arg Ser Arg Ile Pro Gln Ser
 785 790 795 800
 Pro Pro Glu Glu Ala Val Leu Leu Asp Lys Gln Gln Ala Ala Ile Lys
 805 810 815

Val Val Cys Asn Ser Val Tyr Gly Phe Thr Gly Ala Gln His Gly Leu
 820 825 830
 Leu Pro Cys Leu His Val Ala Ala Thr Val Thr Thr Ile Gly Arg Glu
 835 840 845
 Met Leu Leu Ala Thr Arg Ala Tyr Val His Ala Arg Trp Ala Glu Phe
 850 855 860
 Asp Gln Leu Leu Ala Asp Phe Pro Glu Ala Ala Gly Met Arg Ala Pro
 865 870 875 880
 Gly Pro Tyr Ser Met Arg Ile Ile Tyr Gly Asp Thr Asp Ser Ile Phe
 885 890 895
 Val Leu Cys Arg Gly Leu Thr Ala Ala Gly Leu Val Ala Met Gly Asp
 900 905 910
 Lys Met Ala Ser His Ile Ser Arg Ala Leu Phe Leu Pro Pro Ile Lys
 915 920 925
 Leu Glu Cys Glu Lys Thr Phe Thr Lys Leu Leu Leu Ile Ala Lys Lys
 930 935 940
 Lys Tyr Ile Gly Val Ile Cys Gly Gly Lys Met Leu Ile Lys Gly Val
 945 950 955 960
 Asp Leu Val Arg Lys Asn Asn Cys Ala Phe Ile Asn Arg Thr Ser Arg
 965 970 975
 Ala Leu Val Asp Leu Leu Phe Tyr Asp Asp Thr Val Ser Gly Ala Ala
 980 985 990
 Ala Ala Leu Ala Glu Arg Pro Ala Glu Glu Trp Leu Ala Arg Pro Leu
 995 1000 1005
 Pro Glu Gly Leu Gln Ala Phe Gly Ala Val Leu Val Asp Ala His
 1010 1015 1020
 Arg Arg Ile Thr Asp Pro Glu Arg Asp Ile Gln Asp Phe Val Leu
 1025 1030 1035
 Thr Ala Glu Leu Ser Arg His Pro Arg Ala Tyr Thr Asn Lys Arg
 1040 1045 1050
 Leu Ala His Leu Thr Val Tyr Tyr Lys Leu Met Ala Arg Arg Ala
 1055 1060 1065
 Gln Val Pro Ser Ile Lys Asp Arg Ile Pro Tyr Val Ile Val Ala
 1070 1075 1080
 Gln Thr Arg Glu Val Glu Glu Thr Val Ala Arg Leu Ala Ala Leu
 1085 1090 1095
 Arg Glu Leu Asp Ala Ala Ala Pro Gly Asp Glu Pro Ala Pro Pro
 1100 1105 1110
 Ala Ala Leu Pro Ser Pro Ala Lys Arg Pro Arg Glu Thr Pro Ser
 1115 1120 1125
 His Ala Asp Pro Pro Gly Gly Ala Ser Lys Pro Arg Lys Leu Leu

| | | |
|---|------|------|
| 1130 | 1135 | 1140 |
| Val Ser Glu Leu Ala Glu Asp Pro Gly Tyr Ala Ile Ala Arg Gly | | |
| 1145 | 1150 | 1155 |
| Val Pro Leu Asn Thr Asp Tyr Tyr Phe Ser His Leu Leu Gly Ala | | |
| 1160 | 1165 | 1170 |
| Ala Cys Val Thr Phe Lys Ala Leu Phe Gly Asn Asn Ala Lys Ile | | |
| 1175 | 1180 | 1185 |
| Thr Glu Ser Leu Leu Lys Arg Phe Ile Pro Glu Thr Trp His Pro | | |
| 1190 | 1195 | 1200 |
| Pro Asp Asp Val Ala Ala Arg Leu Arg Ala Ala Gly Phe Gly Pro | | |
| 1205 | 1210 | 1215 |
| Ala Gly Ala Gly Ala Thr Ala Glu Glu Thr Arg Arg Met Leu His | | |
| 1220 | 1225 | 1230 |
| Arg Ala Phe Asp Thr Leu Ala | | |
| 1235 | 1240 | |

<210> 5
 <211> 3708
 <212> DNA
 <213> herpes simplex

<400> 5
 atgttttccg gtggcggcgg cccgctgtcc cccggaggaa agtcggcggc cagggcggcg 60
 tccgggtttt ttgcgccgc cgccctcgc ggagccggcc ggggaccccc gccttgtttg 120
 aggcaaaact ttacaaccc ctacctcgc ccagtcggga cgcaacagaa gccgaccggg 180
 ccaaccagc gccatacgta ctatagcgaa tgcgatgaat ttcgattcat cgcgccggcg 240
 gtgctggacg aggatgcccc cccggagaag cgcgccgggg tgcacgacgg tcacctcaag 300
 cgcgccccca aggtgtactg cggggggggac gagcgcgacg tcttcgcgt cgggtcgggc 360
 ggcttctggc cgcggcgctc gcgcctgtgg ggccggcgtg accacgcccc ggcgggggtc 420
 aacccaccg tcaccgtctt tcacgtgtac gacatcctgg agaactgga gcacgcgtac 480
 ggcacgcgcg cggcccagtt ccacgcgcgg tttatggacg ccatcacacc gacggggacc 540
 gtcacacgc tctgggct gactccgaa ggccaccggg tggccgttca cgtttacggc 600
 acgcggcagt acttttacat gaacaaggag gaggttgaca ggcacctaca atgccgcgc 660
 ccacgagatc tctgcgagcg catggccgcg gccctgcgcg agtccccggg cgcgtcgttc 720
 cgcggcatct ccgcggacca cttcgaggcg gaggtggtgg agcgcaccga cgtgtactac 780
 tacgagacgc gccccgtct gttttaccgc gtctacgtcc gaagcgggcg cgtgctgtcg 840
 tacctgtgcg acaacttctg cccggccatc aagaagtacg aggggtgggt cgacgccacc 900
 acccggttca tctgggacaa ccccggttc gtcacctcg gctggtaccg tctcaaaccg 960
 ggccggaaca acacgctagc ccagccgcgg gcccgatgg ccttcgggac atccagcgac 1020

gtcgagttta actgtacggc ggacaacctg gccatcgagg ggggcatgag cgacctaccg 1080
 gcatacaagc tcatgtgctt cgatatcgaa tgcaaggcgg ggggggagga cgagctggcc 1140
 tttccggtgg ccgggcaccc ggaggacctg gttattcaga taccctgtct gctctacgac 1200
 ctgtccacca ccgccctgga gcacgtctc ctgttttcgc tcggttcctg cgacctcccc 1260
 gaatccacc tgaacgagct ggcgccagg ggcccgcca cggcgtggg tctggaattc 1320
 gacagcgaat tcgagatgct gttggccttc atgacccttg tgaaacagta cggccccgag 1380
 ttcgtgaccg ggtacaacat catcaacttc gactggccct tcttgctggc caagttgacg 1440
 gacatttaca aggtccccct ggacgggtac ggccgcatga acggccgggg cgtgtttcgc 1500
 gtgtgggaca taggccagag ccacttccag aagcgcagca agataaagggt gaacggcatg 1560
 gtgaacatcg acatgtacgg gatcataacc gacaagatca agctctcgag ctacaagctc 1620
 aacgccgtgg ccgaagccgt cctgaaggac aagaagaagg acctgagcta tcgcgacatc 1680
 cccgcctact acgccgccgg gcccgcgcaa cgcgggggtga tcggcgagta ctgcatacag 1740
 gattccctgc tgggtgggcca gctgtttttt aagtttttgc cccatctgga gctctcggcc 1800
 gtcgcgcgct tggcggggtat taacatcacc cgcaccatct acgacggcca gcagatccgc 1860
 gtcttttacgt gcctgctgcg cctggccgac cagaagggtt ttattctgcc ggacaccag 1920
 gggcgattta ggggcgccgg gggggaggcg cccaagcgtc cggccgcagc ccgggaggac 1980
 gaggagcggc cagaggagga gggggaggac gaggacgaac gcgaggaggg cgggggagcag 2040
 cgggagccgg agggcgcgcg ggagaccgcc ggccggcacg tggggtacca gggggccagg 2100
 gtccttgacc ccacttccgg gtttcacgtg aaccccggtg tgggtgttca ctttgccagc 2160
 ctgtacccca gcatcatcca ggcccacaac ctgtgcttca gcacgtctc cctgagggcc 2220
 gacgcagtgg cgcacctgga ggccggcaag gactacctgg agatcgagggt gggggggcga 2280
 cggctgttct tcgtcaaggc tcacgtgcga gagagcctcc tcagcatcct cctgcgggac 2340
 tggctcgcca tgcgaaagca gatccgctcg cggattcccc agagcagccc cgaggaggcc 2400
 gtgctcctgg acaagcagca ggccgccatc aaggctgtgt gtaactcggg gtacgggttc 2460
 acgggagcgc agcacggaet cctgcctgct ctgcacgttg ccgcgacggg gacgaccatc 2520
 ggccgcgaga tgctgctcgc gaccgcgag tacgtccacg ccgctgggg ggcccttcgaa 2580
 cagctcctgg ccgatttccc ggaggcgcc gacatgcgcg cccccggg ccatttccatg 2640
 cgcacatct acggggacac ggactccata tttgtgctgt gcccgggcct cacggccgcc 2700
 gggctgacgg ccatgggcca caagatggcg agccacatct cgcgcgcgct gtttctgccc 2760
 cccatcaaac tcgagtgcga aaagacgttc accaagctgc tgctgatcgc caagaaaaag 2820
 tacatcggcg tcactacgg gggtaagatg ctcatcaagg gcgtggatct ggtgcgcaaa 2880

aacaactgcg cgtttatcaa cgcacacctcc agggccctgg tcgacctgct gttttacgac 2940
gataccgtat cgggagcggc cgccgcgtta gccgagcgcc ccgcagagga gtggctggcg 3000
cgacccctgc ccgagggact gcaggcggtc ggggccgtcc tcgtagacgc ccatcggcg 3060
atcacccgacc cggagagggg catccaggac tttgtcctca ccgccgaact gagcagacac 3120
ccgcgcgcgt acaccaacaa gcgcctggcc cacctgacgg tgtattacaa gctcatggcc 3180
cgccgcgcgc aggtcccgtc catcaaggac cggatcccg acgtgatcgt ggcccagacc 3240
cgcgaggtag aggagacggt cgcgcggtg gccgccctcc gcgagctaga cgccgccgcc 3300
ccagggggacg agcccccccc ccccgcgggc ctgccctccc cggccaagcg cccccgggag 3360
acgccgtcgc atgccgaccc cccgggaggg gcgtccaagc cccgcaagct gctggtgtcc 3420
gagctggccg aggatcccg atacgccatt gccacggcg tcgccctgaa cacggactat 3480
tactttctccc acctgttggg ggccggcgtgc gtgacattca aggccctgtt tgggaataac 3540
gccaagatca ccgagagtct gttaaaaagg tttattcccg aagtgtggca cccccggac 3600
gacgtggccg cgccgctccg ggccgcaggg ttccggggcg tgggtgccgg cgctacggcg 3660
gaggaaactc gtcgaatgtt gcatagagcc tttgatactc tagcatga 3708

<210> 6
<211> 1235
<212> PRT
<213> herpes simplex

<400> 6

Met Phe Ser Gly Gly Gly Gly Pro Leu Ser Pro Gly Gly Lys Ser Ala
1 5 10 15
Ala Arg Ala Ala Ser Gly Phe Phe Ala Pro Ala Gly Pro Arg Gly Ala
20 25 30
Gly Arg Gly Pro Pro Pro Cys Leu Arg Gln Asn Phe Tyr Asn Pro Tyr
35 40 45
Leu Ala Pro Val Gly Thr Gln Gln Lys Pro Thr Gly Pro Thr Gln Arg
50 55 60
His Thr Tyr Tyr Ser Glu Cys Asp Glu Phe Arg Phe Ile Ala Pro Arg
65 70 75 80
Val Leu Asp Glu Asp Ala Pro Pro Glu Lys Arg Ala Gly Val His Asp
85 90 95
Gly His Leu Lys Arg Ala Pro Lys Val Tyr Cys Gly Gly Asp Glu Arg
100 105 110
Asp Val Leu Arg Val Gly Ser Gly Gly Phe Trp Pro Arg Arg Ser Arg
115 120 125
Leu Trp Gly Gly Val Asp His Ala Pro Ala Gly Phe Asn Pro Thr Val

| 130 | 135 | 140 |
|---|-----|-------------|
| Thr Val Phe His Val Tyr Asp Ile Leu Glu Asn Val Glu His Ala Tyr | | |
| 145 | 150 | 155 160 |
| Gly Met Arg Ala Ala Gln Phe His Ala Arg Phe Met Asp Ala Ile Thr | | |
| | 165 | 170 175 |
| Pro Thr Gly Thr Val Ile Thr Leu Leu Gly Leu Thr Pro Glu Gly His | | |
| | 180 | 185 190 |
| Arg Val Ala Val His Val Tyr Gly Thr Arg Gln Tyr Phe Tyr Met Asn | | |
| | 195 | 200 205 |
| Lys Glu Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp Leu | | |
| | 210 | 215 220 |
| Cys Glu Arg Met Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser Phe | | |
| | 225 | 230 235 240 |
| Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg Thr | | |
| | 245 | 250 255 |
| Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Ala Leu Phe Tyr Arg Val Tyr | | |
| | 260 | 265 270 |
| Val Arg Ser Gly Arg Val Leu Ser Tyr Leu Cys Asp Asn Phe Cys Pro | | |
| | 275 | 280 285 |
| Ala Ile Lys Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe Ile | | |
| | 290 | 295 300 |
| Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys Pro | | |
| | 305 | 310 315 320 |
| Gly Arg Asn Asn Thr Leu Ala Gln Pro Arg Ala Pro Met Ala Phe Gly | | |
| | 325 | 330 335 |
| Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala Ile | | |
| | 340 | 345 350 |
| Glu Gly Gly Met Ser Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe Asp | | |
| | 355 | 360 365 |
| Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val Ala | | |
| | 370 | 375 380 |
| Gly His Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr Asp | | |
| | 385 | 390 395 400 |
| Leu Ser Thr Thr Ala Leu Glu His Val Leu Leu Phe Ser Leu Gly Ser | | |
| | 405 | 410 415 |
| Cys Asp Leu Pro Glu Ser His Leu Asn Glu Leu Ala Ala Arg Gly Leu | | |
| | 420 | 425 430 |
| Pro Thr Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu Leu | | |
| | 435 | 440 445 |
| Ala Phe Met Thr Leu Val Lys Gln Tyr Gly Pro Glu Phe Val Thr Gly | | |
| | 450 | 455 460 |

Tyr Asn Ile Ile Asn Phe Asp Trp Pro Phe Leu Leu Ala Lys Leu Thr
 465 470 475 480
 Asp Ile Tyr Lys Val Pro Leu Asp Gly Tyr Gly Arg Met Asn Gly Arg
 485 490 495
 Gly Val Phe Arg Val Trp Asp Ile Gly Gln Ser His Phe Gln Lys Arg
 500 505 510
 Ser Lys Ile Lys Val Asn Gly Met Val Asn Ile Asp Met Tyr Gly Ile
 515 520 525
 Ile Thr Asp Lys Ile Lys Leu Ser Ser Tyr Lys Leu Asn Ala Val Ala
 530 535 540
 Glu Ala Val Leu Lys Asp Lys Lys Lys Asp Leu Ser Tyr Arg Asp Ile
 545 550 555 560
 Pro Ala Tyr Tyr Ala Ala Gly Pro Ala Gln Arg Gly Val Ile Gly Glu
 565 570 575
 Tyr Cys Ile Gln Asp Ser Leu Leu Val Gly Gln Leu Phe Phe Lys Phe
 580 585 590
 Leu Pro His Leu Glu Leu Ser Ala Val Ala Arg Leu Ala Gly Ile Asn
 595 600 605
 Ile Thr Arg Thr Ile Tyr Asp Gly Gln Gln Ile Arg Val Phe Thr Cys
 610 615 620
 Leu Leu Arg Leu Ala Asp Gln Lys Gly Phe Ile Leu Pro Asp Thr Gln
 625 630 635 640
 Gly Arg Phe Arg Gly Ala Gly Gly Glu Ala Pro Lys Arg Pro Ala Ala
 645 650 655
 Ala Arg Glu Asp Glu Glu Arg Pro Glu Glu Glu Gly Glu Asp Glu Asp
 660 665 670
 Glu Arg Glu Glu Gly Gly Gly Glu Arg Glu Pro Glu Gly Ala Arg Glu
 675 680 685
 Thr Ala Gly Arg His Val Gly Tyr Gln Gly Ala Arg Val Leu Asp Pro
 690 695 700
 Thr Ser Gly Phe His Val Asn Pro Val Val Val Phe Asp Phe Ala Ser
 705 710 715 720
 Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu Cys Phe Ser Thr Leu
 725 730 735
 Ser Leu Arg Ala Asp Ala Val Ala His Leu Glu Ala Gly Lys Asp Tyr
 740 745 750
 Leu Glu Ile Glu Val Gly Gly Arg Arg Leu Phe Phe Val Lys Ala His
 755 760 765
 Val Arg Glu Ser Leu Leu Ser Ile Leu Leu Arg Asp Trp Leu Ala Met
 770 775 780
 Arg Lys Gln Ile Arg Ser Arg Ile Pro Gln Ser Ser Pro Glu Glu Ala
 785 790 795 800

Val Leu Leu Asp Lys Gln Gln Ala Ala Ile Lys Val Val Cys Asn Ser
 805 810 815
 Val Tyr Gly Phe Thr Gly Ala Gln His Gly Leu Leu Pro Cys Leu His
 820 825 830
 Val Ala Ala Thr Val Thr Thr Ile Gly Arg Glu Met Leu Leu Ala Thr
 835 840 845
 Arg Glu Tyr Val His Ala Arg Trp Ala Ala Phe Glu Gln Leu Leu Ala
 850 855 860
 Asp Phe Pro Glu Ala Ala Asp Met Arg Ala Pro Gly Pro Tyr Ser Met
 865 870 875 880
 Arg Ile Ile Tyr Gly Asp Thr Asp Ser Ile Phe Val Leu Cys Arg Gly
 885 890 895
 Leu Thr Ala Ala Gly Leu Thr Ala Met Gly Asp Lys Met Ala Ser His
 900 905 910
 Ile Ser Arg Ala Leu Phe Leu Pro Pro Ile Lys Leu Glu Cys Glu Lys
 915 920 925
 Thr Phe Thr Lys Leu Leu Leu Ile Ala Lys Lys Lys Tyr Ile Gly Val
 930 935 940
 Ile Tyr Gly Gly Lys Met Leu Ile Lys Gly Val Asp Leu Val Arg Lys
 945 950 955 960
 Asn Asn Cys Ala Phe Ile Asn Arg Thr Ser Arg Ala Leu Val Asp Leu
 965 970 975
 Leu Phe Tyr Asp Asp Thr Val Ser Gly Ala Ala Ala Ala Leu Ala Glu
 980 985 990
 Arg Pro Ala Glu Glu Trp Leu Ala Arg Pro Leu Pro Glu Gly Leu Gln
 995 1000 1005
 Ala Phe Gly Ala Val Leu Val Asp Ala His Arg Arg Ile Thr Asp
 1010 1015 1020
 Pro Glu Arg Asp Ile Gln Asp Phe Val Leu Thr Ala Glu Leu Ser
 1025 1030 1035
 Arg His Pro Arg Ala Tyr Thr Asn Lys Arg Leu Ala His Leu Thr
 1040 1045 1050
 Val Tyr Tyr Lys Leu Met Ala Arg Arg Ala Gln Val Pro Ser Ile
 1055 1060 1065
 Lys Asp Arg Ile Pro Tyr Val Ile Val Ala Gln Thr Arg Glu Val
 1070 1075 1080
 Glu Glu Thr Val Ala Arg Leu Ala Ala Leu Arg Glu Leu Asp Ala
 1085 1090 1095
 Ala Ala Pro Gly Asp Glu Pro Ala Pro Pro Ala Ala Leu Pro Ser
 1100 1105 1110
 Pro Ala Lys Arg Pro Arg Glu Thr Pro Ser His Ala Asp Pro Pro

| | | |
|---|------|------|
| 1115 | 1120 | 1125 |
| Gly Gly Ala Ser Lys Pro Arg Lys Leu Leu Val Ser Glu Leu Ala | | |
| 1130 | 1135 | 1140 |
| Glu Asp Pro Ala Tyr Ala Ile Ala His Gly Val Ala Leu Asn Thr | | |
| 1145 | 1150 | 1155 |
| Asp Tyr Tyr Phe Ser His Leu Leu Gly Ala Ala Cys Val Thr Phe | | |
| 1160 | 1165 | 1170 |
| Lys Ala Leu Phe Gly Asn Asn Ala Lys Ile Thr Glu Ser Leu Leu | | |
| 1175 | 1180 | 1185 |
| Lys Arg Phe Ile Pro Glu Val Trp His Pro Pro Asp Asp Val Ala | | |
| 1190 | 1195 | 1200 |
| Ala Arg Leu Arg Ala Ala Gly Phe Gly Ala Val Gly Ala Gly Ala | | |
| 1205 | 1210 | 1215 |
| Thr Ala Glu Glu Thr Arg Arg Met Leu His Arg Ala Phe Asp Thr | | |
| 1220 | 1225 | 1230 |
| Leu Ala | | |
| 1235 | | |

<210> 7
 <211> 3708
 <212> DNA
 <213> herpes simplex

<400> 7
 atgtttttccg gtggcgggcgg cccgctgtcc cccggaggaa agtcggcgggc cagggcgggcg 60
 tccgggtttt ttgcgcccgc cggccctcgc ggagccggcc ggggaccccc gccttgett 120
 aggcaaaact ttacaaccc ctacctcgcc ccagtcggga cgcaacagaa gccgaccggg 180
 ccaaccacgc gccatacgtat ctatagcgaa tgcgatgaat ttcgattcat cgcgcccgcg 240
 gtgctggacg aggatgcccc cccggagaag cgcgcccgggg tgcacgacgg tcacctcaag 300
 cgcgccccca aggtgtactg cggggggggac gagcgcgacg tcctccgcgt cgggtcgggc 360
 ggcttctggc cgcggcgctc gcgcctgtgg ggcggcgtgg accacgcccc ggcgggggttc 420
 aacccaccgc tcaccgtctt tcacgtgtac gacatcctgg agaacgtgga gcacgcgtac 480
 ggcatgcgcg cggcccagtt ccacgcgcgg tttatggacg ccatcacacc gacggggacc 540
 gtcacacgc tcctgggcct gactccggaa ggccaccggg tggccgttca cgtttacggc 600
 acgcggcagt acttttacat gaacaaggag gaggtcgaca ggcacctaca atgccgcgcc 660
 ccacgagatc tctgcgagcg catggccgcg gccctgcgcg agtccccggg cgcgtcgttc 720
 cgcggcattt ccgcggacca cttcgaggcg gagtggtggt agcgcaccga cgtgtactac 780
 tacgagacgc gccccgctct gttttaccgc gtctacgtcc gaagcggggc cgtgtgtcg 840
 tacctgtgcg acaacttctg cccggccatc aagaagtac aggggtggggc cgacgccacc 900

acccggttca tcctggacaa ccccggttc gtcaccttcg gctggtaccg tctcaaaccg 960
 ggccggaaca acacgctagc ccagccgcgg gccccgatgg ccttcgggac atccagcgac 1020
 gtcgagttta actgtacggc ggacaacctg gccatcgagg ggggcatgag cgacctaccg 1080
 gcatacaagc tcatgtgctt cgatatcgaa tgcaaggcgg ggggggagga cgagctggcc 1140
 tttccggtgg ccgggcaccc ggaggacctg gtcattcaga tatcctgtct gctctacgac 1200
 ctgtccacca ccgccctgga gcacgtcctc ctgttttcgc tcggttcctg cgacctcccc 1260
 gaatcccacc tgaacgagct ggcgccagg ggcccgccca cgcccggtgt tctggaattc 1320
 gacagcgaat tcgagatgct gttggccttc atgacccttg tgaaacagta cggccccgag 1380
 ttcgtgaccg ggtacaacat catcaacttc gactggccct tcttgctggc caagctgacg 1440
 gacatttaca aggtccccct ggacgggtac ggccgcatga acggccgggg cgtgtttcgc 1500
 gtgtgggaca taggccagag ccacttccag aagcgcagca agataaaggt gaacggcatg 1560
 gtgaacatcg acatgtacgg gattataacc gacaagatca agctctcgag ctacaagctc 1620
 aacgcctgg ccgaagccgt cctgaaggac aagaagaagg acctgagcta tcgcgacatc 1680
 cccgcctact acgccgcgg gcccgcgcaa cgcggggtga tcggcgagta ctgcatacag 1740
 gattccctgc tgggtgggcca gctgtttttt aagtttttgc cccatctgga gctctcggcc 1800
 gtcgcgcgct tggcggttat taacatcacc cgcaccatct acgacggcca gcagatccgc 1860
 gtctttacgt gcctgctgcg cctggccgac cagaagggtt ttattctgcc ggacaccag 1920
 gggcgattta gggcgggcgg gggggaggcg cccaagcgtc cggccgcagc ccgggaggac 1980
 gaggagcggc cagaggagga gggggaggac gaggacgaac gcgaggaggg cgggggagcag 2040
 cgggagccgg agggcgcgcg ggagaccgcc ggccggcacg tggggtacca gggggccagg 2100
 gtccttgacc ccacttccgg gtttcatgtg aaccccggtg tgggtgttca ctttgccagc 2160
 ctgtacccca gcatcatcca ggcccacaac ctgtgcttca gacgctctc cctgagggcc 2220
 gacgcagtgg cgcacctgga ggcgggcaag gactacctgg agatcgaggt gggggggcga 2280
 cggctgttct tcgtcaaggc tcacgtgcga gagagcctcc tcagcatcct cctgcgggac 2340
 tggtctgcca tgcgaaagca gatccgctcg cggattcccc agagcagccc cgaggaggcc 2400
 gtgctcctgg acaagcagca ggccgccatc aaggctcgtg gtaactcgtt ttacgggttc 2460
 acgggagcgc agcacggact cctgcctgtc ctgcacgttg ccgcgacggt gacgaccatc 2520
 ggccgcgaga tgctgctcgc gaccgcgag tacgtccacg cgcgctgggc ggccttcgaa 2580
 cagctcctgg ccgatttccc ggaggcggcc gacatgcgcg cccccgggcc ctattccatg 2640
 cgcacatct acggggacac ggactccatc tttgtgctgt gcccgggcct cagggccgcc 2700
 gggctgacgg ccgtgggcca caagatggcg agccacatct cgcgcgcgct gtttctgtcc 2760

```

cccatcaaac tcgagtgcga aaagacgttc accaagctgc tgctgatcgc caagaaaaag 2820
tacatcgggcgc tcatctacgg gggtaagatg ctcatcaagg gcgtggatct ggtgcgcaaa 2880
aacaactgcg cgtttatcaa ccgcacctcc agggccctgg tcgacctgct gttttacgac 2940
gataccgtat ccggagcggc cgccgcgtta gccgagcgcc ccgcagagga gtggctggcg 3000
cgacccctgc ccgagggact gcaggcggtc ggggccgtcc tcgtagacgc ccatcggcgc 3060
atcacccgacc cggagagggga catccaggac tttgtcctca ccgccgaact gagcagacac 3120
ccgcgcgcgt acaccaacaa gcgcctggcc cacctgacgg tgtattacaa gtcacggcc 3180
cgccgcgcgc aggtcccgtc catcaaggac cggatcccgt acgtgatcgt ggcccagacc 3240
cgcgaggtag aggagacggt cgcgcggtg gccgccctcc gcgagctcga cgccgccgcc 3300
ccaggggacg agcccgcccc ccccgcgggc ctgccctccc cggccaagcg cccccgggag 3360
acgccgttgc atgccgacct cccgggaggg gcgtccaagc cccgcaagct gctggtgtcc 3420
gagctggccg aggatcccgc atacgccatt gccacggcg tcgccctgaa cacggactat 3480
tactttctccc acctgttggg ggccggcgtg gtgacattca aggccctgtt tgggaataac 3540
gccaagatca ccgagagtct gttaaaaagg tttattcccg aagtgtggca cccccggac 3600
gacgtggccg cgcggtccg ggccgcaggg ttccggggcg tgggtgccg cgctacggcg 3660
gaggaaaactc gtcgaatgtt gcatagagcc tttgatactc tagcatga 3708

```

```

<210> 8
<211> 1235
<212> PRT
<213> herpes simplex

```

```

<400> 8

```

```

Met Phe Ser Gly Gly Gly Gly Pro Leu Ser Pro Gly Gly Lys Ser Ala
1           5           10           15
Ala Arg Ala Ala Ser Gly Phe Phe Ala Pro Ala Gly Pro Arg Gly Ala
20           25           30
Gly Arg Gly Pro Pro Pro Cys Leu Arg Gln Asn Phe Tyr Asn Pro Tyr
35           40           45
Leu Ala Pro Val Gly Thr Gln Gln Lys Pro Thr Gly Pro Thr Gln Arg
50           55           60
His Thr Tyr Tyr Ser Glu Cys Asp Glu Phe Arg Phe Ile Ala Pro Arg
65           70           75           80
Val Leu Asp Glu Asp Ala Pro Pro Glu Lys Arg Ala Gly Val His Asp
85           90           95
Gly His Leu Lys Arg Ala Pro Lys Val Tyr Cys Gly Gly Asp Glu Arg
100          105          110
Asp Val Leu Arg Val Gly Ser Gly Gly Phe Trp Pro Arg Arg Ser Arg

```

| | | |
|---|-----|-----|
| 115 | 120 | 125 |
| Leu Trp Gly Gly Val Asp His Ala Pro Ala Gly Phe Asn Pro Thr Val | | |
| 130 | 135 | 140 |
| Thr Val Phe His Val Tyr Asp Ile Leu Glu Asn Val Glu His Ala Tyr | | |
| 145 | 150 | 155 |
| Gly Met Arg Ala Ala Gln Phe His Ala Arg Phe Met Asp Ala Ile Thr | | |
| | 165 | 170 |
| Pro Thr Gly Thr Val Ile Thr Leu Leu Gly Leu Thr Pro Glu Gly His | | |
| | 180 | 185 |
| Arg Val Ala Val His Val Tyr Gly Thr Arg Gln Tyr Phe Tyr Met Asn | | |
| | 195 | 200 |
| Lys Glu Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp Leu | | |
| | 210 | 215 |
| Cys Glu Arg Met Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser Phe | | |
| | 225 | 230 |
| Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg Thr | | |
| | 245 | 250 |
| Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Ala Leu Phe Tyr Arg Val Tyr | | |
| | 260 | 265 |
| Val Arg Ser Gly Arg Val Leu Ser Tyr Leu Cys Asp Asn Phe Cys Pro | | |
| | 275 | 280 |
| Ala Ile Lys Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe Ile | | |
| | 290 | 295 |
| Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys Pro | | |
| | 305 | 310 |
| Gly Arg Asn Asn Thr Leu Ala Gln Pro Arg Ala Pro Met Ala Phe Gly | | |
| | 325 | 330 |
| Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala Ile | | |
| | 340 | 345 |
| Glu Gly Gly Met Ser Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe Asp | | |
| | 355 | 360 |
| Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val Ala | | |
| | 370 | 375 |
| Gly His Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr Asp | | |
| | 385 | 390 |
| Leu Ser Thr Thr Ala Leu Glu His Val Leu Leu Phe Ser Leu Gly Ser | | |
| | 405 | 410 |
| Cys Asp Leu Pro Glu Ser His Leu Asn Glu Leu Ala Ala Arg Gly Leu | | |
| | 420 | 425 |
| Pro Thr Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu Leu | | |
| | 435 | 440 |
| | | 445 |

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Phe | Met | Thr | Leu | Val | Lys | Gln | Tyr | Gly | Pro | Glu | Phe | Val | Thr | Gly | 450 | 455 | 460 |
| Tyr | Asn | Ile | Ile | Asn | Phe | Asp | Trp | Pro | Phe | Leu | Leu | Ala | Lys | Leu | Thr | 465 | 470 | 475 |
| Asp | Ile | Tyr | Lys | Val | Pro | Leu | Asp | Gly | Tyr | Gly | Arg | Met | Asn | Gly | Arg | 485 | 490 | 495 |
| Gly | Val | Phe | Arg | Val | Trp | Asp | Ile | Gly | Gln | Ser | His | Phe | Gln | Lys | Arg | 500 | 505 | 510 |
| Ser | Lys | Ile | Lys | Val | Asn | Gly | Met | Val | Asn | Ile | Asp | Met | Tyr | Gly | Ile | 515 | 520 | 525 |
| Ile | Thr | Asp | Lys | Ile | Lys | Leu | Ser | Ser | Tyr | Lys | Leu | Asn | Ala | Val | Ala | 530 | 535 | 540 |
| Glu | Ala | Val | Leu | Lys | Asp | Lys | Lys | Lys | Asp | Leu | Ser | Tyr | Arg | Asp | Ile | 545 | 550 | 555 |
| Pro | Ala | Tyr | Tyr | Ala | Ala | Gly | Pro | Ala | Gln | Arg | Gly | Val | Ile | Gly | Glu | 565 | 570 | 575 |
| Tyr | Cys | Ile | Gln | Asp | Ser | Leu | Leu | Val | Gly | Gln | Leu | Phe | Phe | Lys | Phe | 580 | 585 | 590 |
| Leu | Pro | His | Leu | Glu | Leu | Ser | Ala | Val | Ala | Arg | Leu | Ala | Gly | Ile | Asn | 595 | 600 | 605 |
| Ile | Thr | Arg | Thr | Ile | Tyr | Asp | Gly | Gln | Gln | Ile | Arg | Val | Phe | Thr | Cys | 610 | 615 | 620 |
| Leu | Leu | Arg | Leu | Ala | Asp | Gln | Lys | Gly | Phe | Ile | Leu | Pro | Asp | Thr | Gln | 625 | 630 | 635 |
| Gly | Arg | Phe | Arg | Gly | Gly | Gly | Gly | Glu | Ala | Pro | Lys | Arg | Pro | Ala | Ala | 645 | 650 | 655 |
| Ala | Arg | Glu | Asp | Glu | Glu | Arg | Pro | Glu | Glu | Glu | Gly | Glu | Asp | Glu | Asp | 660 | 665 | 670 |
| Glu | Arg | Glu | Glu | Gly | Gly | Gly | Glu | Arg | Glu | Pro | Glu | Gly | Ala | Arg | Glu | 675 | 680 | 685 |
| Thr | Ala | Gly | Arg | His | Val | Gly | Tyr | Gln | Gly | Ala | Arg | Val | Leu | Asp | Pro | 690 | 695 | 700 |
| Thr | Ser | Gly | Phe | His | Val | Asn | Pro | Val | Val | Val | Phe | Asp | Phe | Ala | Ser | 705 | 710 | 715 |
| Leu | Tyr | Pro | Ser | Ile | Ile | Gln | Ala | His | Asn | Leu | Cys | Phe | Ser | Thr | Leu | 725 | 730 | 735 |
| Ser | Leu | Arg | Ala | Asp | Ala | Val | Ala | His | Leu | Glu | Ala | Gly | Lys | Asp | Tyr | 740 | 745 | 750 |
| Leu | Glu | Ile | Glu | Val | Gly | Gly | Arg | Arg | Leu | Phe | Phe | Val | Lys | Ala | His | 755 | 760 | 765 |
| Val | Arg | Glu | Ser | Leu | Leu | Ser | Ile | Leu | Leu | Arg | Asp | Trp | Leu | Ala | Met | 770 | 775 | 780 |

Arg Lys Gln Ile Arg Ser Arg Ile Pro Gln Ser Ser Pro Glu Glu Ala
 785 790 795 800
 Val Leu Leu Asp Lys Gln Gln Ala Ala Ile Lys Val Val Cys Asn Ser
 805 810 815
 Val Tyr Gly Phe Thr Gly Ala Gln His Gly Leu Leu Pro Cys Leu His
 820 825 830
 Val Ala Ala Thr Val Thr Thr Ile Gly Arg Glu Met Leu Leu Ala Thr
 835 840 845
 Arg Glu Tyr Val His Ala Arg Trp Ala Ala Phe Glu Gln Leu Leu Ala
 850 855 860
 Asp Phe Pro Glu Ala Ala Asp Met Arg Ala Pro Gly Pro Tyr Ser Met
 865 870 875 880
 Arg Ile Ile Tyr Gly Asp Thr Asp Ser Ile Phe Val Leu Cys Arg Gly
 885 890 895
 Leu Thr Ala Ala Gly Leu Thr Ala Val Gly Asp Lys Met Ala Ser His
 900 905 910
 Ile Ser Arg Ala Leu Phe Leu Ser Pro Ile Lys Leu Glu Cys Glu Lys
 915 920 925
 Thr Phe Thr Lys Leu Leu Leu Ile Ala Lys Lys Lys Tyr Ile Gly Val
 930 935 940
 Ile Tyr Gly Gly Lys Met Leu Ile Lys Gly Val Asp Leu Val Arg Lys
 945 950 955 960
 Asn Asn Cys Ala Phe Ile Asn Arg Thr Ser Arg Ala Leu Val Asp Leu
 965 970 975
 Leu Phe Tyr Asp Asp Thr Val Ser Gly Ala Ala Ala Ala Leu Ala Glu
 980 985 990
 Arg Pro Ala Glu Glu Trp Leu Ala Arg Pro Leu Pro Glu Gly Leu Gln
 995 1000 1005
 Ala Phe Gly Ala Val Leu Val Asp Ala His Arg Arg Ile Thr Asp
 1010 1015 1020
 Pro Glu Arg Asp Ile Gln Asp Phe Val Leu Thr Ala Glu Leu Ser
 1025 1030 1035
 Arg His Pro Arg Ala Tyr Thr Asn Lys Arg Leu Ala His Leu Thr
 1040 1045 1050
 Val Tyr Tyr Lys Leu Met Ala Arg Arg Ala Gln Val Pro Ser Ile
 1055 1060 1065
 Lys Asp Arg Ile Pro Tyr Val Ile Val Ala Gln Thr Arg Glu Val
 1070 1075 1080
 Glu Glu Thr Val Ala Arg Leu Ala Ala Leu Arg Glu Leu Asp Ala
 1085 1090 1095
 Ala Ala Pro Gly Asp Glu Pro Ala Pro Pro Ala Ala Leu Pro Ser

| | | |
|-------------------------|---------------------|-----------------|
| 1100 | 1105 | 1110 |
| Pro Ala Lys Arg Pro Arg | Glu Thr Pro Leu His | Ala Asp Pro Pro |
| 1115 | 1120 | 1125 |
| Gly Gly Ala Ser Lys Pro | Arg Lys Leu Leu Val | Ser Glu Leu Ala |
| 1130 | 1135 | 1140 |
| Glu Asp Pro Ala Tyr Ala | Ile Ala His Gly Val | Ala Leu Asn Thr |
| 1145 | 1150 | 1155 |
| Asp Tyr Tyr Phe Ser His | Leu Leu Gly Ala Ala | Cys Val Thr Phe |
| 1160 | 1165 | 1170 |
| Lys Ala Leu Phe Gly Asn | Asn Ala Lys Ile Thr | Glu Ser Leu Leu |
| 1175 | 1180 | 1185 |
| Lys Arg Phe Ile Pro Glu | Val Trp His Pro Pro | Asp Asp Val Ala |
| 1190 | 1195 | 1200 |
| Ala Arg Leu Arg Ala Ala | Gly Phe Gly Ala Val | Gly Ala Gly Ala |
| 1205 | 1210 | 1215 |
| Thr Ala Glu Glu Thr Arg | Arg Met Leu His Arg | Ala Phe Asp Thr |
| 1220 | 1225 | 1230 |
| Leu Ala | | |
| 1235 | | |

<210> 9
 <211> 3708
 <212> DNA
 <213> herpes simplex

<400> 9
 atgtttttccg gtggcggcgg cccgctgtcc cccggaggaa agtcggcggc cagggcggcg 60
 tccgggtttt ttgcgccgc cggccctcgc ggagccggcc ggggaccccc gccttgtttg 120
 aggcaaaact tttaaaccc ctacctcgcc ccagtcggga cgcaacagaa gccgaccggg 180
 ccaaccacgc gccatacgta ctatagcgaa tgcgatgaat ttcgattcat cgcccccgcg 240
 gtgctggacg aggatgcccc cccggagaag cgcgcggggg tgcacgacgg tcacctcaag 300
 cgcgccccca aggtgtactg cggggggggac gagcgcgacg tcctccgcgt cgggtcgggc 360
 ggcttctggc cgcggcgctc ggcctgtgg ggcgcggtgg accacgcccc ggcgggggttc 420
 aacccacccg tcaccgtctt tcacgtgtat gacatcctgg agaactgga gcacgcgtac 480
 ggcatgcgcg cggcccagtt ccacgcgcgg tttatggacg ccatcacacc gacgggggacc 540
 gtcatacgc tcctgggcct gactccggaa ggccaccggg tggccgttca cgtttacggc 600
 acgcggcagt acttttacat gaacaaggag gaggttgaca ggcacctaca atgccgcgcc 660
 ccacgagatc tctgcgagcg catggccgcg gccctgcgcg agtccccggg cgcgtcgttc 720
 cgcggcatct ccgcggacca ctctgaggcg gaggtggtgg agcgcaccga cgtgtactac 780
 tacgagacgc gccccgtct gttttaccgc gtctacgtcc gaagcggggc cgtgctgtcg 840

tacctgtgcg acaacttctg cccggccatc aagaagtacg aggggtggggt cgacgccacc 900
acccggttca tcctggacaa ccccggttc gtcaccttcg gctggtaccg tctcaaaccg 960
ggccggaaca acacgctagc ccagccgcgg gccccgatgg ccttcgggac atccagcgat 1020
gtcgagtta actgtacggc ggacaacctg gccatcgagg ggggcatgag cgacctaccg 1080
gcatacaagc tcatgtgctt cgatatcgaa tgcaaggcgg ggggggagga cgagctggcc 1140
tttccggtgg ccgggcaccc ggaggacctg gtcattccaga tatcctgtct gctctacgac 1200
ctgtccacca ccgccctgga gcacgtctc ctgttttcgc tcggttcctg cgacctcccc 1260
gaatccacc tgaacgagct ggcggccagg ggcctgcca cggcctgggt tctggaattc 1320
gacagcgaat tcgagatgct gttggccttc atgacccttg tgaaacagta cggccccgag 1380
ttcgtgaccg ggtacaacat aatcaacttc gactggcctt tcttgctggc caagctgacg 1440
gacatttaca aggtccccct ggacgggtac ggccgcatga acggccgggg cgtgtttcgc 1500
gtgtgggaca taggccagag ccacttcag aagcgcagca agataaagggt gaacggcatg 1560
gtgaacatcg acatgtacgg gattataacc gacaagatca agctctcgag ctacaagctc 1620
aacgccgtgg ccgaagccgt cctgaaggac aagaagaagg acctgagcta tcgcgacatc 1680
cccacctact acgccgcgg gcccgcgcaa cgcggggtga tcggcgagta ctgcatacag 1740
gattccctgc tgggtgggcca gctgtttttt aagtttttgc cccatctgga gctctcggcc 1800
gtcgcgcgt tggcggtat taacatcacc cgcaccatct acgacggcca gcagatccgc 1860
gtctttacgt gcctgctgcg cctggccgac cagaagggtt ttattctgcc ggacaccag 1920
gggcgattta gggcgccgg gggggaggcg cccaagcgtc cggccgcagc ccgggaggac 1980
gaggagcggc cagaggagga gggggaggac gagaacgaac gcgaggaggg cgggggcgag 2040
cgggagccgg agggcgcgcg ggagaccgcc ggccggcacg tggggtacca gggggccagg 2100
gtccttgacc ccacttcgg gtttcacgtg aaccccgagg tgggtgtcga ctttgccagc 2160
ctgtacccca gcatcatcca ggcccacaac ctgtgcttca gcacgtctc cctgagggcc 2220
gacgcagtgg cgacctgga ggcgggcaag gactacctgg agatcgaggt gggggggcga 2280
cggctgttct tcgtcaaggc tcacgtgca gagagcctcc tcagcatcct cctgcgggac 2340
tggctcgcca tgcgaaagca gatccgctcg cggattcccc agagcagccc cgaggaggcc 2400
gtgctcctgg acaagcagca ggccgccatc aaggctcgtg gtaactcgggt ttacgggttc 2460
acgggagcgc agcacggact cctgccgtgc ctgcacgttg ccgcgacggt gacgaccatc 2520
ggccgcgaga tgctgctcgc gaccgcgag tacgtccacg cgcgctgggc ggccttcgaa 2580
cagctcctgg ccgatttccc ggaggcggcc gacatgcgcg ccccgggcc ctattccatg 2640
cgcatcatct acggggacac ggactccata tttgtgctgt gccgcggcct cacggccgcc 2700

```

gggctgacgg ccgtgggcga caagatggcg agccacatct cgcgcgcgct gtttctgccc 2760
cccatcaaac tcgagtgcga aaagacgttc accaagctgc tgctgatcgc caagaaaaag 2820
tacatcgggc tcatctacgg gggtaagatg ctcatcaagg gcgtggatct ggtgcgcaaa 2880
aacaactgcg cgtttatcaa ccgcacctcc agggccctgg tcgacctgct gttttacgac 2940
gataccgtat ccggagcggc cgccgcgtta gccgagcgcc ccgcagagga gtggctggcg 3000
cgaccctgac ccgagggact gcaggcgttc ggggcccgtcc tcgtagacgc ccatcggcgc 3060
atcaccgacc cggagagggg catccaggac tttgtttctca ccgccgaact gagcagacac 3120
ccgcgcgcgt acaccaacaa gcgcctggcc cacctgacgg tgtattacaa gtcctatggcc 3180
cgccgcgcgc aggtcccgtc catcaaggac cggatcccgt acgtgatcgt ggcccagacc 3240
cgcgaggtag aggagacggt cgcgcggctg gccgccctcc gcgagctaga cgccgccgcc 3300
ccaggggaac agcccgcccc ccccgcggcc ctgccctccc cggccaagcg cccccgggag 3360
acgccgtcgc ctgccgacct cccgggaggc gcgtccaagc cccgcaagct gctggtgtcc 3420
gagctggccg aggatcccgc atacgccatt gcccacggcg tcgccctgaa cacggactat 3480
tactttctcc acctgttggg ggcggcgtgc gtgacattca aggccctgtt tgggaataac 3540
gccaagatca ccgagagtct gttaaaaagg tttattcccg aagtgtggca cccccggac 3600
gacgtggccg cgcggctccg gaccgcaggg ttcggggcgg tgggtgccgg cgctacggcg 3660
gaggaaactc gtcgaatgtt gcatagagcc tttgatactc tagcatga 3708

```

```

<210> 10
<211> 1235
<212> PRT
<213> herpes simplex

```

```

<400> 10

```

```

Met Phe Ser Gly Gly Gly Gly Pro Leu Ser Pro Gly Gly Lys Ser Ala
1          5          10          15
Ala Arg Ala Ala Ser Gly Phe Phe Ala Pro Ala Gly Pro Arg Gly Ala
20          25          30
Gly Arg Gly Pro Pro Pro Cys Leu Arg Gln Asn Phe Tyr Asn Pro Tyr
35          40          45
Leu Ala Pro Val Gly Thr Gln Gln Lys Pro Thr Gly Pro Thr Gln Arg
50          55          60
His Thr Tyr Tyr Ser Glu Cys Asp Glu Phe Arg Phe Ile Ala Pro Arg
65          70          75          80
Val Leu Asp Glu Asp Ala Pro Pro Glu Lys Arg Ala Gly Val His Asp
85          90          95
Gly His Leu Lys Arg Ala Pro Lys Val Tyr Cys Gly Gly Asp Glu Arg

```


| | | |
|---|-----|-----|
| 100 | 105 | 110 |
| Asp Val Leu Arg Val Gly Ser Gly Gly Phe Trp Pro Arg Arg Ser Arg | | |
| 115 | 120 | 125 |
| Leu Trp Gly Gly Val Asp His Ala Pro Ala Gly Phe Asn Pro Thr Val | | |
| 130 | 135 | 140 |
| Thr Val Phe His Val Tyr Asp Ile Leu Glu Asn Val Glu His Ala Tyr | | |
| 145 | 150 | 155 |
| Gly Met Arg Ala Ala Gln Phe His Ala Arg Phe Met Asp Ala Ile Thr | | |
| 165 | 170 | 175 |
| Pro Thr Gly Thr Val Ile Thr Leu Leu Gly Leu Thr Pro Glu Gly His | | |
| 180 | 185 | 190 |
| Arg Val Ala Val His Val Tyr Gly Thr Arg Gln Tyr Phe Tyr Met Asn | | |
| 195 | 200 | 205 |
| Lys Glu Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp Leu | | |
| 210 | 215 | 220 |
| Cys Glu Arg Met Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser Phe | | |
| 225 | 230 | 235 |
| Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg Thr | | |
| 245 | 250 | 255 |
| Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Ala Leu Phe Tyr Arg Val Tyr | | |
| 260 | 265 | 270 |
| Val Arg Ser Gly Arg Val Leu Ser Tyr Leu Cys Asp Asn Phe Cys Pro | | |
| 275 | 280 | 285 |
| Ala Ile Lys Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe Ile | | |
| 290 | 295 | 300 |
| Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys Pro | | |
| 305 | 310 | 315 |
| Gly Arg Asn Asn Thr Leu Ala Gln Pro Arg Ala Pro Met Ala Phe Gly | | |
| 325 | 330 | 335 |
| Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala Ile | | |
| 340 | 345 | 350 |
| Glu Gly Gly Met Ser Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe Asp | | |
| 355 | 360 | 365 |
| Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val Ala | | |
| 370 | 375 | 380 |
| Gly His Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr Asp | | |
| 385 | 390 | 395 |
| Leu Ser Thr Thr Ala Leu Glu His Val Leu Leu Phe Ser Leu Gly Ser | | |
| 405 | 410 | 415 |
| Cys Asp Leu Pro Glu Ser His Leu Asn Glu Leu Ala Ala Arg Gly Leu | | |
| 420 | 425 | 430 |

Pro Thr Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu Leu
 435 440 445
 Ala Phe Met Thr Leu Val Lys Gln Tyr Gly Pro Glu Phe Val Thr Gly
 450 455 460
 Tyr Asn Ile Ile Asn Phe Asp Trp Pro Phe Leu Leu Ala Lys Leu Thr
 465 470 475 480
 Asp Ile Tyr Lys Val Pro Leu Asp Gly Tyr Gly Arg Met Asn Gly Arg
 485 490 495
 Gly Val Phe Arg Val Trp Asp Ile Gly Gln Ser His Phe Gln Lys Arg
 500 505 510
 Ser Lys Ile Lys Val Asn Glu Met Val Asn Ile Asp Met Tyr Gly Ile
 515 520 525
 Ile Thr Asp Lys Ile Lys Leu Ser Ser Tyr Lys Leu Asn Ala Val Ala
 530 535 540
 Glu Ala Val Leu Lys Asp Lys Lys Lys Asp Leu Ser Tyr Arg Asp Ile
 545 550 555 560
 Pro Thr Tyr Tyr Ala Ala Gly Pro Ala Gln Arg Gly Val Ile Gly Glu
 565 570 575
 Tyr Cys Ile Gln Asp Ser Leu Leu Val Gly Gln Leu Phe Phe Lys Phe
 580 585 590
 Leu Pro His Leu Glu Leu Ser Ala Val Ala Arg Leu Ala Gly Ile Asn
 595 600 605
 Ile Thr Arg Thr Ile Tyr Asp Gly Gln Gln Ile Arg Val Phe Thr Cys
 610 615 620
 Leu Leu Arg Leu Ala Asp Gln Lys Gly Phe Ile Leu Pro Asp Thr Gln
 625 630 635 640
 Gly Arg Phe Arg Gly Ala Gly Gly Glu Ala Pro Lys Arg Pro Ala Ala
 645 650 655
 Ala Arg Glu Asp Glu Glu Arg Pro Glu Glu Glu Gly Glu Asp Glu Asn
 660 665 670
 Glu Arg Glu Glu Gly Gly Gly Glu Arg Glu Pro Glu Gly Ala Arg Glu
 675 680 685
 Thr Ala Gly Arg His Val Gly Tyr Gln Gly Ala Arg Val Leu Asp Pro
 690 695 700
 Thr Ser Gly Phe His Val Asn Pro Val Val Phe Asp Phe Ala Ser
 705 710 715 720
 Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu Cys Phe Ser Thr Leu
 725 730 735
 Ser Leu Arg Ala Asp Ala Val Ala His Leu Glu Ala Gly Lys Asp Tyr
 740 745 750
 Leu Glu Ile Glu Val Gly Gly Arg Arg Leu Phe Phe Val Lys Ala His
 755 760 765

Val Arg Glu Ser Leu Leu Ser Ile Leu Leu Arg Asp Trp Leu Ala Met
 770 775 780
 Arg Lys Gln Ile Arg Ser Arg Ile Pro Gln Ser Ser Pro Glu Glu Ala
 785 790 795 800
 Val Leu Leu Asp Lys Gln Gln Ala Ala Ile Lys Val Val Cys Asn Ser
 805 810 815
 Val Tyr Gly Phe Thr Gly Ala Gln His Gly Leu Leu Pro Cys Leu His
 820 825 830
 Val Ala Ala Thr Val Thr Thr Ile Gly Arg Glu Met Leu Leu Ala Thr
 835 840 845
 Arg Glu Tyr Val His Ala Arg Trp Ala Ala Phe Glu Gln Leu Leu Ala
 850 855 860
 Asp Phe Pro Glu Ala Ala Asp Met Arg Ala Pro Gly Pro Tyr Ser Met
 865 870 875 880
 Arg Ile Ile Tyr Gly Asp Thr Asp Ser Ile Phe Val Leu Cys Arg Gly
 885 890 895
 Leu Thr Ala Ala Gly Leu Thr Ala Val Gly Asp Lys Met Ala Ser His
 900 905 910
 Ile Ser Arg Ala Leu Phe Leu Pro Pro Ile Lys Leu Glu Cys Glu Lys
 915 920 925
 Thr Phe Thr Lys Leu Leu Leu Ile Ala Lys Lys Lys Tyr Ile Gly Val
 930 935 940
 Ile Tyr Gly Gly Lys Met Leu Ile Lys Gly Val Asp Leu Val Arg Lys
 945 950 955 960
 Asn Asn Cys Ala Phe Ile Asn Arg Thr Ser Arg Ala Leu Val Asp Leu
 965 970 975
 Leu Phe Tyr Asp Asp Thr Val Ser Gly Ala Ala Ala Ala Leu Ala Glu
 980 985 990
 Arg Pro Ala Glu Glu Trp Leu Ala Arg Pro Leu Pro Glu Gly Leu Gln
 995 1000 1005
 Ala Phe Gly Ala Val Leu Val Asp Ala His Arg Arg Ile Thr Asp
 1010 1015 1020
 Pro Glu Arg Asp Ile Gln Asp Phe Val Leu Thr Ala Glu Leu Ser
 1025 1030 1035
 Arg His Pro Arg Ala Tyr Thr Asn Lys Arg Leu Ala His Leu Thr
 1040 1045 1050
 Val Tyr Tyr Lys Leu Met Ala Arg Arg Ala Gln Val Pro Ser Ile
 1055 1060 1065
 Lys Asp Arg Ile Pro Tyr Val Ile Val Ala Gln Thr Arg Glu Val
 1070 1075 1080
 Glu Glu Thr Val Ala Arg Leu Ala Ala Leu Arg Glu Leu Asp Ala

| 1085 | 1090 | 1095 |
|-------------------------|---------------------|-----------------|
| Ala Ala Pro Gly Asp Glu | Pro Ala Pro Pro Ala | Ala Leu Pro Ser |
| 1100 | 1105 | 1110 |
| Pro Ala Lys Arg Pro Arg | Glu Thr Pro Ser Pro | Ala Asp Pro Pro |
| 1115 | 1120 | 1125 |
| Gly Gly Ala Ser Lys Pro | Arg Lys Leu Leu Val | Ser Glu Leu Ala |
| 1130 | 1135 | 1140 |
| Glu Asp Pro Ala Tyr Ala | Ile Ala His Gly Val | Ala Leu Asn Thr |
| 1145 | 1150 | 1155 |
| Asp Tyr Tyr Phe Ser His | Leu Leu Gly Ala Ala | Cys Val Thr Phe |
| 1160 | 1165 | 1170 |
| Lys Ala Leu Phe Gly Asn | Asn Ala Lys Ile Thr | Glu Ser Leu Leu |
| 1175 | 1180 | 1185 |
| Lys Arg Phe Ile Pro Glu | Val Trp His Pro Pro | Asp Asp Val Ala |
| 1190 | 1195 | 1200 |
| Ala Arg Leu Arg Thr Ala | Gly Phe Gly Ala Val | Gly Ala Gly Ala |
| 1205 | 1210 | 1215 |
| Thr Ala Glu Glu Thr Arg | Arg Met Leu His Arg | Ala Phe Asp Thr |
| 1220 | 1225 | 1230 |
| Leu Ala | | |
| 1235 | | |

<210> 11
 <211> 3729
 <212> DNA
 <213> herpes simplex

<400> 11
 atgttttttca acccgatatct gagcggcggc gtgaccggcg gtgcggtcgc ggggtggccgg 60
 cgtcagcggt cgcagcccggt ctccgcgcag ggctcgggca agcggccgcc acagaaacag 120
 tttttgcaga tcgtgccgcg aggtgtcatg ttcgacggtc agacgggggt gatcaagcat 180
 aagacgggac ggctgcctct catgttctat cgagagatta aacatttggt gagtcatgac 240
 atggtttggc cgtgtccttg gcgcgagacc ctgggtgggtc gcgtgggtggg acctattcgt 300
 tttcacacct acgatcagac ggacgccgtg ctcttcttcg actcgccga aaacgtgtcg 360
 ccgcgctatc gtcagcatct ggtgccttcg gggaacgtgt tgcgtttctt cggggccaca 420
 gaacacgggt acagtatctg cgtcaacgtt ttcgggcagc gcagctactt ttactgtgag 480
 tacagcgaca ccgataggct gcgtgaggtc attgccagcg tgggcgaact agtgcccgaa 540
 ccgcggacgc catacgccgt gtctgtcacg ccggccacca agacctccat ctatgggtac 600
 gggacgcgac ccgtgcccga tttgcagtgt gtgtctatca gcaactggac catggccaga 660
 aaaatcggcg agtatctgct ggagcagggt tttccgtgt acgaggtccg tgtggatccg 720

| | |
|---|------|
| ctgacgcgtt tggatcatcga tcggcggatc accacgttcg gctgggtgctc cgtgaatcgt | 780 |
| tacgactggc ggcagcaggg tcgcgcgtcg acttggtgata tcgaggtaga ctgcgatgtc | 840 |
| tctgacctgg tggctgtgcc cgacgacagc tcgtggccgc gctatcgatg cctgtccttc | 900 |
| gatatcgagt gcatgagcgg cgaggggtgg tttccctgcg ccgagaagtc cgatgacatt | 960 |
| gtcattcaga tctcgtgcgt gtgctacgag acggggggaa acaccgccgt ggatcagggg | 1020 |
| atcccaaacg ggaacgatgg tcggggctgc acttcggagg gtgtgatctt tgggcactcg | 1080 |
| ggtcttcacg tctttacgat cggcacctgc gggcaggtgg gccagacgt ggacgtctac | 1140 |
| gagttccctt ccgaatacga gctgctgctg ggctttatgc ttttctttca acggtacgcg | 1200 |
| ccggcctttg tgaccgggta caacatcaac tcttttgact tgaagtacat cctcacgcgt | 1260 |
| ctcgagtacc tgtataaggt ggactcgcag cgcttctgca agttgcctac ggcgagggc | 1320 |
| ggcgcgtttt ttttacacag ccccgccgtg ggttttaagc ggcagtagcg cgcgcgtttt | 1380 |
| ccctcggtt ctcacaacaa tccggccagc acggccgcca ccaaggtgta tattgccccg | 1440 |
| tcggtggtta tcgacatgta ccctgtatgc atggccaaga ctaactcgcc caactataag | 1500 |
| ctcaacacta tggccgagct ttacctgcgg caacgcaagg atgacctgtc ttacaaggac | 1560 |
| atcccgcggt gtttcgtggc taatgccgag ggccgcgccc aggtaggccg ttactgtctg | 1620 |
| caggacgccg tattggtgcg cgatctgttc aacaccatta attttacta cgaggccggg | 1680 |
| gccatcgcg cgcgtggctaa aattccgttg cggcgtgtca tctttgacgg acagcagatc | 1740 |
| cgtatctaca cctcgtgct ggacgagtgc gcctgccgag attttatcct gcccaccac | 1800 |
| tacagcaaag gtacgacggg gcccgaaacg aatagcgttg ctgtgtcacc taacgtgct | 1860 |
| atcatctcta ccgccgctgt gcccgggcag cgggggtctg tggcggtat gtttcagatg | 1920 |
| tcgcccct tgcaatctgc gccgtccagt caggacggcg tttcaccgg ctcgggcagt | 1980 |
| aacagtagta gcagcgtcg cgttttcagc gtcggctccg gcagtagtg cggcgtcggc | 2040 |
| gtttccaacg acaatcacgg cgccggcggt actgcggcgg tttcgtacca gggcgccacg | 2100 |
| gtgtttgagc ccgaggtggg ttactacaac gaccccggtg ccgtgttcga ctttgccagc | 2160 |
| ctctaccctt ccatcatcat gggccacaac ctctgtact ccaccctgct ggtgccgggt | 2220 |
| ggcgagtacc ctgtggaccc cgccgacgta tacagcgtca cgctagagaa cggcgtgacc | 2280 |
| caccgctttg tgcgtgcttc ggtgcgcgtc tcggtgctct cggaactgct caacaagtgg | 2340 |
| gtttcgcagc ggcgtgccgt gcgcgaatgc atgcgcgagt gtcaagacc tgtgcgccgt | 2400 |
| atgctgctcg acaaggaaca gatggcgtc aaagtaacgt gcaacgctt ctacggtttt | 2460 |
| accggcgcg tgaacgggat gatgccgtgt ctgccatcg ccgccagcat cagcgcac | 2520 |
| ggtcgcgaca tgctagagcg cagggcgcg ttcacaaag acaacttttc agagccgtgt | 2580 |

```

tttttgcaca atttttttaa tcaggaagac tatgtagtgg gaacgcggga gggggattcg 2640
gaggagagca gcgcgttacc ggaggggctc gaaacatcgt cagggggctc gaacgaacgg 2700
cgggtggagg cgcggtcat ctacggggac acggacagcg tgtttgtccg ctttcgtggc 2760
ctgacgccgc aggctctggt ggcgcgtggg cccagcctgg cgcactacgt gacggcctgt 2820
ctttttgtgg agcccgtcaa gctggagttt gaaaaggctt tcgtctctct tatgatgatc 2880
tgcaagaaac gttacatcgg caaagtggag ggcgcctcgg gtctgagcat gaagggcgtg 2940
gatctggtgc gcaagacggc ctgcgagttc gtcaagggcg tcacgcgtga cgtcctctcg 3000
ctgctctttg aggatcgcga ggtctcggaa gcagccgtgc gcctgtcgcg cctctcactc 3060
gatgaagtca agaagtacgg cgtgccacgc ggtttctggc gtatcttacg ccgcttggtg 3120
caggcccgcg acgatctgta cctgcaccgt gtgcgtgtcg aggacctggg gctttcgtcg 3180
gtgctctcta aggacatctc gctgtaccgt caatctaacc tgccgcacat tgccgtcatt 3240
aagcgattgg cggcccgttc tgaggagcta ccctcggtcg gggatcgggt cttttacgtt 3300
ctgacggcgc ccggtgtccg gacggcgccg cagggttcct ccgacaacgg tgattctgta 3360
accgccggcg tggtttcccg gtcggacgcg attgatggca cggacgacga cgctgacggc 3420
ggcggggtag aggagagcaa caggagagga ggagagccgg caaagaagag ggcgcggaaa 3480
ccaccgtcgg ccgtgtgcaa ctacgaggtg gccgaagatc cgagctacgt gcgcgagcac 3540
ggcgtgcca ttcacgccga caagtacttt gagcaggttc tcaaggctgt aactaacgtg 3600
ctgtcgcccg tctttcccg cggcgaaacc gcgcgcaagg acaagttttt gcacatggtg 3660
ctgccgcggc gcttgcactt ggagccggct tttctgccgt acagtgtcaa ggcgcacgaa 3720
tgctgttga 3729

```

<210> 12
 <211> 1242
 <212> PRT
 <213> herpes simplex

<400> 12

```

Met Phe Phe Asn Pro Tyr Leu Ser Gly Gly Val Thr Gly Gly Ala Val
1             5             10             15

Ala Gly Gly Arg Arg Gln Arg Ser Gln Pro Gly Ser Ala Gln Gly Ser
20             25             30

Gly Lys Arg Pro Pro Gln Lys Gln Phe Leu Gln Ile Val Pro Arg Gly
35             40             45

Val Met Phe Asp Gly Gln Thr Gly Leu Ile Lys His Lys Thr Gly Arg
50             55             60

Leu Pro Leu Met Phe Tyr Arg Glu Ile Lys His Leu Leu Ser His Asp
65             70             75             80

```

Met Val Trp Pro Cys Pro Trp Arg Glu Thr Leu Val Gly Arg Val Val
 85 90 95
 Gly Pro Ile Arg Phe His Thr Tyr Asp Gln Thr Asp Ala Val Leu Phe
 100 105 110
 Phe Asp Ser Pro Glu Asn Val Ser Pro Arg Tyr Arg Gln His Leu Val
 115 120 125
 Pro Ser Gly Asn Val Leu Arg Phe Phe Gly Ala Thr Glu His Gly Tyr
 130 135 140
 Ser Ile Cys Val Asn Val Phe Gly Gln Arg Ser Tyr Phe Tyr Cys Glu
 145 150 155 160
 Tyr Ser Asp Thr Asp Arg Leu Arg Glu Val Ile Ala Ser Val Gly Glu
 165 170 175
 Leu Val Pro Glu Pro Arg Thr Pro Tyr Ala Val Ser Val Thr Pro Ala
 180 185 190
 Thr Lys Thr Ser Ile Tyr Gly Tyr Gly Thr Arg Pro Val Pro Asp Leu
 195 200 205
 Gln Cys Val Ser Ile Ser Asn Trp Thr Met Ala Arg Lys Ile Gly Glu
 210 215 220
 Tyr Leu Leu Glu Gln Gly Phe Pro Val Tyr Glu Val Arg Val Asp Pro
 225 230 235 240
 Leu Thr Arg Leu Val Ile Asp Arg Arg Ile Thr Thr Phe Gly Trp Cys
 245 250 255
 Ser Val Asn Arg Tyr Asp Trp Arg Gln Gln Gly Arg Ala Ser Thr Cys
 260 265 270
 Asp Ile Glu Val Asp Cys Asp Val Ser Asp Leu Val Ala Val Pro Asp
 275 280 285
 Asp Ser Ser Trp Pro Arg Tyr Arg Cys Leu Ser Phe Asp Ile Glu Cys
 290 295 300
 Met Ser Gly Glu Gly Gly Phe Pro Cys Ala Glu Lys Ser Asp Asp Ile
 305 310 315 320
 Val Ile Gln Ile Ser Cys Val Cys Tyr Glu Thr Gly Gly Asn Thr Ala
 325 330 335
 Val Asp Gln Gly Ile Pro Asn Gly Asn Asp Gly Arg Gly Cys Thr Ser
 340 345 350
 Glu Gly Val Ile Phe Gly His Ser Gly Leu His Leu Phe Thr Ile Gly
 355 360 365
 Thr Cys Gly Gln Val Gly Pro Asp Val Asp Val Tyr Glu Phe Pro Ser
 370 375 380
 Glu Tyr Glu Leu Leu Leu Gly Phe Met Leu Phe Phe Gln Arg Tyr Ala
 385 390 395 400
 Pro Ala Phe Val Thr Gly Tyr Asn Ile Asn Ser Phe Asp Leu Lys Tyr

| 405 | | | | | 410 | | | | | 415 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Leu | Thr | Arg | Leu | Glu | Tyr | Leu | Tyr | Lys | Val | Asp | Ser | Gln | Arg | Phe |
| | | | 420 | | | | | 425 | | | | | 430 | | |
| Cys | Lys | Leu | Pro | Thr | Ala | Gln | Gly | Gly | Arg | Phe | Phe | Leu | His | Ser | Pro |
| | | 435 | | | | | 440 | | | | | 445 | | | |
| Ala | Val | Gly | Phe | Lys | Arg | Gln | Tyr | Ala | Ala | Ala | Phe | Pro | Ser | Ala | Ser |
| | 450 | | | | | 455 | | | | | 460 | | | | |
| His | Asn | Asn | Pro | Ala | Ser | Thr | Ala | Ala | Thr | Lys | Val | Tyr | Ile | Ala | Gly |
| 465 | | | | | 470 | | | | | 475 | | | | | 480 |
| Ser | Val | Val | Ile | Asp | Met | Tyr | Pro | Val | Cys | Met | Ala | Lys | Thr | Asn | Ser |
| | | | | 485 | | | | | 490 | | | | | 495 | |
| Pro | Asn | Tyr | Lys | Leu | Asn | Thr | Met | Ala | Glu | Leu | Tyr | Leu | Arg | Gln | Arg |
| | | | 500 | | | | | 505 | | | | | 510 | | |
| Lys | Asp | Asp | Leu | Ser | Tyr | Lys | Asp | Ile | Pro | Arg | Cys | Phe | Val | Ala | Asn |
| | | 515 | | | | | 520 | | | | | 525 | | | |
| Ala | Glu | Gly | Arg | Ala | Gln | Val | Gly | Arg | Tyr | Cys | Leu | Gln | Asp | Ala | Val |
| | 530 | | | | | 535 | | | | | 540 | | | | |
| Leu | Val | Arg | Asp | Leu | Phe | Asn | Thr | Ile | Asn | Phe | His | Tyr | Glu | Ala | Gly |
| 545 | | | | | 550 | | | | | 555 | | | | | 560 |
| Ala | Ile | Ala | Arg | Leu | Ala | Lys | Ile | Pro | Leu | Arg | Arg | Val | Ile | Phe | Asp |
| | | | | 565 | | | | | 570 | | | | | 575 | |
| Gly | Gln | Gln | Ile | Arg | Ile | Tyr | Thr | Ser | Leu | Leu | Asp | Glu | Cys | Ala | Cys |
| | | | 580 | | | | | 585 | | | | | 590 | | |
| Arg | Asp | Phe | Ile | Leu | Pro | Asn | His | Tyr | Ser | Lys | Gly | Thr | Thr | Val | Pro |
| | | 595 | | | | | 600 | | | | | 605 | | | |
| Glu | Thr | Asn | Ser | Val | Ala | Val | Ser | Pro | Asn | Ala | Ala | Ile | Ile | Ser | Thr |
| | 610 | | | | | 615 | | | | | 620 | | | | |
| Ala | Ala | Val | Pro | Gly | Asp | Ala | Gly | Ser | Val | Ala | Ala | Met | Phe | Gln | Met |
| 625 | | | | | 630 | | | | | 635 | | | | | 640 |
| Ser | Pro | Pro | Leu | Gln | Ser | Ala | Pro | Ser | Ser | Gln | Asp | Gly | Val | Ser | Pro |
| | | | | 645 | | | | | 650 | | | | | 655 | |
| Gly | Ser | Gly | Ser | Asn | Ser | Ser | Ser | Ser | Val | Gly | Val | Phe | Ser | Val | Gly |
| | | | 660 | | | | | 665 | | | | | 670 | | |
| Ser | Gly | Ser | Ser | Gly | Gly | Val | Gly | Val | Ser | Asn | Asp | Asn | His | Gly | Ala |
| | | 675 | | | | | 680 | | | | | 685 | | | |
| Gly | Gly | Thr | Ala | Ala | Val | Ser | Tyr | Gln | Gly | Ala | Thr | Val | Phe | Glu | Pro |
| | 690 | | | | | 695 | | | | | 700 | | | | |
| Glu | Val | Gly | Tyr | Tyr | Asn | Asp | Pro | Val | Ala | Val | Phe | Asp | Phe | Ala | Ser |
| 705 | | | | | 710 | | | | | 715 | | | | | 720 |
| Leu | Tyr | Pro | Ser | Ile | Ile | Met | Ala | His | Asn | Leu | Cys | Tyr | Ser | Thr | Leu |
| | | | | 725 | | | | | 730 | | | | | 735 | |

Leu Val Pro Gly Gly Glu Tyr Pro Val Asp Pro Ala Asp Val Tyr Ser
 740 745 750
 Val Thr Leu Glu Asn Gly Val Thr His Arg Phe Val Arg Ala Ser Val
 755 760 765
 Arg Val Ser Val Leu Ser Glu Leu Leu Asn Lys Trp Val Ser Gln Arg
 770 775 780
 Arg Ala Val Arg Glu Cys Met Arg Glu Cys Gln Asp Pro Val Arg Arg
 785 790 795 800
 Met Leu Leu Asp Lys Glu Gln Met Ala Leu Lys Val Thr Cys Asn Ala
 805 810 815
 Phe Tyr Gly Phe Thr Gly Ala Leu Asn Gly Met Met Pro Cys Leu Pro
 820 825 830
 Ile Ala Ala Ser Ile Thr Arg Ile Gly Arg Asp Met Leu Glu Arg Thr
 835 840 845
 Ala Arg Phe Ile Lys Asp Asn Phe Ser Glu Pro Cys Phe Leu His Asn
 850 855 860
 Phe Phe Asn Gln Glu Asp Tyr Val Val Gly Thr Arg Glu Gly Asp Ser
 865 870 875 880
 Glu Glu Ser Ser Ala Leu Pro Glu Gly Leu Glu Thr Ser Ser Gly Gly
 885 890 895
 Ser Asn Glu Arg Arg Val Glu Ala Arg Val Ile Tyr Gly Asp Thr Asp
 900 905 910
 Ser Val Phe Val Arg Phe Arg Gly Leu Thr Pro Gln Ala Leu Val Ala
 915 920 925
 Arg Gly Pro Ser Leu Ala His Tyr Val Thr Ala Cys Leu Phe Val Glu
 930 935 940
 Pro Val Lys Leu Glu Phe Glu Lys Val Phe Val Ser Leu Met Met Ile
 945 950 955 960
 Cys Lys Lys Arg Tyr Ile Gly Lys Val Glu Gly Ala Ser Gly Leu Ser
 965 970 975
 Met Lys Gly Val Asp Leu Val Arg Lys Thr Ala Cys Glu Phe Val Lys
 980 985 990
 Gly Val Thr Arg Asp Val Leu Ser Leu Leu Phe Glu Asp Arg Glu Val
 995 1000 1005
 Ser Glu Ala Ala Val Arg Leu Ser Arg Leu Ser Leu Asp Glu Val
 1010 1015 1020
 Lys Lys Tyr Gly Val Pro Arg Gly Phe Trp Arg Ile Leu Arg Arg
 1025 1030 1035
 Leu Val Gln Ala Arg Asp Asp Leu Tyr Leu His Arg Val Arg Val
 1040 1045 1050
 Glu Asp Leu Val Leu Ser Ser Val Leu Ser Lys Asp Ile Ser Leu
 1055 1060 1065

Tyr Arg Gln Ser Asn Leu Pro His Ile Ala Val Ile Lys Arg Leu
 1070 1075 1080
 Ala Ala Arg Ser Glu Glu Leu Pro Ser Val Gly Asp Arg Val Phe
 1085 1090 1095
 Tyr Val Leu Thr Ala Pro Gly Val Arg Thr Ala Pro Gln Gly Ser
 1100 1105 1110
 Ser Asp Asn Gly Asp Ser Val Thr Ala Gly Val Val Ser Arg Ser
 1115 1120 1125
 Asp Ala Ile Asp Gly Thr Asp Asp Asp Ala Asp Gly Gly Gly Val
 1130 1135 1140
 Glu Glu Ser Asn Arg Arg Gly Gly Glu Pro Ala Lys Lys Arg Ala
 1145 1150 1155
 Arg Lys Pro Pro Ser Ala Val Cys Asn Tyr Glu Val Ala Glu Asp
 1160 1165 1170
 Pro Ser Tyr Val Arg Glu His Gly Val Pro Ile His Ala Asp Lys
 1175 1180 1185
 Tyr Phe Glu Gln Val Leu Lys Ala Val Thr Asn Val Leu Ser Pro
 1190 1195 1200
 Val Phe Pro Gly Gly Glu Thr Ala Arg Lys Asp Lys Phe Leu His
 1205 1210 1215
 Met Val Leu Pro Arg Arg Leu His Leu Glu Pro Ala Phe Leu Pro
 1220 1225 1230
 Tyr Ser Val Lys Ala His Glu Cys Cys
 1235 1240

<210> 13
 <211> 1242
 <212> PRT
 <213> herpes simplex

<400> 13

Met Phe Phe Asn Pro Tyr Leu Ser Gly Gly Val Thr Gly Gly Ala Val
 1 5 10 15
 Ala Gly Gly Arg Arg Gln Arg Ser Gln Pro Gly Ser Ala Gln Gly Ser
 20 25 30
 Gly Lys Arg Pro Pro Gln Lys Gln Phe Leu Gln Ile Val Pro Arg Gly
 35 40 45
 Val Met Phe Asp Gly Gln Thr Gly Leu Ile Lys His Lys Thr Gly Arg
 50 55 60
 Leu Pro Leu Met Phe Tyr Arg Glu Ile Lys His Leu Leu Ser His Asp
 65 70 75 80
 Met Val Trp Pro Cys Pro Trp Arg Glu Thr Leu Val Gly Arg Val Val
 85 90 95

Gly Pro Ile Arg Phe His Thr Tyr Asp Gln Thr Asp Ala Val Leu Phe
 100 105 110
 Phe Asp Ser Pro Glu Asn Val Ser Pro Arg Tyr Arg Gln His Leu Val
 115 120 125
 Pro Ser Gly Asn Val Leu Arg Phe Phe Gly Ala Thr Glu His Gly Tyr
 130 135 140
 Ser Ile Cys Val Asn Val Phe Gly Gln Arg Ser Tyr Phe Tyr Cys Glu
 145 150 155 160
 Tyr Ser Asp Thr Asp Arg Leu Arg Glu Val Ile Ala Ser Val Gly Glu
 165 170 175
 Leu Val Pro Glu Pro Arg Thr Pro Tyr Ala Val Ser Val Thr Pro Ala
 180 185 190
 Thr Lys Thr Ser Ile Tyr Gly Tyr Gly Thr Arg Pro Val Pro Asp Leu
 195 200 205
 Gln Cys Val Ser Ile Ser Asn Trp Thr Met Ala Arg Lys Ile Gly Glu
 210 215 220
 Tyr Leu Leu Glu Gln Gly Phe Pro Val Tyr Glu Val Arg Val Asp Pro
 225 230 235 240
 Leu Thr Arg Leu Val Ile Asp Arg Arg Ile Thr Thr Phe Gly Trp Cys
 245 250 255
 Ser Val Asn Arg Tyr Asp Trp Arg Gln Gln Gly Arg Ala Ser Thr Cys
 260 265 270
 Asp Ile Glu Val Asp Cys Asp Val Ser Asp Leu Val Ala Val Pro Asp
 275 280 285
 Asp Ser Ser Trp Pro Arg Tyr Arg Cys Leu Ser Phe Asp Ile Glu Cys
 290 295 300
 Met Ser Gly Glu Gly Gly Phe Pro Cys Ala Glu Lys Ser Asp Asp Ile
 305 310 315 320
 Val Ile Gln Ile Ser Cys Val Cys Tyr Glu Thr Gly Gly Asn Thr Ala
 325 330 335
 Val Asp Gln Gly Ile Pro Asn Gly Asn Asp Gly Arg Gly Cys Thr Ser
 340 345 350
 Glu Gly Val Ile Phe Gly His Ser Gly Leu His Leu Phe Thr Ile Gly
 355 360 365
 Thr Cys Gly Gln Val Gly Pro Asp Val Asp Val Tyr Glu Phe Pro Ser
 370 375 380
 Glu Tyr Glu Leu Leu Leu Gly Phe Met Leu Phe Phe Gln Arg Tyr Ala
 385 390 395 400
 Pro Ala Phe Val Thr Gly Tyr Asn Ile Asn Ser Phe Asp Leu Lys Tyr
 405 410 415
 Ile Leu Thr Arg Leu Glu Tyr Leu Tyr Lys Val Asp Ser Gln Arg Phe
 420 425 430

Cys Lys Leu Pro Thr Ala Gln Gly Gly Arg Phe Phe Leu His Ser Pro
 435 440 445
 Ala Val Gly Phe Lys Arg Gln Tyr Ala Ala Ala Phe Pro Ser Ala Ser
 450 455 460
 His Asn Asn Pro Ala Ser Thr Ala Ala Thr Lys Val Tyr Ile Ala Gly
 465 470 475 480
 Ser Val Val Ile Asp Met Tyr Pro Val Cys Met Ala Lys Thr Asn Ser
 485 490 495
 Pro Asn Tyr Lys Leu Asn Thr Met Ala Glu Leu Tyr Leu Arg Gln Arg
 500 505 510
 Lys Asp Asp Leu Ser Tyr Lys Asp Ile Pro Arg Cys Phe Val Ala Asn
 515 520 525
 Ala Glu Gly Arg Ala Gln Val Gly Arg Tyr Cys Leu Gln Asp Ala Val
 530 535 540
 Leu Val Arg Asp Leu Phe Asn Thr Ile Asn Phe His Tyr Glu Ala Gly
 545 550 555 560
 Ala Ile Ala Arg Leu Ala Lys Ile Pro Leu Arg Arg Val Ile Phe Asp
 565 570 575
 Gly Gln Gln Ile Arg Ile Tyr Thr Ser Leu Leu Asp Glu Cys Ala Cys
 580 585 590
 Arg Asp Phe Ile Leu Pro Asn His Tyr Ser Lys Gly Thr Thr Val Pro
 595 600 605
 Glu Thr Asn Ser Val Ala Val Ser Pro Asn Ala Ala Ile Ile Ser Thr
 610 615 620
 Ala Ala Val Pro Gly Asp Ala Gly Ser Val Ala Ala Met Phe Gln Met
 625 630 635 640
 Ser Pro Pro Leu Gln Ser Ala Pro Ser Ser Gln Asp Gly Val Ser Pro
 645 650 655
 Gly Ser Gly Ser Asn Ser Ser Ser Ser Val Gly Val Phe Ser Val Gly
 660 665 670
 Ser Gly Ser Ser Gly Gly Val Gly Val Ser Asn Asp Asn His Gly Ala
 675 680 685
 Gly Gly Thr Ala Ala Val Ser Tyr Gln Gly Ala Thr Val Phe Glu Pro
 690 695 700
 Glu Val Gly Tyr Tyr Asn Asp Pro Val Ala Val Phe Asp Phe Ala Ser
 705 710 715 720
 Leu Tyr Pro Ser Ile Ile Met Ala His Asn Leu Cys Tyr Ser Thr Leu
 725 730 735
 Leu Val Pro Gly Gly Glu Tyr Pro Val Asp Pro Ala Asp Val Tyr Ser
 740 745 750
 Val Thr Leu Glu Asn Gly Val Thr His Arg Phe Val Arg Ala Ser Val

| | | |
|---|------|------|
| 755 | 760 | 765 |
| Arg Val Ser Val Leu Ser Glu Leu Leu Asn Lys Trp Val Ser Gln Arg | | |
| 770 | 775 | 780 |
| Arg Ala Val Arg Glu Cys Met Arg Glu Cys Gln Asp Pro Val Arg Arg | | |
| 785 | 790 | 795 |
| Met Leu Leu Asp Lys Glu Gln Met Ala Leu Lys Val Thr Cys Asn Ala | | |
| | 805 | 810 |
| Phe Tyr Gly Phe Thr Gly Val Val Asn Gly Met Met Pro Cys Leu Pro | | |
| | 820 | 825 |
| Ile Ala Ala Ser Ile Thr Arg Ile Gly Arg Asp Met Leu Glu Arg Thr | | |
| | 835 | 840 |
| Ala Arg Phe Ile Lys Asp Asn Phe Ser Glu Pro Cys Phe Leu His Asn | | |
| | 850 | 855 |
| Phe Phe Asn Gln Glu Asp Tyr Val Val Gly Thr Arg Glu Gly Asp Ser | | |
| | 865 | 870 |
| Glu Glu Ser Ser Ala Leu Pro Glu Gly Leu Glu Thr Ser Ser Gly Gly | | |
| | 885 | 890 |
| Ser Asn Glu Arg Arg Val Glu Ala Arg Val Ile Tyr Gly Asp Thr Asp | | |
| | 900 | 905 |
| Ser Val Phe Val Arg Phe Arg Gly Leu Thr Pro Gln Ala Leu Val Ala | | |
| | 915 | 920 |
| Arg Gly Pro Ser Leu Ala His Tyr Val Thr Ala Cys Leu Phe Val Glu | | |
| | 930 | 935 |
| Pro Val Lys Leu Glu Phe Glu Lys Val Phe Val Ser Leu Met Met Ile | | |
| | 945 | 950 |
| Cys Lys Lys Arg Tyr Ile Gly Lys Val Glu Gly Ala Ser Gly Leu Ser | | |
| | 965 | 970 |
| Met Lys Gly Val Asp Leu Val Arg Lys Thr Ala Cys Glu Phe Val Lys | | |
| | 980 | 985 |
| Gly Val Thr Arg Asp Val Leu Ser Leu Leu Phe Glu Asp Arg Glu Val | | |
| | 995 | 1000 |
| Ser Glu Ala Ala Val Arg Leu Ser Arg Leu Ser Leu Asp Glu Val | | |
| | 1010 | 1015 |
| Lys Lys Tyr Gly Val Pro Arg Gly Phe Trp Arg Ile Leu Arg Arg | | |
| | 1025 | 1030 |
| Leu Val Gln Ala Arg Asp Asp Leu Tyr Leu His Arg Val Arg Val | | |
| | 1040 | 1045 |
| Glu Asp Leu Val Leu Ser Ser Val Leu Ser Lys Asp Ile Ser Leu | | |
| | 1055 | 1060 |
| Tyr Arg Gln Ser Asn Leu Pro His Ile Ala Val Ile Lys Arg Leu | | |
| | 1070 | 1075 |
| | | 1080 |

Ala Ala Arg Ser Glu Glu Leu Pro Ser Val Gly Asp Arg Val Phe
1085 1090 1095

Tyr Val Leu Thr Ala Pro Gly Val Arg Thr Ala Pro Gln Gly Ser
1100 1105 1110

Ser Asp Asn Gly Asp Ser Val Thr Ala Gly Val Val Ser Arg Ser
1115 1120 1125

Asp Ala Ile Asp Gly Thr Asp Asp Asp Ala Asp Gly Gly Gly Val
1130 1135 1140

Glu Glu Ser Asn Arg Arg Gly Gly Glu Pro Ala Lys Lys Arg Ala
1145 1150 1155

Arg Lys Pro Pro Ser Ala Val Cys Asn Tyr Glu Val Ala Glu Asp
1160 1165 1170

Pro Ser Tyr Val Arg Glu His Gly Val Pro Ile His Ala Asp Lys
1175 1180 1185

Tyr Phe Glu Gln Val Leu Lys Ala Val Thr Asn Val Leu Ser Pro
1190 1195 1200

Val Phe Pro Gly Gly Glu Thr Ala Arg Lys Asp Lys Phe Leu His
1205 1210 1215

Met Val Leu Pro Arg Arg Leu His Leu Glu Pro Ala Phe Leu Pro
1220 1225 1230

Tyr Ser Val Lys Ala His Glu Cys Cys
1235 1240

<210> 14

<211> 1238

<212> PRT

<213> herpes simplex

<400> 14

Met Phe Cys Ala Ala Gly Gly Pro Thr Ser Pro Gly Gly Lys Ser Ala
1 5 10 15

Ala Arg Ala Ala Ser Gly Phe Phe Ala Pro His Asn Pro Arg Gly Ala
20 25 30

Thr Gln Thr Ala Pro Pro Pro Cys Arg Arg Gln Asn Phe Tyr Asn Pro
35 40 45

His Leu Ala Gln Thr Gly Thr Gln Pro Lys Ala Pro Gly Pro Ala Gln
50 55 60

Arg His Thr Tyr Tyr Ser Glu Cys Asp Glu Phe Arg Phe Ile Ala Pro
65 70 75 80

Arg Ser Leu Asp Glu Asp Ala Pro Ala Glu Gln Arg Thr Gly Val His
85 90 95

Asp Gly Arg Leu Arg Arg Ala Pro Lys Val Tyr Cys Gly Gly Asp Glu
100 105 110

Arg Asp Val Leu Arg Val Gly Pro Glu Gly Phe Trp Pro Arg Arg Leu

| | | |
|---|-----|-----|
| 115 | 120 | 125 |
| Arg Leu Trp Gly Gly Ala Asp His Ala Pro Lys Gly Phe Asp Pro Thr | | |
| 130 | 135 | 140 |
| Val Thr Val Phe His Val Tyr Asp Ile Leu Glu His Val Glu His Ala | | |
| 145 | 150 | 155 |
| Tyr Ser Met Arg Ala Ala Gln Leu His Glu Arg Phe Met Asp Ala Ile | | |
| | 165 | 170 |
| Thr Pro Ala Gly Thr Val Ile Thr Leu Leu Gly Leu Thr Pro Glu Gly | | |
| | 180 | 185 |
| His Arg Val Ala Val His Val Tyr Gly Thr Arg Gln Tyr Phe Tyr Met | | |
| | 195 | 200 |
| Asn Lys Ala Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp | | |
| | 210 | 215 |
| Leu Cys Glu Arg Leu Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser | | |
| | 225 | 230 |
| Phe Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg | | |
| | 245 | 250 |
| Ala Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Thr Leu Tyr Tyr Arg Val | | |
| | 260 | 265 |
| Phe Val Arg Ser Gly Arg Ala Leu Ala Tyr Leu Cys Asp Asn Phe Cys | | |
| | 275 | 280 |
| Pro Ala Ile Arg Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe | | |
| | 290 | 295 |
| Ile Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys | | |
| | 305 | 310 |
| Pro Gly Arg Gly Asn Ala Pro Ala Gln Pro Arg Pro Pro Thr Ala Phe | | |
| | 325 | 330 |
| Gly Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala | | |
| | 340 | 345 |
| Val Glu Gly Ala Met Cys Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe | | |
| | 355 | 360 |
| Asp Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val | | |
| | 370 | 375 |
| Ala Glu Arg Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr | | |
| | 385 | 390 |
| Asp Leu Ser Thr Thr Ala Leu Glu His Ile Leu Leu Phe Ser Leu Gly | | |
| | 405 | 410 |
| Ser Cys Asp Leu Pro Glu Ser His Leu Ser Asp Leu Ala Ser Arg Gly | | |
| | 420 | 425 |
| Leu Pro Ala Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu | | |
| | 435 | 440 |
| | | 445 |

Leu Ala Phe Met Thr Phe Val Lys Gln Tyr Gly Pro Glu Phe Val Thr
 450 455 460
 Gly Tyr Asn Ile Ile Asn Phe Asp Trp Pro Phe Val Leu Thr Lys Leu
 465 470 475 480
 Thr Glu Ile Tyr Lys Val Pro Leu Asp Gly Tyr Gly Arg Met Asn Gly
 485 490 495
 Arg Gly Val Phe Arg Val Trp Asp Ile Gly Gln Ser His Phe Gln Lys
 500 505 510
 Arg Ser Lys Ile Lys Val Asn Gly Met Val Asn Ile Asp Met Tyr Gly
 515 520 525
 Ile Ile Thr Asp Lys Val Lys Leu Ser Ser Tyr Lys Leu Asn Ala Val
 530 535 540
 Ala Glu Ala Val Leu Lys Asp Lys Lys Lys Asp Leu Ser Tyr Arg Asp
 545 550 555 560
 Ile Pro Ala Tyr Tyr Ala Ser Gly Pro Ala Gln Arg Gly Val Ile Gly
 565 570 575
 Glu Tyr Cys Val Gln Asp Ser Leu Leu Val Gly Gln Leu Phe Phe Lys
 580 585 590
 Phe Leu Pro His Leu Glu Leu Ser Ala Val Ala Arg Leu Ala Gly Ile
 595 600 605
 Asn Ile Thr Arg Thr Ile Tyr Asp Gly Gln Gln Ile Arg Val Phe Thr
 610 615 620
 Cys Leu Leu Arg Leu Ala Gly Gln Lys Gly Phe Ile Leu Pro Asp Thr
 625 630 635 640
 Gln Gly Arg Phe Arg Gly Leu Asp Lys Glu Ala Pro Lys Arg Pro Ala
 645 650 655
 Val Pro Arg Gly Glu Gly Glu Arg Pro Gly Asp Gly Asn Gly Asp Glu
 660 665 670
 Asp Lys Asp Asp Asp Glu Asp Glu Asp Gly Asp Glu Arg Glu Glu Val
 675 680 685
 Ala Arg Glu Thr Gly Gly Arg His Val Gly Tyr Gln Gly Ala Arg Val
 690 695 700
 Leu Asp Pro Thr Ser Gly Phe His Val Asp Pro Val Val Val Phe Asp
 705 710 715 720
 Phe Ala Ser Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu Cys Phe
 725 730 735
 Ser Thr Leu Ser Leu Arg Pro Glu Ala Val Ala His Leu Glu Ala Asp
 740 745 750
 Arg Asp Tyr Leu Glu Ile Glu Val Gly Gly Arg Arg Leu Phe Phe Val
 755 760 765
 Lys Ala His Val Arg Glu Ser Leu Leu Ser Ile Leu Leu Arg Asp Trp
 770 775 780

Leu Ala Met Arg Lys Gln Ile Arg Ser Arg Ile Pro Gln Ser Thr Pro
 785 790 795 800
 Glu Glu Ala Val Leu Leu Asp Lys Gln Gln Ala Ala Ile Lys Val Val
 805 810 815
 Cys Asn Ser Val Tyr Gly Phe Thr Gly Val Gln His Gly Leu Leu Pro
 820 825 830
 Cys Leu His Val Ala Ala Thr Val Thr Thr Ile Gly Arg Glu Met Leu
 835 840 845
 Leu Ala Thr Arg Ala Tyr Val His Ala Arg Trp Ala Glu Phe Asp Gln
 850 855 860
 Leu Leu Ala Asp Phe Pro Glu Ala Ala Gly Met Arg Ala Pro Gly Pro
 865 870 875 880
 Tyr Ser Met Arg Ile Ile Tyr Gly Asp Thr Asp Ser Ile Phe Val Leu
 885 890 895
 Cys Arg Gly Leu Thr Ala Ala Gly Leu Val Ala Met Gly Asp Lys Met
 900 905 910
 Ala Ser His Ile Ser Arg Ala Leu Phe Leu Pro Pro Ile Lys Leu Glu
 915 920 925
 Cys Glu Lys Thr Phe Thr Lys Leu Leu Leu Ile Ala Lys Lys Lys Tyr
 930 935 940
 Ile Gly Val Ile Cys Gly Gly Lys Met Leu Ile Lys Gly Val Asp Leu
 945 950 955 960
 Val Arg Lys Asn Asn Cys Ala Phe Ile Asn Arg Thr Ser Arg Ala Leu
 965 970 975
 Val Asp Leu Leu Phe Tyr Asp Asp Thr Val Ser Gly Ala Ala Ala Ala
 980 985 990
 Leu Ala Glu Arg Pro Ala Glu Glu Trp Leu Ala Arg Pro Leu Pro Glu
 995 1000 1005
 Gly Leu Gln Ala Phe Gly Ala Val Leu Val Asp Ala His Arg Arg
 1010 1015 1020
 Ile Thr Asp Pro Glu Arg Asp Ile Gln Asp Phe Val Leu Thr Ala
 1025 1030 1035
 Glu Leu Ser Arg His Pro Arg Ala Tyr Thr Asn Lys Arg Leu Ala
 1040 1045 1050
 His Leu Thr Val Tyr Tyr Lys Leu Met Ala Arg Arg Ala Gln Val
 1055 1060 1065
 Pro Ser Ile Lys Asp Arg Ile Pro Tyr Val Ile Val Ala Gln Thr
 1070 1075 1080
 Arg Glu Val Glu Glu Thr Val Ala Arg Leu Ala Ala Leu Arg Glu
 1085 1090 1095
 Leu Asp Ala Ala Ala Pro Gly Asp Glu Pro Ala Pro Pro Ala Ala

| | | |
|-----------------------------|-------------------------------------|-------------|
| 1100 | 1105 | 1110 |
| Leu Pro Ser Pro Ala Lys Arg | Pro Arg Glu Thr Pro | Ser His Ala |
| 1115 | 1120 | 1125 |
| Asp Pro Pro Gly Gly Ala Ser | Lys Pro Arg Lys Leu | Leu Val Ser |
| 1130 | 1135 | 1140 |
| Glu Leu Ala Glu Asp Pro Gly | Tyr Ala Ile Ala Arg | Gly Val Pro |
| 1145 | 1150 | 1155 |
| Leu Asn Thr Asp Tyr Tyr Phe | Ser His Leu Leu Gly | Ala Ala Cys |
| 1160 | 1165 | 1170 |
| Val Thr Phe Lys Ala Leu Phe | Gly Asn Asn Ala Lys | Ile Thr Glu |
| 1175 | 1180 | 1185 |
| Ser Leu Leu Lys Arg Phe Ile | Pro Glu Thr Trp His | Pro Pro Asp |
| 1190 | 1195 | 1200 |
| Asp Val Ala Ala Arg Leu Arg | Ala Ala Gly Phe Gly | Pro Ala Gly |
| 1205 | 1210 | 1215 |
| Ala Gly Ala Thr Ala Glu Glu | Thr Arg Arg Met Leu | His Arg Ala |
| 1220 | 1225 | 1230 |
| Phe Asp Thr Leu Ala | | |
| 1235 | | |
| <210> 15 | | |
| <211> 1240 | | |
| <212> PRT | | |
| <213> herpes simplex | | |
| <400> 15 | | |
| Met Phe Cys Ala Ala Gly Gly | Pro Ala Ser Pro Gly Gly Lys | Ser Ala |
| 1 | 5 | 10 |
| Ala Arg Ala Ala Ser Gly Phe | Phe Ala Pro His Asn Pro Arg Gly | Ala |
| 20 | 25 | 30 |
| Thr Gln Thr Ala Pro Pro Pro | Cys Arg Arg Gln Asn Phe Tyr Asn Pro | |
| 35 | 40 | 45 |
| His Leu Ala Gln Thr Gly Thr | Gln Pro Lys Ala Pro Gly Pro Ala Gln | |
| 50 | 55 | 60 |
| Arg His Thr Tyr Tyr Ser Glu | Cys Asp Glu Phe Arg Phe Ile Ala Pro | |
| 65 | 70 | 75 |
| Arg Ser Leu Asp Glu Asp Ala | Pro Ala Glu Gln Arg Thr Gly Val His | |
| 85 | 90 | 95 |
| Asp Gly Arg Leu Arg Arg Ala | Pro Lys Val Tyr Cys Gly Gly Asp Glu | |
| 100 | 105 | 110 |
| Arg Asp Val Leu Arg Val Gly | Pro Glu Gly Phe Trp Pro Arg Arg Leu | |
| 115 | 120 | 125 |
| Arg Leu Trp Gly Gly Ala Asp | His Ala Pro Glu Gly Phe Asp Pro Thr | |
| 130 | 135 | 140 |

Val Thr Val Phe His Val Tyr Asp Ile Leu Glu His Val Glu His Ala
 145 150 155 160
 Tyr Ser Met Arg Ala Ala Gln Leu His Glu Arg Phe Met Asp Ala Ile
 165 170 175
 Thr Pro Ala Gly Thr Val Ile Thr Leu Leu Gly Leu Thr Pro Glu Gly
 180 185 190
 His Arg Val Ala Val His Val Tyr Gly Thr Arg Gln Tyr Phe Tyr Met
 195 200 205
 Asn Lys Ala Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp
 210 215 220
 Leu Cys Glu Arg Leu Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser
 225 230 235 240
 Phe Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg
 245 250 255
 Ala Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Thr Leu Tyr Tyr Arg Val
 260 265 270
 Phe Val Arg Ser Gly Arg Ala Leu Ala Tyr Leu Cys Asp Asn Phe Cys
 275 280 285
 Pro Ala Ile Arg Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe
 290 295 300
 Ile Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys
 305 310 315 320
 Pro Gly Arg Gly Asn Ala Pro Ala Gln Pro Arg Pro Pro Thr Ala Phe
 325 330 335
 Gly Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala
 340 345 350
 Val Glu Gly Ala Met Cys Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe
 355 360 365
 Asp Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val
 370 375 380
 Ala Glu Arg Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr
 385 390 395 400
 Asp Leu Ser Thr Thr Ala Leu Glu His Ile Leu Leu Phe Ser Leu Gly
 405 410 415
 Ser Cys Asp Leu Pro Glu Ser His Leu Ser Asp Leu Ala Ser Arg Gly
 420 425 430
 Leu Pro Ala Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu
 435 440 445
 Leu Ala Phe Met Thr Phe Val Lys Gln Tyr Gly Pro Glu Phe Val Thr
 450 455 460
 Gly Tyr Asn Ile Ile Asn Phe Asp Trp Pro Phe Val Leu Thr Lys Leu

| | | | | | | |
|---|-----|-----|-----|-----|-----|-----|
| 465 | | 470 | | 475 | | 480 |
| Thr Glu Ile Tyr Lys Val Pro Leu Asp Gly Tyr Gly Arg Met Asn Gly | 485 | | 490 | | 495 | |
| Arg Gly Val Phe Arg Val Trp Asp Ile Gly Gln Ser His Phe Gln Lys | 500 | | 505 | | 510 | |
| Arg Ser Lys Ile Lys Val Asn Gly Met Val Asn Ile Asp Met Tyr Gly | 515 | | 520 | | 525 | |
| Ile Ile Thr Asp Lys Val Lys Leu Ser Ser Tyr Lys Leu Asn Ala Val | 530 | | 535 | | 540 | |
| Ala Glu Ala Val Leu Lys Asp Lys Lys Lys Asp Leu Ser Tyr Arg Asp | 545 | | 550 | | 555 | 560 |
| Ile Pro Ala Tyr Tyr Ala Ser Gly Pro Ala Gln Arg Gly Val Ile Gly | 565 | | 570 | | 575 | |
| Glu Tyr Cys Val Gln Asp Ser Leu Leu Val Gly Gln Leu Phe Phe Lys | 580 | | 585 | | 590 | |
| Phe Leu Pro His Leu Glu Leu Ser Ala Val Ala Arg Leu Ala Gly Ile | 595 | | 600 | | 605 | |
| Asn Ile Thr Arg Thr Ile Tyr Asp Gly Gln Gln Ile Arg Val Phe Thr | 610 | | 615 | | 620 | |
| Cys Leu Leu Arg Leu Ala Gly Gln Lys Gly Phe Ile Leu Pro Asp Thr | 625 | | 630 | | 635 | 640 |
| Gln Gly Arg Phe Arg Gly Leu Asp Lys Glu Ala Pro Lys Arg Pro Ala | 645 | | 650 | | 655 | |
| Val Pro Arg Gly Glu Gly Glu Arg Pro Gly Asp Gly Asn Gly Asp Glu | 660 | | 665 | | 670 | |
| Asp Lys Asp Asp Asp Glu Asp Gly Asp Glu Asp Gly Asp Glu Arg Glu | 675 | | 680 | | 685 | |
| Glu Val Ala Arg Glu Thr Gly Gly Arg His Val Gly Tyr Gln Gly Ala | 690 | | 695 | | 700 | |
| Arg Val Leu Asp Pro Thr Ser Gly Phe His Val Asp Pro Val Val Val | 705 | | 710 | | 715 | 720 |
| Phe Asp Phe Ala Ser Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu | 725 | | 730 | | 735 | |
| Cys Phe Ser Thr Leu Ser Leu Arg Pro Glu Ala Val Ala His Leu Glu | 740 | | 745 | | 750 | |
| Ala Asp Arg Asp Tyr Leu Glu Ile Glu Val Gly Gly Arg Arg Leu Phe | 755 | | 760 | | 765 | |
| Phe Val Lys Ala His Val Arg Glu Ser Leu Leu Ser Ile Leu Leu Arg | 770 | | 775 | | 780 | |
| Asp Trp Leu Ala Met Arg Lys Gln Ile Arg Ser Arg Ile Pro Gln Ser | 785 | | 790 | | 795 | 800 |

Pro Pro Glu Glu Ala Val Leu Leu Asp Lys Gln Gln Ala Ala Ile Lys
 805 810 815
 Val Val Cys Asn Ser Val Tyr Gly Phe Thr Gly Val Gln His Gly Leu
 820 825 830
 Leu Pro Cys Leu His Val Ala Ala Thr Val Thr Thr Ile Gly Arg Glu
 835 840 845
 Met Leu Leu Ala Thr Arg Ala Tyr Val His Ala Arg Trp Ala Glu Phe
 850 855 860
 Asp Gln Leu Leu Ala Asp Phe Pro Glu Ala Ala Gly Met Arg Ala Pro
 865 870 875 880
 Gly Pro Tyr Ser Met Arg Ile Ile Tyr Gly Asp Thr Asp Ser Ile Phe
 885 890 895
 Val Leu Cys Arg Gly Leu Thr Ala Ala Gly Leu Val Ala Met Gly Asp
 900 905 910
 Lys Met Ala Ser His Ile Ser Arg Ala Leu Phe Leu Pro Pro Ile Lys
 915 920 925
 Leu Glu Cys Glu Lys Thr Phe Thr Lys Leu Leu Leu Ile Ala Lys Lys
 930 935 940
 Lys Tyr Ile Gly Val Ile Cys Gly Gly Lys Met Leu Ile Lys Gly Val
 945 950 955 960
 Asp Leu Val Arg Lys Asn Asn Cys Ala Phe Ile Asn Arg Thr Ser Arg
 965 970 975
 Ala Leu Val Asp Leu Leu Phe Tyr Asp Asp Thr Val Ser Gly Ala Ala
 980 985 990
 Ala Ala Leu Ala Glu Arg Pro Ala Glu Glu Trp Leu Ala Arg Pro Leu
 995 1000 1005
 Pro Glu Gly Leu Gln Ala Phe Gly Ala Val Leu Val Asp Ala His
 1010 1015 1020
 Arg Arg Ile Thr Asp Pro Glu Arg Asp Ile Gln Asp Phe Val Leu
 1025 1030 1035
 Thr Ala Glu Leu Ser Arg His Pro Arg Ala Tyr Thr Asn Lys Arg
 1040 1045 1050
 Leu Ala His Leu Thr Val Tyr Tyr Lys Leu Met Ala Arg Arg Ala
 1055 1060 1065
 Gln Val Pro Ser Ile Lys Asp Arg Ile Pro Tyr Val Ile Val Ala
 1070 1075 1080
 Gln Thr Arg Glu Val Glu Glu Thr Val Ala Arg Leu Ala Ala Leu
 1085 1090 1095
 Arg Glu Leu Asp Ala Ala Ala Pro Gly Asp Glu Pro Ala Pro Pro
 1100 1105 1110
 Ala Ala Leu Pro Ser Pro Ala Lys Arg Pro Arg Glu Thr Pro Ser
 1115 1120 1125

His Ala Asp Pro Pro Gly Gly Ala Ser Lys Pro Arg Lys Leu Leu
1130 1135 1140

Val Ser Glu Leu Ala Glu Asp Pro Gly Tyr Ala Ile Ala Arg Gly
1145 1150 1155

Val Pro Leu Asn Thr Asp Tyr Tyr Phe Ser His Leu Leu Gly Ala
1160 1165 1170

Ala Cys Val Thr Phe Lys Ala Leu Phe Gly Asn Asn Ala Lys Ile
1175 1180 1185

Thr Glu Ser Leu Leu Lys Arg Phe Ile Pro Glu Thr Trp His Pro
1190 1195 1200

Pro Asp Asp Val Ala Ala Arg Leu Arg Ala Ala Gly Phe Gly Pro
1205 1210 1215

Ala Gly Ala Gly Ala Thr Ala Glu Glu Thr Arg Arg Met Leu His
1220 1225 1230

Arg Ala Phe Asp Thr Leu Ala
1235 1240

<210> 16

<211> 1235

<212> PRT

<213> herpes simplex

<400> 16

Met Phe Ser Gly Gly Gly Gly Pro Leu Ser Pro Gly Gly Lys Ser Ala
1 5 10 15

Ala Arg Ala Ala Ser Gly Phe Phe Ala Pro Ala Gly Pro Arg Gly Ala
20 25 30

Gly Arg Gly Pro Pro Pro Cys Leu Arg Gln Asn Phe Tyr Asn Pro Tyr
35 40 45

Leu Ala Pro Val Gly Thr Gln Gln Lys Pro Thr Gly Pro Thr Gln Arg
50 55 60

His Thr Tyr Tyr Ser Glu Cys Asp Glu Phe Arg Phe Ile Ala Pro Arg
65 70 75 80

Val Leu Asp Glu Asp Ala Pro Pro Glu Lys Arg Ala Gly Val His Asp
85 90 95

Gly His Leu Lys Arg Ala Pro Lys Val Tyr Cys Gly Gly Asp Glu Arg
100 105 110

Asp Val Leu Arg Val Gly Ser Gly Gly Phe Trp Pro Arg Arg Ser Arg
115 120 125

Leu Trp Gly Gly Val Asp His Ala Pro Ala Gly Phe Asn Pro Thr Val
130 135 140

Thr Val Phe His Val Tyr Asp Ile Leu Glu Asn Val Glu His Ala Tyr
145 150 155 160

Gly Met Arg Ala Ala Gln Phe His Ala Arg Phe Met Asp Ala Ile Thr
 165 170 175
 Pro Thr Gly Thr Val Ile Thr Leu Leu Gly Leu Thr Pro Glu Gly His
 180 185 190
 Arg Val Ala Val His Val Tyr Gly Thr Arg Gln Tyr Phe Tyr Met Asn
 195 200 205
 Lys Glu Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp Leu
 210 215 220
 Cys Glu Arg Met Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser Phe
 225 230 235 240
 Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg Thr
 245 250 255
 Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Ala Leu Phe Tyr Arg Val Tyr
 260 265 270
 Val Arg Ser Gly Arg Val Leu Ser Tyr Leu Cys Asp Asn Phe Cys Pro
 275 280 285
 Ala Ile Lys Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe Ile
 290 295 300
 Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys Pro
 305 310 315 320
 Gly Arg Asn Asn Thr Leu Ala Gln Pro Arg Ala Pro Met Ala Phe Gly
 325 330 335
 Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala Ile
 340 345 350
 Glu Gly Gly Met Ser Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe Asp
 355 360 365
 Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val Ala
 370 375 380
 Gly His Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr Asp
 385 390 395 400
 Leu Ser Thr Thr Ala Leu Glu His Val Leu Leu Phe Ser Leu Gly Ser
 405 410 415
 Cys Asp Leu Pro Glu Ser His Leu Asn Glu Leu Ala Ala Arg Gly Leu
 420 425 430
 Pro Thr Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu Leu
 435 440 445
 Ala Phe Met Thr Leu Val Lys Gln Tyr Gly Pro Glu Phe Val Thr Gly
 450 455 460
 Tyr Asn Ile Ile Asn Phe Asp Trp Pro Phe Leu Leu Ala Lys Leu Thr
 465 470 475 480
 Asp Ile Tyr Lys Val Pro Leu Asp Gly Tyr Gly Arg Met Asn Gly Arg
 485 490 495

Gly Val Phe Arg Val Trp Asp Ile Gly Gln Ser His Phe Gln Lys Arg
 500 505 510
 Ser Lys Ile Lys Val Asn Gly Met Val Asn Ile Asp Met Tyr Gly Ile
 515 520 525
 Ile Thr Asp Lys Ile Lys Leu Ser Ser Tyr Lys Leu Asn Ala Val Ala
 530 535 540
 Glu Ala Val Leu Lys Asp Lys Lys Lys Asp Leu Ser Tyr Arg Asp Ile
 545 550 555 560
 Pro Ala Tyr Tyr Ala Ala Gly Pro Ala Gln Arg Gly Val Ile Gly Glu
 565 570 575
 Tyr Cys Ile Gln Asp Ser Leu Leu Val Gly Gln Leu Phe Phe Lys Phe
 580 585 590
 Leu Pro His Leu Glu Leu Ser Ala Val Ala Arg Leu Ala Gly Ile Asn
 595 600 605
 Ile Thr Arg Thr Ile Tyr Asp Gly Gln Gln Ile Arg Val Phe Thr Cys
 610 615 620
 Leu Leu Arg Leu Ala Asp Gln Lys Gly Phe Ile Leu Pro Asp Thr Gln
 625 630 635 640
 Gly Arg Phe Arg Gly Ala Gly Gly Glu Ala Pro Lys Arg Pro Ala Ala
 645 650 655
 Ala Arg Glu Asp Glu Glu Arg Pro Glu Glu Glu Gly Glu Asp Glu Asp
 660 665 670
 Glu Arg Glu Glu Gly Gly Gly Glu Arg Glu Pro Glu Gly Ala Arg Glu
 675 680 685
 Thr Ala Gly Arg His Val Gly Tyr Gln Gly Ala Arg Val Leu Asp Pro
 690 695 700
 Thr Ser Gly Phe His Val Asn Pro Val Val Val Phe Asp Phe Ala Ser
 705 710 715 720
 Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu Cys Phe Ser Thr Leu
 725 730 735
 Ser Leu Arg Ala Asp Ala Val Ala His Leu Glu Ala Gly Lys Asp Tyr
 740 745 750
 Leu Glu Ile Glu Val Gly Gly Arg Arg Leu Phe Phe Val Lys Ala His
 755 760 765
 Val Arg Glu Ser Leu Leu Ser Ile Leu Leu Arg Asp Trp Leu Ala Met
 770 775 780
 Arg Lys Gln Ile Arg Ser Arg Ile Pro Gln Ser Ser Pro Glu Glu Ala
 785 790 795 800
 Val Leu Leu Asp Lys Gln Gln Ala Ala Ile Lys Val Val Cys Asn Ser
 805 810 815
 Val Tyr Gly Phe Thr Gly Val Gln His Gly Leu Leu Pro Cys Leu His

| 820 | | | | | | | | | | 825 | | | | | | | | | | 830 | | | | | | | | | | | | | |
|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|-----|--|--|--|--|------|--|--|--|--|--|--|--|--|--|--|--|--|--|
| Val | Ala | Ala | Thr | Val | Thr | Thr | Ile | Gly | Arg | Glu | Met | Leu | Leu | Ala | Thr | | | | | | | | | | | | | | | | | | |
| 835 | | | | | | | | | | 840 | | | | | | | | | | 845 | | | | | | | | | | | | | |
| Arg | Glu | Tyr | Val | His | Ala | Arg | Trp | Ala | Ala | Phe | Glu | Gln | Leu | Leu | Ala | | | | | | | | | | | | | | | | | | |
| 850 | | | | | | | | | | 855 | | | | | | | | | | 860 | | | | | | | | | | | | | |
| Asp | Phe | Pro | Glu | Ala | Ala | Asp | Met | Arg | Ala | Pro | Gly | Pro | Tyr | Ser | Met | | | | | | | | | | | | | | | | | | |
| 865 | | | | | | | | | | 870 | | | | | | | | | | 875 | | | | | | | | | | | | | |
| Arg | Ile | Ile | Tyr | Gly | Asp | Thr | Asp | Ser | Ile | Phe | Val | Leu | Cys | Arg | Gly | | | | | | | | | | | | | | | | | | |
| 885 | | | | | | | | | | 890 | | | | | | | | | | 895 | | | | | | | | | | | | | |
| Leu | Thr | Ala | Ala | Gly | Leu | Thr | Ala | Met | Gly | Asp | Lys | Met | Ala | Ser | His | | | | | | | | | | | | | | | | | | |
| 900 | | | | | | | | | | 905 | | | | | | | | | | 910 | | | | | | | | | | | | | |
| Ile | Ser | Arg | Ala | Leu | Phe | Leu | Pro | Pro | Ile | Lys | Leu | Glu | Cys | Glu | Lys | | | | | | | | | | | | | | | | | | |
| 915 | | | | | | | | | | 920 | | | | | | | | | | 925 | | | | | | | | | | | | | |
| Thr | Phe | Thr | Lys | Leu | Leu | Leu | Ile | Ala | Lys | Lys | Lys | Tyr | Ile | Gly | Val | | | | | | | | | | | | | | | | | | |
| 930 | | | | | | | | | | 935 | | | | | | | | | | 940 | | | | | | | | | | | | | |
| Ile | Tyr | Gly | Gly | Lys | Met | Leu | Ile | Lys | Gly | Val | Asp | Leu | Val | Arg | Lys | | | | | | | | | | | | | | | | | | |
| 945 | | | | | | | | | | 950 | | | | | | | | | | 955 | | | | | | | | | | | | | |
| Asn | Asn | Cys | Ala | Phe | Ile | Asn | Arg | Thr | Ser | Arg | Ala | Leu | Val | Asp | Leu | | | | | | | | | | | | | | | | | | |
| 965 | | | | | | | | | | 970 | | | | | | | | | | 975 | | | | | | | | | | | | | |
| Leu | Phe | Tyr | Asp | Asp | Thr | Val | Ser | Gly | Ala | Ala | Ala | Ala | Leu | Ala | Glu | | | | | | | | | | | | | | | | | | |
| 980 | | | | | | | | | | 985 | | | | | | | | | | 990 | | | | | | | | | | | | | |
| Arg | Pro | Ala | Glu | Glu | Trp | Leu | Ala | Arg | Pro | Leu | Pro | Glu | Gly | Leu | Gln | | | | | | | | | | | | | | | | | | |
| 995 | | | | | | | | | | 1000 | | | | | | | | | | 1005 | | | | | | | | | | | | | |
| Ala | Phe | Gly | Ala | Val | Leu | Val | Asp | Ala | His | Arg | Arg | Ile | Thr | Asp | | | | | | | | | | | | | | | | | | | |
| 1010 | | | | | | | | | | 1015 | | | | | | | | | | 1020 | | | | | | | | | | | | | |
| Pro | Glu | Arg | Asp | Ile | Gln | Asp | Phe | Val | Leu | Thr | Ala | Glu | Leu | Ser | | | | | | | | | | | | | | | | | | | |
| 1025 | | | | | | | | | | 1030 | | | | | | | | | | 1035 | | | | | | | | | | | | | |
| Arg | His | Pro | Arg | Ala | Tyr | Thr | Asn | Lys | Arg | Leu | Ala | His | Leu | Thr | | | | | | | | | | | | | | | | | | | |
| 1040 | | | | | | | | | | 1045 | | | | | | | | | | 1050 | | | | | | | | | | | | | |
| Val | Tyr | Tyr | Lys | Leu | Met | Ala | Arg | Arg | Ala | Gln | Val | Pro | Ser | Ile | | | | | | | | | | | | | | | | | | | |
| 1055 | | | | | | | | | | 1060 | | | | | | | | | | 1065 | | | | | | | | | | | | | |
| Lys | Asp | Arg | Ile | Pro | Tyr | Val | Ile | Val | Ala | Gln | Thr | Arg | Glu | Val | | | | | | | | | | | | | | | | | | | |
| 1070 | | | | | | | | | | 1075 | | | | | | | | | | 1080 | | | | | | | | | | | | | |
| Glu | Glu | Thr | Val | Ala | Arg | Leu | Ala | Ala | Leu | Arg | Glu | Leu | Asp | Ala | | | | | | | | | | | | | | | | | | | |
| 1085 | | | | | | | | | | 1090 | | | | | | | | | | 1095 | | | | | | | | | | | | | |
| Ala | Ala | Pro | Gly | Asp | Glu | Pro | Ala | Pro | Pro | Ala | Ala | Leu | Pro | Ser | | | | | | | | | | | | | | | | | | | |
| 1100 | | | | | | | | | | 1105 | | | | | | | | | | 1110 | | | | | | | | | | | | | |
| Pro | Ala | Lys | Arg | Pro | Arg | Glu | Thr | Pro | Ser | His | Ala | Asp | Pro | Pro | | | | | | | | | | | | | | | | | | | |
| 1115 | | | | | | | | | | 1120 | | | | | | | | | | 1125 | | | | | | | | | | | | | |
| Gly | Gly | Ala | Ser | Lys | Pro | Arg | Lys | Leu | Leu | Val | Ser | Glu | Leu | Ala | | | | | | | | | | | | | | | | | | | |
| 1130 | | | | | | | | | | 1135 | | | | | | | | | | 1140 | | | | | | | | | | | | | |

Glu Asp Pro Ala Tyr Ala Ile Ala His Gly Val Ala Leu Asn Thr
 1145 1150 1155

Asp Tyr Tyr Phe Ser His Leu Leu Gly Ala Ala Cys Val Thr Phe
 1160 1165 1170

Lys Ala Leu Phe Gly Asn Asn Ala Lys Ile Thr Glu Ser Leu Leu
 1175 1180 1185

Lys Arg Phe Ile Pro Glu Val Trp His Pro Pro Asp Asp Val Ala
 1190 1195 1200

Ala Arg Leu Arg Ala Ala Gly Phe Gly Ala Val Gly Ala Gly Ala
 1205 1210 1215

Thr Ala Glu Glu Thr Arg Arg Met Leu His Arg Ala Phe Asp Thr
 1220 1225 1230

Leu Ala
 1235

<210> 17
 <211> 1235
 <212> PRT
 <213> herpes simplex

<400> 17

Met Phe Ser Gly Gly Gly Gly Pro Leu Ser Pro Gly Gly Lys Ser Ala
 1 5 10 15

Ala Arg Ala Ala Ser Gly Phe Phe Ala Pro Ala Gly Pro Arg Gly Ala
 20 25 30

Gly Arg Gly Pro Pro Pro Cys Leu Arg Gln Asn Phe Tyr Asn Pro Tyr
 35 40 45

Leu Ala Pro Val Gly Thr Gln Gln Lys Pro Thr Gly Pro Thr Gln Arg
 50 55 60

His Thr Tyr Tyr Ser Glu Cys Asp Glu Phe Arg Phe Ile Ala Pro Arg
 65 70 75 80

Val Leu Asp Glu Asp Ala Pro Pro Glu Lys Arg Ala Gly Val His Asp
 85 90 95

Gly His Leu Lys Arg Ala Pro Lys Val Tyr Cys Gly Gly Asp Glu Arg
 100 105 110

Asp Val Leu Arg Val Gly Ser Gly Gly Phe Trp Pro Arg Arg Ser Arg
 115 120 125

Leu Trp Gly Gly Val Asp His Ala Pro Ala Gly Phe Asn Pro Thr Val
 130 135 140

Thr Val Phe His Val Tyr Asp Ile Leu Glu Asn Val Glu His Ala Tyr
 145 150 155 160

Gly Met Arg Ala Ala Gln Phe His Ala Arg Phe Met Asp Ala Ile Thr
 165 170 175

Pro Thr Gly Thr Val Ile Thr Leu Leu Gly Leu Thr Pro Glu Gly His

| | | |
|---|-----|-----|
| 180 | 185 | 190 |
| Arg Val Ala Val His Val Tyr Gly Thr Arg Gln Tyr Phe Tyr Met Asn | | |
| 195 | 200 | 205 |
| Lys Glu Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp Leu | | |
| 210 | 215 | 220 |
| Cys Glu Arg Met Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser Phe | | |
| 225 | 230 | 235 |
| Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg Thr | | |
| | 245 | 250 |
| Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Ala Leu Phe Tyr Arg Val Tyr | | |
| | 260 | 265 |
| Val Arg Ser Gly Arg Val Leu Ser Tyr Leu Cys Asp Asn Phe Cys Pro | | |
| | 275 | 280 |
| Ala Ile Lys Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe Ile | | |
| | 290 | 295 |
| Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys Pro | | |
| 305 | 310 | 315 |
| Gly Arg Asn Asn Thr Leu Ala Gln Pro Arg Ala Pro Met Ala Phe Gly | | |
| | 325 | 330 |
| Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala Ile | | |
| | 340 | 345 |
| Glu Gly Gly Met Ser Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe Asp | | |
| | 355 | 360 |
| Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val Ala | | |
| | 370 | 375 |
| Gly His Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr Asp | | |
| 385 | 390 | 395 |
| Leu Ser Thr Thr Ala Leu Glu His Val Leu Leu Phe Ser Leu Gly Ser | | |
| | 405 | 410 |
| Cys Asp Leu Pro Glu Ser His Leu Asn Glu Leu Ala Ala Arg Gly Leu | | |
| | 420 | 425 |
| Pro Thr Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu Leu | | |
| | 435 | 440 |
| Ala Phe Met Thr Leu Val Lys Gln Tyr Gly Pro Glu Phe Val Thr Gly | | |
| | 450 | 455 |
| Tyr Asn Ile Ile Asn Phe Asp Trp Pro Phe Leu Leu Ala Lys Leu Thr | | |
| 465 | 470 | 475 |
| Asp Ile Tyr Lys Val Pro Leu Asp Gly Tyr Gly Arg Met Asn Gly Arg | | |
| | 485 | 490 |
| Gly Val Phe Arg Val Trp Asp Ile Gly Gln Ser His Phe Gln Lys Arg | | |
| | 500 | 505 |
| | | 510 |

Ser Lys Ile Lys Val Asn Gly Met Val Asn Ile Asp Met Tyr Gly Ile
 515 520 525
 Ile Thr Asp Lys Ile Lys Leu Ser Ser Tyr Lys Leu Asn Ala Val Ala
 530 535 540
 Glu Ala Val Leu Lys Asp Lys Lys Lys Asp Leu Ser Tyr Arg Asp Ile
 545 550 555 560
 Pro Ala Tyr Tyr Ala Ala Gly Pro Ala Gln Arg Gly Val Ile Gly Glu
 565 570 575
 Tyr Cys Ile Gln Asp Ser Leu Leu Val Gly Gln Leu Phe Phe Lys Phe
 580 585 590
 Leu Pro His Leu Glu Leu Ser Ala Val Ala Arg Leu Ala Gly Ile Asn
 595 600 605
 Ile Thr Arg Thr Ile Tyr Asp Gly Gln Gln Ile Arg Val Phe Thr Cys
 610 615 620
 Leu Leu Arg Leu Ala Asp Gln Lys Gly Phe Ile Leu Pro Asp Thr Gln
 625 630 635 640
 Gly Arg Phe Arg Gly Ala Gly Gly Glu Ala Pro Lys Arg Pro Ala Ala
 645 650 655
 Ala Arg Glu Asp Glu Glu Arg Pro Glu Glu Glu Gly Glu Asp Glu Asp
 660 665 670
 Glu Arg Glu Glu Gly Gly Gly Glu Arg Glu Pro Glu Gly Ala Arg Glu
 675 680 685
 Thr Ala Gly Arg His Val Gly Tyr Gln Gly Ala Arg Val Leu Asp Pro
 690 695 700
 Ile Ser Gly Phe His Val Asn Pro Val Val Val Phe Asp Phe Ala Ser
 705 710 715 720
 Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu Cys Phe Ser Thr Leu
 725 730 735
 Ser Leu Arg Ala Asp Ala Val Ala His Leu Glu Ala Gly Lys Asp Tyr
 740 745 750
 Leu Glu Ile Glu Val Gly Gly Arg Arg Leu Phe Phe Val Lys Ala His
 755 760 765
 Val Arg Glu Ser Leu Leu Ser Ile Leu Leu Arg Asp Trp Leu Ala Met
 770 775 780
 Arg Lys Gln Ile Arg Ser Arg Ile Pro Gln Ser Ser Pro Glu Glu Ala
 785 790 795 800
 Val Leu Leu Asp Lys Gln Gln Ala Ala Ile Lys Val Val Cys Asn Ser
 805 810 815
 Val Tyr Gly Phe Thr Gly Val Gln His Gly Leu Leu Pro Cys Leu His
 820 825 830
 Val Ala Ala Thr Val Thr Thr Ile Gly Arg Glu Met Leu Leu Ala Thr
 835 840 845

Arg Glu Tyr Val His Ala Arg Trp Ala Ala Phe Glu Gln Leu Leu Ala
 850 855 860
 Asp Phe Pro Glu Ala Ala Asp Met Arg Ala Pro Gly Pro Tyr Ser Met
 865 870 875 880
 Arg Ile Ile Tyr Gly Asp Thr Asp Ser Ile Phe Val Leu Cys Arg Gly
 885 890 895
 Leu Thr Ala Ala Gly Leu Thr Ala Met Gly Asp Lys Met Ala Ser His
 900 905 910
 Ile Ser Arg Ala Leu Phe Leu Pro Pro Ile Lys Leu Glu Cys Glu Lys
 915 920 925
 Thr Phe Thr Lys Leu Leu Leu Ile Ala Lys Lys Lys Tyr Ile Gly Val
 930 935 940
 Ile Tyr Gly Gly Lys Met Leu Ile Lys Gly Val Asp Leu Val Arg Lys
 945 950 955 960
 Asn Asn Cys Ala Phe Ile Asn Arg Thr Ser Arg Ala Leu Val Asp Leu
 965 970 975
 Leu Phe Tyr Asp Asp Thr Val Ser Gly Ala Ala Ala Ala Leu Ala Glu
 980 985 990
 Arg Pro Ala Glu Glu Trp Leu Ala Arg Pro Leu Pro Glu Gly Leu Gln
 995 1000 1005
 Ala Phe Gly Ala Val Leu Val Asp Ala His Arg Arg Ile Thr Asp
 1010 1015 1020
 Pro Glu Arg Asp Ile Gln Asp Phe Val Leu Thr Ala Glu Leu Ser
 1025 1030 1035
 Arg His Pro Arg Ala Tyr Thr Asn Lys Arg Leu Ala His Leu Thr
 1040 1045 1050
 Val Tyr Tyr Lys Leu Met Ala Arg Arg Ala Gln Val Pro Ser Ile
 1055 1060 1065
 Lys Asp Arg Ile Pro Tyr Val Ile Val Ala Gln Thr Arg Glu Val
 1070 1075 1080
 Glu Glu Thr Val Ala Arg Leu Ala Ala Leu Arg Glu Leu Asp Ala
 1085 1090 1095
 Ala Ala Pro Gly Asp Glu Pro Ala Pro Pro Ala Ala Leu Pro Ser
 1100 1105 1110
 Pro Ala Lys Arg Pro Arg Glu Thr Pro Ser Pro Ala Asp Pro Pro
 1115 1120 1125
 Gly Gly Ala Ser Lys Pro Arg Lys Leu Leu Val Ser Glu Leu Ala
 1130 1135 1140
 Glu Asp Pro Ala Tyr Ala Ile Ala His Gly Val Ala Leu Asn Thr
 1145 1150 1155
 Asp Tyr Tyr Phe Ser His Leu Leu Gly Ala Ala Cys Val Thr Phe

| | | |
|---|------|------|
| 1160 | 1165 | 1170 |
| Lys Ala Leu Phe Gly Asn Asn Ala Lys Ile Thr Glu Ser Leu Leu | | |
| 1175 | 1180 | 1185 |
| Lys Arg Phe Ile Pro Glu Val Trp His Pro Pro Asp Asp Val Thr | | |
| 1190 | 1195 | 1200 |
| Ala Arg Leu Arg Ala Ala Gly Phe Gly Ala Val Gly Ala Gly Ala | | |
| 1205 | 1210 | 1215 |
| Thr Ala Glu Glu Thr Arg Arg Met Leu His Arg Ala Phe Asp Thr | | |
| 1220 | 1225 | 1230 |
| Leu Ala | | |
| 1235 | | |
| <210> 18 | | |
| <211> 1235 | | |
| <212> PRT | | |
| <213> herpes simplex | | |
| <400> 18 | | |
| Met Phe Ser Gly Gly Gly Gly Pro Leu Ser Pro Gly Gly Lys Ser Ala | | |
| 1 5 10 15 | | |
| Ala Arg Ala Ala Ser Gly Phe Phe Ala Pro Ala Gly Pro Arg Gly Ala | | |
| 20 25 30 | | |
| Gly Arg Gly Pro Pro Pro Cys Leu Arg Gln Asn Phe Tyr Asn Pro Tyr | | |
| 35 40 45 | | |
| Leu Ala Pro Val Gly Thr Gln Gln Lys Pro Thr Gly Pro Thr Gln Arg | | |
| 50 55 60 | | |
| His Thr Tyr Tyr Ser Glu Cys Asp Glu Phe Arg Phe Ile Ala Pro Arg | | |
| 65 70 75 80 | | |
| Val Leu Asp Glu Asp Ala Pro Pro Glu Lys Arg Ala Gly Val His Asp | | |
| 85 90 95 | | |
| Gly His Leu Lys Arg Ala Pro Lys Val Tyr Cys Gly Gly Asp Glu Arg | | |
| 100 105 110 | | |
| Asp Val Leu Arg Val Gly Ser Gly Gly Phe Trp Pro Arg Arg Ser Arg | | |
| 115 120 125 | | |
| Leu Trp Gly Gly Val Asp His Ala Pro Ala Gly Phe Asn Pro Thr Val | | |
| 130 135 140 | | |
| Thr Val Phe His Val Tyr Asp Ile Leu Glu Asn Val Glu His Ala Tyr | | |
| 145 150 155 160 | | |
| Gly Met Arg Ala Ala Gln Phe His Ala Arg Phe Met Asp Ala Ile Thr | | |
| 165 170 175 | | |
| Pro Thr Gly Thr Val Ile Thr Leu Leu Gly Leu Thr Pro Glu Gly His | | |
| 180 185 190 | | |
| Arg Val Ala Val His Val Tyr Gly Thr Arg Gln Tyr Phe Tyr Met Asn | | |
| 195 200 205 | | |

Lys Glu Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp Leu
 210 215 220
 Cys Glu Arg Met Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser Phe
 225 230 235 240
 Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg Thr
 245 250 255
 Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Ala Leu Phe Tyr Arg Val Tyr
 260 265 270
 Val Arg Ser Gly Arg Val Leu Ser Tyr Leu Cys Asp Asn Phe Cys Pro
 275 280 285
 Ala Ile Lys Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe Ile
 290 295 300
 Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys Pro
 305 310 315 320
 Gly Arg Asn Asn Thr Leu Ala Gln Pro Arg Ala Pro Met Ala Phe Gly
 325 330 335
 Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala Ile
 340 345 350
 Glu Gly Gly Met Ser Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe Asp
 355 360 365
 Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val Ala
 370 375 380
 Gly His Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr Asp
 385 390 395 400
 Leu Ser Thr Thr Ala Leu Glu His Val Leu Leu Phe Ser Leu Gly Ser
 405 410 415
 Cys Asp Leu Pro Glu Ser His Leu Asn Glu Leu Ala Ala Arg Gly Leu
 420 425 430
 Pro Thr Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu Leu
 435 440 445
 Ala Phe Met Thr Leu Val Lys Gln Tyr Gly Pro Glu Phe Val Thr Gly
 450 455 460
 Tyr Asn Ile Ile Asn Phe Asp Trp Pro Phe Leu Leu Ala Lys Leu Thr
 465 470 475 480
 Asp Ile Tyr Lys Val Pro Leu Asp Gly Tyr Gly Arg Met Asn Gly Arg
 485 490 495
 Gly Val Phe Arg Val Trp Asp Ile Gly Gln Ser His Phe Gln Lys Arg
 500 505 510
 Ser Lys Ile Lys Val Asn Gly Met Val Asn Ile Asp Met Tyr Gly Ile
 515 520 525
 Ile Thr Asp Lys Ile Lys Leu Ser Ser Tyr Lys Leu Asn Ala Val Ala

| 530 | | | | | 535 | | | | | 540 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Ala | Val | Leu | Lys | Asp | Lys | Lys | Lys | Asp | Leu | Ser | Tyr | Arg | Asp | Ile |
| 545 | | | | | 550 | | | | | 555 | | | | | 560 |
| Pro | Thr | Tyr | Tyr | Ala | Ala | Gly | Pro | Ala | Gln | Arg | Gly | Val | Ile | Gly | Glu |
| | | | | 565 | | | | | 570 | | | | | 575 | |
| Tyr | Cys | Ile | Gln | Asp | Ser | Leu | Leu | Val | Gly | Gln | Leu | Phe | Phe | Lys | Phe |
| | | | 580 | | | | | 585 | | | | | 590 | | |
| Leu | Pro | His | Leu | Glu | Leu | Ser | Ala | Val | Ala | Arg | Leu | Ala | Gly | Ile | Asn |
| | | 595 | | | | | 600 | | | | | 605 | | | |
| Ile | Thr | Arg | Thr | Ile | Tyr | Asp | Gly | Gln | Gln | Ile | Arg | Val | Phe | Thr | Cys |
| | 610 | | | | | 615 | | | | | 620 | | | | |
| Leu | Leu | Arg | Leu | Ala | Asp | Gln | Lys | Gly | Phe | Ile | Leu | Pro | Asp | Thr | Gln |
| 625 | | | | | 630 | | | | | 635 | | | | | 640 |
| Gly | Arg | Phe | Arg | Gly | Ala | Gly | Gly | Glu | Ala | Pro | Lys | Arg | Pro | Ala | Ala |
| | | | | 645 | | | | | 650 | | | | | 655 | |
| Ala | Arg | Glu | Asp | Glu | Glu | Arg | Pro | Glu | Glu | Glu | Gly | Glu | Asp | Glu | Asn |
| | | | 660 | | | | | 665 | | | | | 670 | | |
| Glu | Arg | Glu | Glu | Gly | Gly | Gly | Glu | Arg | Glu | Pro | Glu | Gly | Ala | Arg | Glu |
| | | | 675 | | | | 680 | | | | | | 685 | | |
| Thr | Ala | Gly | Arg | His | Val | Gly | Tyr | Gln | Gly | Ala | Arg | Val | Leu | Asp | Pro |
| | 690 | | | | | 695 | | | | | 700 | | | | |
| Thr | Ser | Gly | Phe | His | Val | Asn | Pro | Val | Val | Val | Phe | Asp | Phe | Ala | Ser |
| 705 | | | | | 710 | | | | | 715 | | | | | 720 |
| Leu | Tyr | Pro | Ser | Ile | Ile | Gln | Ala | His | Asn | Leu | Cys | Phe | Ser | Thr | Leu |
| | | | | 725 | | | | | 730 | | | | | 735 | |
| Ser | Leu | Arg | Ala | Asp | Ala | Val | Ala | His | Leu | Glu | Ala | Gly | Lys | Asp | Tyr |
| | | | 740 | | | | | 745 | | | | | 750 | | |
| Leu | Glu | Ile | Glu | Val | Gly | Gly | Arg | Arg | Leu | Phe | Phe | Val | Lys | Ala | His |
| | 755 | | | | | | 760 | | | | | 765 | | | |
| Val | Arg | Glu | Ser | Leu | Leu | Ser | Ile | Leu | Leu | Arg | Asp | Trp | Leu | Ala | Met |
| | 770 | | | | | 775 | | | | | 780 | | | | |
| Arg | Lys | Gln | Ile | Arg | Ser | Arg | Ile | Pro | Gln | Ser | Ser | Pro | Glu | Glu | Ala |
| 785 | | | | | 790 | | | | | 795 | | | | | 800 |
| Val | Leu | Leu | Asp | Lys | Gln | Gln | Ala | Ala | Ile | Lys | Val | Val | Cys | Asn | Ser |
| | | | | 805 | | | | | 810 | | | | | 815 | |
| Val | Tyr | Gly | Phe | Thr | Gly | Val | Gln | His | Gly | Leu | Leu | Pro | Cys | Leu | His |
| | | | 820 | | | | 825 | | | | | | 830 | | |
| Val | Ala | Ala | Thr | Val | Thr | Thr | Ile | Gly | Arg | Glu | Met | Leu | Leu | Ala | Thr |
| | 835 | | | | | | 840 | | | | 845 | | | | |
| Arg | Glu | Tyr | Val | His | Ala | Arg | Trp | Ala | Ala | Phe | Glu | Gln | Leu | Leu | Ala |
| | 850 | | | | | 855 | | | | | 860 | | | | |

Asp Phe Pro Glu Ala Ala Asp Met Arg Ala Pro Gly Pro Tyr Ser Met
 865 870 875 880
 Arg Ile Ile Tyr Gly Asp Thr Asp Ser Ile Phe Val Leu Cys Arg Gly
 885 890 895
 Leu Thr Ala Ala Gly Leu Thr Ala Val Gly Asp Lys Met Ala Ser His
 900 905 910
 Ile Ser Arg Ala Leu Phe Leu Pro Pro Ile Lys Leu Glu Cys Glu Lys
 915 920 925
 Thr Phe Thr Lys Leu Leu Leu Ile Ala Lys Lys Lys Tyr Ile Gly Val
 930 935 940
 Ile Tyr Gly Gly Lys Met Leu Ile Lys Gly Val Asp Leu Val Arg Lys
 945 950 955 960
 Asn Asn Cys Ala Phe Ile Asn Arg Thr Ser Arg Ala Leu Val Asp Leu
 965 970 975
 Leu Phe Tyr Asp Asp Thr Val Ser Gly Ala Ala Ala Ala Leu Ala Glu
 980 985 990
 Arg Pro Ala Glu Glu Trp Leu Ala Arg Pro Leu Pro Glu Gly Leu Gln
 995 1000 1005
 Ala Phe Gly Ala Val Leu Val Asp Ala His Arg Arg Ile Thr Asp
 1010 1015 1020
 Pro Glu Arg Asp Ile Gln Asp Phe Val Leu Thr Ala Glu Leu Ser
 1025 1030 1035
 Arg His Pro Arg Ala Tyr Thr Asn Lys Arg Leu Ala His Leu Thr
 1040 1045 1050
 Val Tyr Tyr Lys Leu Met Ala Arg Arg Ala Gln Val Pro Ser Ile
 1055 1060 1065
 Lys Asp Arg Ile Pro Tyr Val Ile Val Ala Gln Thr Arg Glu Val
 1070 1075 1080
 Glu Glu Thr Val Ala Arg Leu Ala Ala Leu Arg Glu Leu Asp Ala
 1085 1090 1095
 Ala Ala Pro Gly Asp Glu Pro Ala Pro Pro Ala Ala Leu Pro Ser
 1100 1105 1110
 Pro Ala Lys Arg Pro Arg Glu Thr Pro Ser Pro Ala Asp Pro Pro
 1115 1120 1125
 Gly Gly Ala Ser Lys Pro Arg Lys Leu Leu Val Ser Glu Leu Ala
 1130 1135 1140
 Glu Asp Pro Ala Tyr Ala Ile Ala His Gly Val Ala Leu Asn Thr
 1145 1150 1155
 Asp Tyr Tyr Phe Ser His Leu Leu Gly Ala Ala Cys Val Thr Phe
 1160 1165 1170
 Lys Ala Leu Phe Gly Asn Asn Ala Lys Ile Thr Glu Ser Leu Leu
 1175 1180 1185

Lys Arg Phe Ile Pro Glu Val Trp His Pro Pro Asp Asp Val Ala
 1190 1195 1200

Ala Arg Leu Arg Thr Ala Gly Phe Gly Ala Val Gly Ala Gly Ala
 1205 1210 1215

Thr Ala Glu Glu Thr Arg Arg Met Leu His Arg Ala Phe Asp Thr
 1220 1225 1230

Leu Ala
 1235

<210> 19

<211> 1235

<212> PRT

<213> herpes simplex

<400> 19

Met Phe Ser Gly Gly Gly Gly Pro Leu Ser Pro Gly Gly Lys Ser Ala
 1 5 10 15

Ala Arg Ala Ala Ser Gly Phe Phe Ala Pro Ala Gly Pro Arg Gly Ala
 20 25 30

Gly Arg Gly Pro Pro Pro Cys Leu Arg Gln Asn Phe Tyr Asn Pro Tyr
 35 40 45

Leu Ala Pro Val Gly Thr Gln Gln Lys Pro Thr Gly Pro Thr Gln Arg
 50 55 60

His Thr Tyr Tyr Ser Glu Cys Asp Glu Phe Arg Phe Ile Ala Pro Arg
 65 70 75 80

Val Leu Asp Glu Asp Ala Pro Pro Glu Lys Arg Ala Gly Val His Asp
 85 90 95

Gly His Leu Lys Arg Ala Pro Lys Val Tyr Cys Gly Gly Asp Glu Arg
 100 105 110

Asp Val Leu Arg Val Gly Ser Gly Gly Phe Trp Pro Arg Arg Ser Arg
 115 120 125

Leu Trp Gly Gly Val Asp His Ala Pro Ala Gly Phe Asn Pro Thr Val
 130 135 140

Thr Val Phe His Val Tyr Asp Ile Leu Glu Asn Val Glu His Ala Tyr
 145 150 155 160

Gly Met Arg Ala Ala Gln Phe His Ala Arg Phe Met Asp Ala Ile Thr
 165 170 175

Pro Thr Gly Thr Val Ile Thr Leu Leu Gly Leu Thr Pro Glu Gly His
 180 185 190

Arg Val Ala Val His Val Tyr Gly Thr Arg Gln Tyr Phe Tyr Met Asn
 195 200 205

Lys Glu Glu Val Asp Arg His Leu Gln Cys Arg Ala Pro Arg Asp Leu
 210 215 220

Cys Glu Arg Met Ala Ala Ala Leu Arg Glu Ser Pro Gly Ala Ser Phe
 225 230 235 240
 Arg Gly Ile Ser Ala Asp His Phe Glu Ala Glu Val Val Glu Arg Thr
 245 250 255
 Asp Val Tyr Tyr Tyr Glu Thr Arg Pro Ala Leu Phe Tyr Arg Val Tyr
 260 265 270
 Val Arg Ser Gly Arg Val Leu Ser Tyr Leu Cys Asp Asn Phe Cys Pro
 275 280 285
 Ala Ile Lys Lys Tyr Glu Gly Gly Val Asp Ala Thr Thr Arg Phe Ile
 290 295 300
 Leu Asp Asn Pro Gly Phe Val Thr Phe Gly Trp Tyr Arg Leu Lys Pro
 305 310 315 320
 Gly Arg Asn Asn Thr Leu Ala Gln Pro Arg Ala Pro Met Ala Phe Gly
 325 330 335
 Thr Ser Ser Asp Val Glu Phe Asn Cys Thr Ala Asp Asn Leu Ala Ile
 340 345 350
 Glu Gly Gly Met Ser Asp Leu Pro Ala Tyr Lys Leu Met Cys Phe Asp
 355 360 365
 Ile Glu Cys Lys Ala Gly Gly Glu Asp Glu Leu Ala Phe Pro Val Ala
 370 375 380
 Gly His Pro Glu Asp Leu Val Ile Gln Ile Ser Cys Leu Leu Tyr Asp
 385 390 395 400
 Leu Ser Thr Thr Ala Leu Glu His Val Leu Leu Phe Ser Leu Gly Ser
 405 410 415
 Cys Asp Leu Pro Glu Ser His Leu Asn Glu Leu Ala Ala Arg Gly Leu
 420 425 430
 Pro Thr Pro Val Val Leu Glu Phe Asp Ser Glu Phe Glu Met Leu Leu
 435 440 445
 Ala Phe Met Thr Leu Val Lys Gln Tyr Gly Pro Glu Phe Val Thr Gly
 450 455 460
 Tyr Asn Ile Ile Asn Phe Asp Trp Pro Phe Leu Leu Ala Lys Leu Thr
 465 470 475 480
 Asp Ile Tyr Lys Val Pro Leu Asp Gly Tyr Gly Arg Met Asn Gly Arg
 485 490 495
 Gly Val Phe Arg Val Trp Asp Ile Gly Gln Ser His Phe Gln Lys Arg
 500 505 510
 Ser Lys Ile Lys Val Asn Gly Met Val Asn Ile Asp Met Tyr Gly Ile
 515 520 525
 Ile Thr Asp Lys Ile Lys Leu Ser Ser Tyr Lys Leu Asn Ala Val Ala
 530 535 540
 Glu Ala Val Leu Lys Asp Lys Lys Lys Asp Leu Ser Tyr Arg Asp Ile
 545 550 555 560

Pro Ala Tyr Tyr Ala Ala Gly Pro Ala Gln Arg Gly Val Ile Gly Glu
 565 570 575
 Tyr Cys Ile Gln Asp Ser Leu Leu Val Gly Gln Leu Phe Phe Lys Phe
 580 585 590
 Leu Pro His Leu Glu Leu Ser Ala Val Ala Arg Leu Ala Gly Ile Asn
 595 600 605
 Ile Thr Arg Thr Ile Tyr Asp Gly Gln Gln Ile Arg Val Phe Thr Cys
 610 615 620
 Leu Leu Arg Leu Ala Asp Gln Lys Gly Phe Ile Leu Pro Asp Thr Gln
 625 630 635 640
 Gly Arg Phe Arg Gly Gly Gly Gly Glu Ala Pro Lys Arg Pro Ala Ala
 645 650 655
 Ala Arg Glu Asp Glu Glu Arg Pro Glu Glu Glu Gly Glu Asp Glu Asp
 660 665 670
 Glu Arg Glu Glu Gly Gly Gly Glu Arg Glu Pro Glu Gly Ala Arg Glu
 675 680 685
 Thr Ala Gly Arg His Val Gly Tyr Gln Gly Ala Arg Val Leu Asp Pro
 690 695 700
 Thr Ser Gly Phe His Val Asn Pro Val Val Val Phe Asp Phe Ala Ser
 705 710 715 720
 Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu Cys Phe Ser Thr Leu
 725 730 735
 Ser Leu Arg Ala Asp Ala Val Ala His Leu Glu Ala Gly Lys Asp Tyr
 740 745 750
 Leu Glu Ile Glu Val Gly Gly Arg Arg Leu Phe Phe Val Lys Ala His
 755 760 765
 Val Arg Glu Ser Leu Leu Ser Ile Leu Leu Arg Asp Trp Leu Ala Met
 770 775 780
 Arg Lys Gln Ile Arg Ser Arg Ile Pro Gln Ser Ser Pro Glu Glu Ala
 785 790 795 800
 Val Leu Leu Asp Lys Gln Gln Ala Ala Ile Lys Val Val Cys Asn Ser
 805 810 815
 Val Tyr Gly Phe Thr Gly Val Gln His Gly Leu Leu Pro Cys Leu His
 820 825 830
 Val Ala Ala Thr Val Thr Thr Ile Gly Arg Glu Met Leu Leu Ala Thr
 835 840 845
 Arg Glu Tyr Val His Ala Arg Trp Ala Ala Phe Glu Gln Leu Leu Ala
 850 855 860
 Asp Phe Pro Glu Ala Ala Asp Met Arg Ala Pro Gly Pro Tyr Ser Met
 865 870 875 880
 Arg Ile Ile Tyr Gly Asp Thr Asp Ser Ile Phe Val Leu Cys Arg Gly

| 885 | 890 | 895 |
|--|------|------|
| Leu Thr Ala Ala Gly Leu Thr Ala Val Gly Asp Lys Met Ala Ser His 900 | 905 | 910 |
| Ile Ser Arg Ala Leu Phe Leu Ser Pro Ile Lys Leu Glu Cys Glu Lys 915 | 920 | 925 |
| Thr Phe Thr Lys Leu Leu Leu Ile Ala Lys Lys Lys Tyr Ile Gly Val 930 | 935 | 940 |
| Ile Tyr Gly Gly Lys Met Leu Ile Lys Gly Val Asp Leu Val Arg Lys 945 | 950 | 955 |
| Asn Asn Cys Ala Phe Ile Asn Arg Thr Ser Arg Ala Leu Val Asp Leu 965 | 970 | 975 |
| Leu Phe Tyr Asp Asp Thr Val Ser Gly Ala Ala Ala Ala Leu Ala Glu 980 | 985 | 990 |
| Arg Pro Ala Glu Glu Trp Leu Ala Arg Pro Leu Pro Glu Gly Leu Gln 995 | 1000 | 1005 |
| Ala Phe Gly Ala Val Leu Val Asp Ala His Arg Arg Ile Thr Asp 1010 | 1015 | 1020 |
| Pro Glu Arg Asp Ile Gln Asp Phe Val Leu Thr Ala Glu Leu Ser 1025 | 1030 | 1035 |
| Arg His Pro Arg Ala Tyr Thr Asn Lys Arg Leu Ala His Leu Thr 1040 | 1045 | 1050 |
| Val Tyr Tyr Lys Leu Met Ala Arg Arg Ala Gln Val Pro Ser Ile 1055 | 1060 | 1065 |
| Lys Asp Arg Ile Pro Tyr Val Ile Val Ala Gln Thr Arg Glu Val 1070 | 1075 | 1080 |
| Glu Glu Thr Val Ala Arg Leu Ala Ala Leu Arg Glu Leu Asp Ala 1085 | 1090 | 1095 |
| Ala Ala Pro Gly Asp Glu Pro Ala Pro Pro Ala Ala Leu Pro Ser 1100 | 1105 | 1110 |
| Pro Ala Lys Arg Pro Arg Glu Thr Pro Leu His Ala Asp Pro Pro 1115 | 1120 | 1125 |
| Gly Gly Ala Ser Lys Pro Arg Lys Leu Leu Val Ser Glu Leu Ala 1130 | 1135 | 1140 |
| Glu Asp Pro Ala Tyr Ala Ile Ala His Gly Val Ala Leu Asn Thr 1145 | 1150 | 1155 |
| Asp Tyr Tyr Phe Ser His Leu Leu Gly Ala Ala Cys Val Thr Phe 1160 | 1165 | 1170 |
| Lys Ala Leu Phe Gly Asn Asn Ala Lys Ile Thr Glu Ser Leu Leu 1175 | 1180 | 1185 |
| Lys Arg Phe Ile Pro Glu Val Trp His Pro Pro Asp Asp Val Ala 1190 | 1195 | 1200 |

Ala Arg Leu Arg Ala Ala Gly Phe Gly Ala Val Gly Ala Gly Ala
1205 1210 1215

Thr Ala Glu Glu Thr Arg Arg Met Leu His Arg Ala Phe Asp Thr
1220 1225 1230

Leu Ala
1235